Development of MRI as an Enabling Technology for Tissue Science and Engineering by Demers-Peel, Evan Arthur et al.
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2010
Development of MRI as an Enabling Technology
for Tissue Science and Engineering
Evan Arthur Demers-Peel
Worcester Polytechnic Institute
Jayanth Bisa
Worcester Polytechnic Institute
Matthew A. Gonsalves
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Demers-Peel, E. A., Bisa, J., & Gonsalves, M. A. (2010). Development of MRI as an Enabling Technology for Tissue Science and
Engineering. Retrieved from https://digitalcommons.wpi.edu/mqp-all/1255
WORCESTER POLYTECHNIC INSTITUTE 
 
Development of MRI as an 
Enabling Technology for 
Tissue Science and 
Engineering 
 
Jayanth Bisa 
Evan Demers-Peel 
Matthew Gonsalves 
 
 
Advisors: 
Prof Christopher Sotak 
Prof. George Pins 
 
 
April 29, 2010 
2 
 
Table of Contents 
Authorship ...................................................................................................................................... 6 
Acknowledgements ......................................................................................................................... 7 
Abstract ........................................................................................................................................... 8 
1.0 Introduction .............................................................................................................................. 9 
2.0 Literature Review .................................................................................................................... 13 
2.1 Basic Functions of the Heart ............................................................................................... 13 
2.2 Myocardial Infarction .......................................................................................................... 14 
2.3 Clinical Treatments of Myocardial Infarction ...................................................................... 16 
2.4 Human Mesenchymal Stem Cells ........................................................................................ 19 
2.5 Stem Cell Delivery Techniques ............................................................................................ 20 
2.5.1 Infusion Techniques ...................................................................................................... 20 
2.5.2 Injection Techniques ..................................................................................................... 22 
2.5.3 Biomaterials for Cardiac Regeneration ........................................................................ 24 
2.6 Histological Techniques – Evidence base for non-invasive techniques. ............................. 29 
2.7 MRI Overview ...................................................................................................................... 31 
2.7.1 Nuclear Spin in a Magnetic Field .................................................................................. 31 
2.8 MRI Parameters and Their Physical Origins ........................................................................ 34 
2.8.1 Longitudinal Relaxation ................................................................................................ 35 
2.8.2 Transverse Relaxation................................................................................................... 37 
2.8.3 Image Acquisition ......................................................................................................... 39 
2.8.4 Image Weighting ........................................................................................................... 42 
2.9 Contrast Enhanced Imaging ................................................................................................ 42 
3.0 Project Strategy ....................................................................................................................... 44 
3.1 Initial Client Statement ....................................................................................................... 44 
3.2 Objectives Functions & Specifications ................................................................................ 44 
3.2.1 Objectives: .................................................................................................................... 44 
3.2.2 Constraints: ................................................................................................................... 48 
3.2.3 Functions: ..................................................................................................................... 49 
3 
 
3.3 Specifications ....................................................................................................................... 50 
3.4 Revised Client Statement .................................................................................................... 52 
3.5 Project Approach ................................................................................................................. 52 
3.5.1    Project Assumptions .................................................................................................. 52 
3.5.2 Project Goals ................................................................................................................. 53 
3.6 Project Hypotheses ............................................................................................................. 54 
3.6.1 Hypothesis #1 ............................................................................................................... 54 
3.6.2 Hypothesis #2 ............................................................................................................... 55 
3.6.3 Hypothesis #3 ............................................................................................................... 56 
4.0 Design Alternatives ............................................................................................................. 57 
4.0.1 Pairwise Comparison Charts ......................................................................................... 57 
4.0.2 Needs Analysis .............................................................................................................. 59 
4.1 Conceptual Designs ............................................................................................................. 60 
4.1.1 Cardiac Phantom Modeling System ............................................................................. 61 
4.1.2 Data Acquisition ............................................................................................................ 63 
4.1.3 Data Analysis ................................................................................................................. 63 
4.1.4 Design Evaluation ......................................................................................................... 64 
4.2 Feasibility Study for Alternative Designs ............................................................................. 66 
4.2.1 Feasibility for Cardiac Phantom .................................................................................... 66 
4.2.2 Feasibility for Data Acquisition ..................................................................................... 70 
4.2.3 Feasibility for Data Analysis .......................................................................................... 71 
4.3 Preliminary Experiments ..................................................................................................... 72 
4.3.1 Phosphate Buffered Saline Preparation ....................................................................... 72 
4.3.2 Gelatin Formation Analysis ........................................................................................... 72 
4.3.3 Gelatin Reconstruction ................................................................................................. 74 
4.3.4 Ferumoxtran (AMI 227) Preparation ............................................................................ 74 
4.3.5 Imaging Process and Parameters ................................................................................. 75 
4.3.6 Curve Fitting and Data Analysis .................................................................................... 77 
4.3.7 Preliminary Data Results and Conclusions ................................................................... 79 
4 
 
5.0 Design Verification .................................................................................................................. 84 
5.1 Collagen Microthread Production ....................................................................................... 84 
5.1.1 Preparation of acid-soluble collagen ............................................................................ 84 
5.1.2 Collagen thread Extrusion ............................................................................................ 85 
5.2 Gelatin Production .............................................................................................................. 86 
5.2.1 Phosphate Buffered Saline (PBS) Production ............................................................... 86 
5.2.2 Gelatin Concentration & PBS Integration ..................................................................... 87 
5.3 Microthread Contrast Agent Application ............................................................................ 88 
5.4 Cardiac Phantom Construction ........................................................................................... 90 
5.5 Imaging Process and Parameters ........................................................................................ 91 
5.5.1 Air-Dried Phantom Imaging .......................................................................................... 93 
5.5.2 Hydrated Phantom Imaging ......................................................................................... 93 
5.5.3 T1-Weighted Image Acquisition .................................................................................... 94 
5.5.3 T2-Weighted Images Acquisition .................................................................................. 95 
5.6 Data Analysis Procedure ..................................................................................................... 96 
5.6.1 Hydrated Microthread Diameter Measurements ............................................................ 98 
5.6.2 Air-Dried Microthread Diameter Measurements ......................................................... 99 
5.6.3 Contrast as a Function of TE ........................................................................................... 100 
5.6.4 Image Artifacts ............................................................................................................... 102 
5.7 3D- Reconstruction Design ................................................................................................ 104 
5.7.1 3-D Reconstruction Results ............................................................................................ 105 
6.0 Discussion .............................................................................................................................. 108 
6.1 T1-Weighted Images .......................................................................................................... 108 
6.2 T2-Weighted Images .......................................................................................................... 108 
6.3 Image Artifacts .................................................................................................................. 109 
6.4 Effectiveness of Contrast Agent ........................................................................................ 110 
6.5 Effect of Microthread Preparation Type ........................................................................... 110 
6.6 Contrast as a Function of TE .............................................................................................. 111 
6.7 Project Applications .......................................................................................................... 111 
5 
 
6.7.1 Economics ................................................................................................................... 111 
6.7.2 Environmental Impact ................................................................................................ 112 
6.7.3 Societal Influence ....................................................................................................... 112 
6.7.4 Political Ramifications................................................................................................. 113 
6.7.5 Ethics ........................................................................................................................... 113 
6.7.6 Health and Safety ....................................................................................................... 114 
6.7.7 Manufacturability ....................................................................................................... 114 
6.7.8 Sustainability .............................................................................................................. 115 
7.0 Final Design and Validation ................................................................................................... 116 
8.0 Conclusions and Future Recommendations ......................................................................... 119 
Table of Figures ........................................................................................................................... 121 
Table of Tables ............................................................................................................................ 124 
Works Cited ................................................................................................................................. 125 
Glossary ....................................................................................................................................... 129 
Appendix 1: Client Meeting Minutes .......................................................................................... 131 
Appendix 2: Objectives ............................................................................................................... 132 
Appendix 3: Functions ................................................................................................................ 135 
Appendix 4: Calculations for Specifications ................................................................................ 137 
Appendix 5: Design Alternatives ................................................................................................. 144 
Appendix 6: Preliminary Data ..................................................................................................... 151 
Appendix 7: Results ..................................................................................................................... 165 
Appendix 8: Compiled and Revised Gantt Charts ....................................................................... 169 
 
 
 
6 
 
Authorship 
The three project team members, Jaynath Bisa, Evan Demers-Peel, and Matthew Gonsalves, 
contributed equally to the content found in this report. Extensive collaboration was 
demonstrated on each section while writing, revising, compiling, and finalizing the report   
  
7 
 
Acknowledgements 
The project team would like to thank the following group of individuals and organizations for 
their assistance in completion of the project.  
• Funding from Biomedical Engineering Department at WPI 
• MRI from Radiology Department at UMass Medical School  
• Salman Shazeeb for assistance with MRI testing  
• Jon Grasman, Deepti Kalluri, & the Microthread MQP Team for collagen microthread 
production 
Most especially the team would like to thank our MQP advisors Professor Christopher Sotak, 
Ph.D. and Professor George Pins, Ph.D. Their guidance and expertise over the past academic 
year has not only aided in the quality of our report, but also in the development of professional 
engineering design and written skills that will be utilized for years to come.     
 
 
 
 
 
 
 
 
8 
 
Abstract 
Magnetic resonance imaging (MRI) was used for accurate and dynamic monitoring of tissue 
embedded microthreads; a novel biomaterial utilized to promote cardiac regeneration. An in 
vitro cardiac modeling system was developed that mimicked the MRI properties of native 
cardiac tissue by using gelatin of varying concentrations.  Microthreads were treated with an 
iron-based superparamagnetic MRI contrast agent (ferumoxtran), embedded into the cardiac 
modeling system, and then imaged using MRI. Based on experimental measurements, the 
concentration of MRI contrast agent used to treat the microthread was chosen to optimize 
the MRI contrast between the microthread and the surrounding gelatin in the cardiac 
modeling system.  T1- and T2-weighted MR images showed no statistical difference between 
actual thread location and diameter when compared with the same measurements obtained 
from optical images of the same cardiac modeling system. Microthread location and diameter 
measurements were affected by susceptibility artifacts caused by the ferromagnetic 
properties of the applied MRI contrast agent. 
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1.0 Introduction 
Myocardial infarction (MI) – more commonly known as a heart attack – has become an 
increasingly prevalent topic of interest in the medical field today, particularly as a result of its 
increasing incidence. Affecting 8 million Americans in 2005 alone, and resulting in the death of 
roughly 1 in every 40 incidents, MI has been a leading contributor to cardiac related deaths. 
[17] A myocardial infarction (MI) occurs when blood flow from the pathways within the 
coronary arteries to the cardiomyocytes are significantly restricted. If the restriction is large 
enough or persists for an extended amount of time, a portion of the cardiac muscle becomes 
ischemic and eventually dies. [24] Unfortunately, lost cardiomyocytes, which can total up to 25 
percent of the cells found in the heart, are unable to be regenerated via natural processes. The 
inability of the heart to restore a significant portion of cellular myocardium lost after infarction, 
if left untreated, can result in further cardiac-related health issues, including reductions in 
cardiac performance and increases in the risk of ventricular aneurysm and rupture. [41] 
Currently, treatments for myocardial infarction are limited to interventions that only limit the 
subsequent effects and include prescription medications, coronary-artery-bypass grafting 
(CABG), and ventricular remodeling via surgery.  
The application of human mesenchymal stem cells (hMSCs), have been proposed for 
cardiac cell therapy post MI, primarily because they can be grown efficiently in culture and 
possess the potential to differentiate into cardiomyocytes. [42] Currently, in pre-clinical and 
clinical studies, there is an assortment of means to transplant hMSCs into the heart to promote 
myocardial regeneration. These means can be generally categorized into infusion, injection, and 
biomaterial techniques. Progression of infusion and injection techniques of stem cells have 
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been limited, as cell retention, differentiation, and integration rates have been minimal. The 
development of specific biomaterials designed to direct cellular behavior; an attribute that the 
previous methods have lacked, however, is an emerging technique implemented to control 
local cellular microenvironments and increase proliferation rates. [20] In general, there are still 
limitations to these biomaterials, specifically in their inability to diffuse growth and 
differentiation factors into the infarcted area. A solution to this current problem could 
potentially be found utilizing recently developed tissue-embedded microthreads. These 
microthreads provide superior structural properties and the ability for site-specific and 
controlled scaffold placement. [6,7] 
Currently, monitoring methods for microthread placement are limited to histological 
techniques.  Histology allows for the effective examination of the anatomy and physiology of 
complex organs, as well as cell activity and function. A histological slide or “section” of tissue is 
prepared by first cutting a thin slice, typically anywhere from 3 to 10 microns thick, from the 
extracted tissue.[14,26] Staining (enhancement of cell components), mounting, and covering of 
the section then must occur prior to observation and analysis. The process as a whole is long 
and arduous, but unavoidable in order to effectively view static cell activity and function. [4,14] 
The compilation and examination of the anatomy and physiology of complex organs via 
histological analysis is  laborious, intricate, and inefficient. 
The goal of this project was to develop a method to efficiently and effectively monitor 
the placement and functionality of microthreads using Magnetic Resonance Imaging (MRI). MRI 
is a noninvasive imaging tool that is able to noninvasively deduce the nuclear magnetic 
resonance (NMR) properties of tissue and interstitial space within the body.  The varying 
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relaxation rates of water protons within a specific body, tissue, or specimen varies. These 
variations in relaxation rates correspond to varying spatial signal intensities and ultimately 
create contrast in the acquired image that allow for distinction of anatomy.  [15, 21]   
Following a detailed design process during which project objectives, constraints, 
functions, specifications were defined and alternative designs were created and tested. 
Ultimately the final design consisted of a simple and inexpensive gelatin-based cardiac 
modeling system, where gelatin of varying concentrations was used to mimic the MR relaxation 
properties of normal and diseased cardiac tissue. Collagen microthreads were soaked in 
Ferumoxtran, superparamagnetic iron oxide nanoparticles that serve as a “negative” MRI 
contrast agent.  Ferumoxtran produces more contrast (I.e., MRI signal intensity difference) 
between the threads and surrounding tissue, effectively increasing the ability to locate the 
threads and differentiate their boundaries. To produce results consisted with project goals, 
gelatin and contrast agent concentrations were determined via initial MR relaxivity 
measurements as a function concentration. Utilizing the preliminary data and the knowledge of 
MR imaging, appropriate parameters for the final design could be determined. With the project 
team confident the modeling system would mimic in vivo results and embedded microthreads 
would be easily distinguishable, design variables – specifically contrast agent exposure time – 
were varied to further optimize results. Thread exposure time and hydration were both 
examined to determine if they had an effect on resulting thread signal contrast and thus 
differentiation.  
Results and conclusion from the experiment verified the calculations made regarding 
properly designed cardiac phantom and MR parameters. The microthread location in the 
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cardiac phantom was apparent and statistically similar in diameter regardless of the agent 
application process. Apparent microthread diameter estimated from the MR images was 
statistically comparable to that measured from optical images of the same microthreads, 
suggesting that the current design and procedure is highly accurate. Accurate in vivo thread 
location and measurements using MRI techniques requires significantly less time as compared 
to histological methods.  This approach offers the client and all potential users a significantly 
improved method for not only thread visualization, but also as a means to evaluate stem cell 
delivery and potential myocardial regeneration.            
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2.0 Literature Review 
2.1 Basic Functions of the Heart 
The circulation of blood throughout the body is achieved by the constant, repeated 
contraction and relaxation of the heart. [31] The heart acts as a mechanical pump, taking in 
deoxygenated blood via the vena cava, cycling it through the lungs, and pumping out 
oxygenated blood to the body. The heart can be divided into two sections; the right and left 
side.  To help summarize the process in which deoxygenated blood becomes oxygenated and 
circulated throughout the body, Figure 1 below illustrates the passage of blood flow into and 
out of the heart. 
 
Figure 1: Cross Section and Blood Flow of Heart [18] 
The right side of the heart functions to receive deoxygenated blood from the body and 
transfer it into the lungs. Deoxygenated blood is pumped into the heart at the right atrium, a 
thin-walled muscular chamber, via the superior vena cava, inferior vena cava, and the coronary 
sinus. During ventricular diastole a pressure gradient causes blood to flow through the tricuspid 
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valve, into the right ventricle. The right ventricle then contracts, expelling the blood through 
the pulmonary arteries and into the lungs where oxygenation occurs between the alveolar sacs 
of the lungs and the surrounding capillary beds. [31] 
The left side of the heart functions to receive oxygenated blood from the lungs and 
deliver and distribute it around the body as needed. The oxygenated blood from the lungs 
enters the left side of the heart at the left atrium, a thin-walled chamber similar to the right 
atrium, via the pulmonary veins. The pressure gradient from the atrium to the ventricle caused 
during diastole results in the flow of blood to flow through the bicuspid valve, into the left 
ventricle. The left ventricle then contracts, increasing the ventricular pressure, causing the 
aortic valve to open, and allowing circulation throughout the body. The increased pressure in 
the left ventricle, during the ventricular contraction is known as systole and forces the bicuspid 
valve close, preventing blood from re-entering the left atrium. As a result of the corresponding 
forces necessary to generate sufficient pressure to transport blood through the body it is 
important to note that the left ventricle is typically three times thicker than the right ventricle. 
[31]  
2.2 Myocardial Infarction 
Every segment of the heart plays a significant role in the circulation of blood. The 
cardiac muscle composing the walls of the heart, known as the myocardium, is responsible for 
the diastolic and systolic functions of the ventricles which ultimately transports blood. In order 
for the myocardium to perform these rhythmic contractions, it must receive oxygenated blood 
from the coronary arteries. If blood vessels within the coronary arteries are blocked, the 
surrounding myocardium is deprived of oxygen and nutrients, and metabolic and physiological 
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changes occur within seconds. [24] Immediately after all of the available oxygen in the 
myocardium is consumed the tissue becomes oxygen deprived and the means by which energy 
is metabolized in the heart changes from aerobic to anaerobic glycolysis. As a result the 
myocardium expands with each subsequent cardiac cycle because it no longer has sufficient 
energy to contract. This lack of energy is caused by the cardiomyocytes, which demand more 
ATP (in an attempt to cause contraction) than anaerobic glycolysis can supply. Hydrogen ions 
accumulate in the myocardium as anaerobic glycolysis continues and the pH of cardiomyocytes 
decreases, ultimately causing edema in the myocardium. Over time, the formation of edema 
causes the heart to swell and the surrounding cardiomyocytes to permanently die. This 
physiological phenomenon is known as a myocardial infarction (MI). [13,18,24] The dead or 
infarcted tissue forms a scar within weeks to months of MI as fibroblasts accumulate fibrous 
collagen in the area of infarct. Further expansion of the infarcted tissue and myocardial 
collagen degradation occurs when neutrophils infiltrate the area of infarct and release matrix 
metalloproteinase (MMPs) as an inflammatory response. [39]   
According to the American Heart Association, MI affected 8 million Americans in 2005 
alone [17]. Those who have survived an MI are likely experience lifelong side-effects and 
increased cardiac-related health risks caused by their permanently weakened heart. [18] 
Unfortunately, 50-70% of heart attack survivors die within 5 years because of a lack of effective 
treatments. [42] 
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2.3 Clinical Treatments of Myocardial Infarction 
 The inability of the heart to restore the often significant portion of cellular myocardium 
lost via myocardial infarction, if left untreated, can result in further cardiac-related health 
issues. In particular, the region of dead, scarred tissue that replace necrotic tissue in 
subsequent weeks following an infarction often become increasingly thin and dyskinetic, 
resulting in the deformation of the left ventricular cavity. [14, 15] This deformation, in 
conjunction with the initial loss of functional myocardium, results in significant reductions of 
cardiac performance. The ejection fraction, defined as the fraction of blood ejected from the 
total volume contained within the ventricle, has been noted to decrease with increasing infarct 
size. The decrease in the ejection ratio results in an array of compensatory responses, initiated 
in attempts to maintain adequate stroke volumes and thus cardiac functionality. As depicted in 
Figure 2, larger ventricular volumes are generated to maintain proper ejection volumes but 
result in an undesirable increase in ventricular pressure, putting the chamber at risk of 
aneurysm and rupture, particularly in the area of thin infarct tissue. [41]   
 
Figure 2: Increase in LV Pressure (B) in an attempt to 
Maintain Efficient Stroke Volume [23] 
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Currently, treatment methods of myocardial infarction are limited to interventions that 
only treat its effects. Prescription medications and coronary artery bypass grafting (CABG) are 
the most commonly utilized treatments although relatively new remodeling techniques have 
gained popularity over the past 5 years. [22] Therapeutic intervention via medication aim to 
improve cardiac heart function post MI through the usage of cardio-stimulatory and vasodilator 
drugs. Cardio-stimulatory drugs increase cardiac output by increasing heart rate and myocardial 
contractility. Pumping small volumes of blood more rapidly and efficiently, as opposed to 
pumping greater volumes less often, significantly reduces undesirable ventricular pressures and 
the associated risks. Vasodilator drugs aim to reduce the high blood pressure and stress on 
ventricular chambers caused by post MI responses via relaxation of smooth muscle and dilation 
of the corresponding blood vessels. Vasodilator drugs can achieve reduced blood pressure via 
dilatation of arterial or venous vessels, with most consisting of a mixture of the two. [22]  
 Although increasingly popular, the application of prescription medication to maximize 
cardiac output normalcy has obvious limitations. Medications do well in easing the stress on the 
ailing heart, but do nothing to restore it back to its original condition. The significant loss of 
cardiomyocytes, thinning of ventricular walls, and bodily compensatory responses post MI 
make heart failure imminent, as five-year survival rates drop below 50%. [42] Regardless of the 
survival forecasts, the lack of better treatment methods has resulted in continual market 
growth, as sales of post-MI therapeutics are projected to exceed $13 billion in 2012. [11]   
 Developed in 1954 by Charles Bailey, the evolution and use of ventricular remodeling 
methods over the past half decade has becoming increasing popular as clinical trials have begun 
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to demonstrate its effectiveness. [1] Currently, the two surgical procedures of choice in 
remodeling are direct linear closure and endoventricular patch plasty.  Although numerous 
studies and clinical trials of these surgical methods have been implemented, it is not yet clear 
which, if any, offer significantly better short and longer term results. [1,41] In direct linear 
closure, remodeling of the misshapen and malfunctioning tissue involves removal of the 
infarcted myocardium. The remaining heart tissue is then directly sutured back together in a 
way that maximizes restoration of the elliptical shape of the left ventricle. This procedure is 
extremely invasive, and also has many complications that could occur. If, however, there is not 
sufficient myocardial tissue available to achieve the proper ventricular dimensions, the use of a 
patch is employed. [25] In endoventricular patch plasty, patches typically 2.5 – 5 cm in diameter 
are sutured in place of the removed infarct to ensure sufficient ventricular volume and shape. 
[41] A balloon with a known volume of typically 60 mL/m2 is inflated within the left ventricle as 
a guide, with sutures placed around the incision to tighten the ventricle to the shape of the 
balloon. Remodeling of the misshapen heart using this procedure can be seen below in Figure 
3.  
 
 
 
Figure 3: Endoventricular Patch Plasty or Dor Procedure 
Photo Credit: Kathleen Wagner, Medical Illustrator 
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While this surgical technique restores normal ventricular dimensions and pressures, it 
does not accommodate for the loss of cardiomyocytes and ventricular contractile force. 
Furthermore, the materials utilized for the patch are often significantly stronger than native 
myocardium and produce surrounding areas of fibrosis, contributing further to variances in 
regards to normal cardiac functionality. The unwillingness of numerous surgeons to exclude 
necrotic normal appearing segments, often encountered after early reperfusion, has further 
attributed to the lack of method implementation. [2] Instead, coronary artery bypass grafting 
(CABG) is performed and the non-functioning muscle segment is left undisturbed. CABG is done 
to restore blood flow to tissue beyond coronary blockages; however, this procedure does 
nothing to treat the infarct. 
  In spite of its disadvantages, the overall decrease in cardiac output via patch plasty and 
linear closure appears to have limited impact on morality rates in comparison to therapeutic 
treatments. Cumulative survival rates for both methods at 5, 10, and 15 years were 91, 81, and 
74%, respectively. [1] The procedure itself however, is particularly invasive and dangerous in 
comparison to proposed methods, as it requires opening of the chest cavity and fully arresting 
the heart. The thirty-day post-operation mortality rates among various studies were averaged 
and found to be, approximately 1 in 40. [1,25,41]  
2.4 Human Mesenchymal Stem Cells 
Human mesenchymal stem cells (hMSCs) are stem cells found in adult tissues, such as 
bone marrow, periosteum, trabecular bone, adipose tissue, synovium, skeletal muscle, and 
deciduous teeth. [42] Adult hMSCs are mostly found in bone marrow and like any other type of 
stem cell, hMSCs can divide indefinitely and differentiate into other types of cells, such as those 
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found in cartilage, fat, bone, and muscle. [42,32] Although hMSCs only represent about 0.001% 
to 0.01% of the nucleated cells in bone marrow, these cells can easily be isolated and 
developed in culture. Because they can be grown so efficiently in culture and possess the 
potential to differentiate into cardiomyocytes, hMSCs have been proposed for use in cardiac 
cell therapy after MI. [42,45] 
There have been several pre-clinical and clinical studies in which hMSCs have shown 
promise in cardiac cell therapy. In one study, five weeks after MI in a rat and four weeks after 
hMSC delivery into an infarcted rat heart, it was concluded that left ventricular function was 
significantly improved. [45] Another study done with the same time specifications as the 
previous one proved a significant decrease in infarct size and increase in left ventricular wall 
thickness. [40] Although such early studies have demonstrated the safety and effectiveness of 
hMSC in cardiac cell therapy, there are still several questions regarding the means by which the 
hMSCs differentiate into cardiomyocytes and ultimately improve cardiac function. [42]      
2.5 Stem Cell Delivery Techniques 
Currently there are a few different stem cell delivery techniques that are being 
employed in pre-clinical and clinical trials. The common means to deliver these cells are 
through infusion, injection, or with biomaterials. [42] 
2.5.1 Infusion Techniques 
The easiest way being researched to deliver stem cells into the heart today is by 
intravenous infusion. In this process, the stem cells are infused within a vein of the subject via a 
catheter (as shown in Figure 4). Although it is a simple procedure, the crucial drawback is its 
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inefficiency. It has been proven that a significant number of cells fail to reach the infarcted 
myocardium after infusion and reside in other organs. In one study, which was done 48 hours 
after MI, less than 1% of the stem cells actually reached the infarcted myocardium four hours 
after infusion. [42] 
 
 
Figure 4: Intravenous Infusion Method for Stem Cell Delivery [42] 
The most commonly practiced stem cell delivery technique in clinical trials today is 
intracoronary infusion. With this method, cells are delivered into the distal end of the infarcted 
coronary artery using an over-the-wire balloon catheter (as shown in Figure 5). A balloon 
catheter is necessary in this case to prevent backflow of the stem cells. The advantages of this 
technique are that it is inexpensive, easy to conduct, and repeatable. Unfortunately, there are 
numerous disadvantages of this procedure as well. One potential risk to the subject is coronary 
artery re-stenosis, which is the re-narrowing of the coronary artery. This re-stenosis is usually a 
result of expanding the artery via inflation of a balloon catheter (coronary angioplasty). There 
have also been noted instances of decreased coronary blood flow in the subject, as well as 
micro-infarctions in the artery caused by the infused stem cells impeding the passage of blood 
in the vessels. Another drawback of this procedure is its inefficiency, as the majority of the cells 
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do not remain in the heart and migrate to other organs. In one study, less than 10% of the 
infused stem cells remained in the myocardium. [42] 
 
 
Figure 5: Intracoronary Infusion Method for Stem Cell Delivery [42] 
2.5.2 Injection Techniques 
Transepicardial injection is emerging as a common practice in cardiac cell therapy and is 
often used in pre-clinical trials. This is a repeatable method, which is carried out by directly 
injecting the stem cells into the infarcted myocardium (as shown in Figure 6). This is performed 
usually through a small incision in the chest through which a needle is inserted directly into the 
heart wall. Experimental data suggests that this type of cell delivery may overcome the 
problems associated with intravenous and intracoronary infusion. The more significant 
advantage of transepicardial injection is that it is extremely effective in delivering the cells to 
the region of interest. An MRI study suggested that a significant number of injected stem cells 
remained in the target area, three days following the injection [66]. Some cells however 
migrated to other organs, such as the spleen, lung, and liver. Although one study has suggested 
that cell delivery by this method is relatively more efficient, other studies involving injectable 
procedures into the heart have indicated that the injected cells have only a limited amount of 
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time to adhere to the infarcted region. The cells that could not sufficiently adhere flowed back 
out of the heart from the point of entry. Thus, the efficiency of transepicardial injection is not 
yet clear [7,42]. 
 
Figure 6: Transepicardial Injection Method for Stem Cell Delivery [42] 
An emerging, new modality of stem cell delivery is transendocardial injection. With this 
method, stem cells are injected intra-ventricularly via an injection catheter into the border of 
the infarcted myocardium (as shown in Figure 7). The injection catheter is guided by a cardiac 
mapping system, which identifies the infarcted region. The mapping system is extremely 
reliable and currently both skin contact and non-contact systems are being evaluated. The 
NOGA™ System is an FDA-approved minimally invasive platform developed by Biosense 
Webster (Diamond Bar, CA) for catheter-based intra-myocardial navigation and mapping. This 
system utilizes low intensity, active magnetic field energy and sensor-tipped catheters to locate 
the position of the catheter in three-dimensional space. The NOGA™ mapping system requires 
skin contact with the use of body surface electrodes, while other systems such as the ESI™ 
system developed by Endocardial Solutions (St. Paul, MN), does not. The advantage of this 
guided method is that it overcomes the problem of site-specific delivery associated with 
intravenous and intracoronary infusion. One disadvantage of such technologically-advanced 
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electrophysiological cardiac-mapping systems is its relative cost in comparison to the previously 
discussed techniques. Another drawback is that this is an injectable procedure such as this 
allows only a limited time for the injected cells to adhere to the infarcted region of the heart, 
making its efficiency unclear [7,42].  
 
Figure 7: Transendocardial Injection with Cardiac Mapping System for Stem Cell Delivery [42] 
2.5.3 Biomaterials for Cardiac Regeneration 
 Induced cellular growth and differentiation is an extremely particular process, often 
requiring highly specific conditions and growth factors orchestrated in the surrounding cell 
microenvironment. [20] In current studies, central to cellular regeneration, the 
microenvironments in which cells are successfully delivered are of particular interest. The 
development of specific biomaterials designed to direct cellular behavior – an attribute that 
previous delivery methods have lacked – is an emerging technique to control local cellular 
microenvironments and increase proliferation rates.[20] Scaffolding materials are chosen and  
designed based upon various parameters necessary for possible regeneration, with common 
focal points including material degradation, compliance, porosity, and cellular adhesion. [20] 
 The optimization of biomaterials to satisfy the conditions necessary for the functional 
repair of infarcted myocardium has proven to be a daunting task. Biomaterials currently studied 
at the pre-clinical level for cardiac applications are numerous and most notably include 
25 
 
alginate, gelatin, collagen, Matrigel, self-assembling peptides, and fibrin. [7,22,27,33,34,38] 
Although these materials possess many of the qualities necessary for guided cell growth, 
chemical modifications prior to implantation are often made due to poor vascularization and 
cellular adhesion, inflammatory responses, instability, and toxic degradation. [7,46] Pre-clinical 
testing of various “optimized” biomaterials has shown great promise in both cellular delivery 
and cardiac regeneration via increased neovascularization, myofibroblasts, and cardiac 
function. [6,22,27,34,38] Currently, an outstanding issue of material delivery has been a limiting 
factor in the progression of the concept.  
2.5.3.1 Patches and Gels 
 There are many proposed delivery techniques used to introduce these biomaterials 
including injectable gels, patches, and glues. [10,34,38,27,22] While the previously mentioned 
biomaterials show much promise in their ability to mimic the specific conditions needed for 
cellular growth and differentiation, integration of the biomaterial, particularly in the heart, has 
been met with little success. Delivery via injectable gels and glues typically results in limited 
amounts of cellular retention and transplant survival. [6] The bolus injected is given a limited 
amount of time to solidify or adhere to the area of infarct, and is often extruded away from the 
target area by the beating heart through the point of entry.  The uneven cellular distribution 
found in injected gels is also a limitation in treating specific target areas in full. [6,20] The 
application of bioengineered patches on the region of infarction is similarly plagued with 
problems.  Typically several millimeters in thickness, they are often unable to induce cellular 
diffusion towards the intended necrotic tissue, resulting in minute delivery percentages. The 
average thicknesses of the patches are also typically too large to support vascularization and 
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nutrient diffusion throughout the scaffold thickness, limiting the feasibility of the construct 
while in vivo. [6,33] 
 Ultimately, the absence of a technique that addresses the needs of a biomaterial 
construct in full has led to limited progress towards the fulfillment of significant myocardial 
regeneration. In order to become a viable technique, site-specific and controlled scaffold 
delivery must be obtained while suitable to the highly specific conditions regarding cellular 
diffusion, growth, viability, and differentiation.  
2.5.3.2 Tissue Embedded Microthreads 
 As opposed to the previously mentioned biomaterials, the application of microthreads 
as engineered scaffolds for cardiac regeneration has been a more promising development due 
to their combination of structural properties and compatibility. [8,9] Microthreads, which are 
often similar in structure and mechanical strength to natural tissue, are known to aid in cellular 
migration, and are biocompatible and bioreabsorbable. In particular, collagen and fibrin have 
been the material of choice for experimental thread-based delivery based upon numerous 
structural and cellular properties.   
 Collagen is the major insoluble fibrous protein in the extracellular matrix and in 
connective tissue. This matrix in the heart is a major determinant of myocardial stiffness as it is 
responsible for the support and alignment of myocytes and capillaries. [12] Found in the later 
stages of wound healing, collagen deposition increases the strength of the wound. Collagen is 
also a natural substrate for cellular attachment, growth and differentiation, and promotes 
cellular proliferation and differentiation. [35] Although there are numerous types of collagen in 
the body, approximately 85 percent consists of types I, II, and III. [35] To date, collagen 
27 
 
biomaterial experimentations have been largely based upon type I collagen in the form of gels, 
glues, and most recently microthreads. [35] In many cases, collagen gels have encouraged 
cellular growth; however, these materials often lack sufficient mechanical strength necessary 
for the regeneration of load-bearing tissue. [8] Collagen is also a biodegradable molecule 
broken down by metabolic processes. The biodegradability of collagen can be reduced 
however, by the introduction of cross-linking. [5] Threads composed of collagen have been 
investigated in vitro and in vivo for regeneration of various tissues with promising results 
regarding cellular attachment and proliferation. [8] 
 Fibrin is a fibrous protein formed from the conversion of fibrinogen, a glycoprotein in 
the blood, into fibrin by the enzyme thrombin. In the body, fibrin plays a large role in the initial 
stages of tissue regeneration via a provisional matrix that fills the wounded area and promotes 
the infiltration and containment of cytokines. These matrices assembled from fibrin, 
fibronectin, and vitronectin regulate cell migration, proliferation, and gene expression through 
integrin signaling. [9,36] The role fibrin plays in the provisional matrix, biocompatibility, and 
high binding affinity for growth factors has led to research and development of fibrin 
biomaterials for applications central to cardiac regeneration. To date, fibrin biomaterials 
produced have been gel- or glue-based, with varying mechanical and structural properties 
dependent on fibrin concentrations. [6, 7] Similar to collagen gels, these materials often lack 
sufficient mechanical strength necessary for the regeneration of load-bearing tissue. [8] 
 Fibrin microthreads have recently been developed and tested as a scaffold for cardiac 
regeneration. Experiments have demonstrated that fibrin microthreads have similar structural 
homology to native tissues and significantly greater mechanical strength in comparison to fibrin 
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gels. [6,9] In vitro studies have also proven the ability of fibrin threads to form 
microenvironments that mimic the highly specific physiologic conditions necessary for hMSC 
growth, migration, and differentiation. As depicted in Figure 8, microthreads range from 20-50 
μm, are roughly circular, able to be cross-linked for increased strength and stiffness, and can be 
loaded with growth factors to influence cellular processes. [9] Additionally, studies have shown 
that the substrata of microthreads woven together aid in the natural alignment and orientation 
of cells. [9] The ability of microthreads to be specifically placed in infarct target areas, as 
depicted Figure 9, in conjunction with optimal cell orientations, offer additional advantages in 
comparison to fibrin gels, as thread and cell containment increases the efficiency of cellular 
delivery.  
 
Figure 8: Microthread Size 
Photo Credit: George Pins PhD 
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2.6 Histological Techniques – Evidence base for non-invasive techniques. 
 The methods of tissue preparation fall in two distinct groups, the observation of living 
cells and that of preserved or “fixed” dead cells. *26+ The majority of tissue evaluations derive 
from fixed and prepared slides each of which is more or less permanent. A slide or “section” of 
tissue is prepared by first preserving the protoplasm, commonly in neutral buffered formalin, in 
a process called fixation. The tissue is then processed, using concentrated ethanol to dehydrate 
the sample and paraffin wax, turning the tissue into a hard paraffin block. The hard block is 
then cut into thin slices, typically anywhere from 3 to 10 microns thick, using a microtome. [14, 
26] Tissue mounting, staining (enhancement of cell components), and covering of the section 
then must occur prior to observation and analysis. This process as a whole is a long and 
laborious method, in which a days’ work typically yields only a handful of photographs, but 
unavoidable in order to effectively view static cell activity and function. [4, 14]     
 The examination of the anatomy and physiology of complex organs via histological 
analysis is similarly a laborious and intricate process. In theory, histological techniques have 
Figure 9: Site Specific Placement Tissue Embedded Microthread  
Photo credit: Glenn Gaudette PhD 
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been noted to produce superior spatial resolution and discrimination of cell types in 
comparison to magnetic resonance imaging (MRI), but are limited by their preparation and 
compilation processes. One must compile from the numerous two-dimensional sections, a 
three-dimensional picture in order to determine the significance of cellular activity. Histological 
images have to be registered, slice by slice, and transformed to create a 3D histological stack as 
depicted in Figure 10. [4] Compilation time aside, accurate tissue slice alignment is often lost 
during mounting and 2D imaging, resulting in the distortion of the 3D image. It must also be 
noted that static preservation techniques are not perfect and in instances can result in 
inaccurate representations prior to image compilation. Alterations in static conditions dubbed 
“artifacts” result in tissue shrinkage, folding, or wrinkling of sections, and can be attributed to 
various chemicals or imperfect sectioning during the preparation process. [26]     
 
 
 
 
 
 Studying the structure and function of living cells is less common, but holds numerous 
advantages in that these attributes can be observed simultaneously. The obvious limitation of 
observing living cells relates to the short time period in which they are usable. Preservation of 
living cells outside of the body has been achieved through the development of a technique 
known as tissue culture, in which the extracted tissue is placed in a physiological medium 
mimicking the natural environment.  
Figure 10: 3D Construct Via Histological Sectioning [26] 
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2.7 MRI Overview 
Magnetic Resonance Imaging (MRI) has proven to be an effective tool in the medical 
industry and has increasingly become the modality of choice for radiological examinations since 
its development and introduction in the 1970s. The imaging method, based principally on 
signals from water protons, allows for noninvasive evaluation of tissue and the surrounding 
medium in real time. Advancements in recent years have revealed its potential not only to 
visualize anatomy but also physiological processes, including cardiac regeneration. The physical 
principles regarding MR image acquisition are moderately complex, and thus great depth of the 
process will not be defined in this text. This section will cover a brief but concise description of 
fundamental nuclear magnetic resonance (NMR) principles, how this nuclear phenomenon is 
acquired to construct an accurate image, and an overview of different types of images and their 
image acquisition parameters. This section, adapted from Haacke[15], Hornak [21], 
McRobbie[29], Smith[37], and a dissertation by Stuart Howes[63], will help to provide an 
adequate understanding of the MRI principles necessary to follow the subsequent experimental 
design and analysis. If the reader wishes for a more in depth description of MRI and NMR they 
should refer to the texts cited for a more thorough description. 
2.7.1 Nuclear Spin in a Magnetic Field 
 Biological tissue contains a high concentration of water and the attached hydrogen 
atoms each have a magnetic dipole moment, which arises from the nuclear spin associated the 
unpaired proton in the nucleus. The associated magnetic field can be considered comparable to 
microscopic bar magnet (Figure 11) and is commonly represented as a vector quantity with 
both direction and magnitude. [29]  
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Figure 11: Magnetic Moment of a Nuclear Dipole 
 These nuclear magnetic moments are oriented randomly in normal tissue, however, in 
the presence of an external magnetic field Bo provided by the MRI system, the nuclear magnetic 
moments of the water protons will aligned themselves in one of two possible directions 
(parallel or anit-parallel) with respect to the Bo field direction as shown in Figure 12.  The B0 
field is typically denoted in the Z-direction of a Cartesian coordinate system. The magnetic 
energy it takes for the nuclear magnetic moments  to align parallel to Bo is slightly less than the 
energy required to align in the anti-parallel orientation, resulting in a slightly greater number of 
protons aligned in the parallel direction. [15] Since each nuclear dipole in the anti-parallel state 
cancels out one nuclear dipole in the parallel state, there is a slight excess of nuclei in the lower 
Figure 12: Parallel and Anti-Parallel Orientation 
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energy state at equilibrium, resulting in an overall net magnetization vector M0, shown as the 
red arrow in Figure 13, which is aligned with the B0 field.  
 
Figure 13: M0 Vector 
 As depicted in Figure 14, the B0 field also exerts a force (torque) on each of the 
individual nuclear magnetic moments which, because of quantum mechanical constraints, are 
inclined at an angle with respect to Bo.  As a result, the nuclear magnetic moments precess 
about the direction of the B0 field. [37] This precessional motion is characterized by an angular 
frequency which is denoted as ω0. The angular frequency of protons, known as the Lamor 
frequency, is proportional to the applied external magnetic field given by: 
ω0 = B0 
Equation 1: Larmor Equation [29] 
where γ is the gyromagnetic ratio, a constant unique to each nuclei, and B0 is the strength of 
the external magnetic field. For a hydrogen proton, γ is approximately 2.68 x 108 rad/s/Tesla. 
The range of the angular frequencies experienced by atoms in typical magnetic fields is 
approximately equivalent to the frequency range of radio waves (3 KHz to 300 GHz). [37]  
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Figure 14: Nuclear Precession and Angle 
2.8 MRI Parameters and Their Physical Origins 
When at equilibrium, the protons in the system align with the applied B0 magnetic field, 
producing an overall net magnetization (M0) that is completely aligned in the z-direction and is 
often referred to as the longitudinal or Mz magnetization. At this point, MZ is equal to M0 and 
there is no magnetization within the plane perpendicular to the magnetic field; this is referred 
to as the transverse or X, Y plane (Figure 15). The transverse magnetization, MXY, is equal to 
zero at equilibrium. [21]   
 
Figure 15: NMRI Coordinate System 
A radiofrequency (RF) coil is used to excite the protons within the system and move 
them out of equilibrium by sending a current through the RF coil.  This current is at a frequency 
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equal to the precession frequency of the protons in the system.  This creates a resonance 
condition and forces a transfer of energy to the nuclei. The applied current can be controlled in 
order to force the net magnetization vector, M0, of the system to be rotated at a specific angle 
away from the direction of the B0 magnetic field depending on the duration of the RF 
excitation. [15] In the process, transverse, MXY, magnetization is created. The system then 
returns to equilibrium as a function of time. The RF coil that excites the nuclei can also be used 
as a current detector.  This coil detects the current that is induced by the transverse, MXY, 
magnetization as it returns to its equilibrium state.  This detection forms a signal which looks 
like a dampened sine wave.  This is known as the free induction decay (FID), which in normal 
MR imaging is never directly measured. Instead signal echoes are created and measured which 
are described in the following sections.[29] 
2.8.1 Longitudinal Relaxation 
The longitudinal relaxation is also referred to as the spin-lattice relaxation time.  As 
depicted in Figure 16, an applied 90° RF pulse causes the net magnetization of the M0 vector to 
rotate from the MZ into the MXY plane. Immediately after the 90° RF pulse MZ equals zero and 
MXY equals M0. [21] The nuclei then relax back to their alignment along the MZ direction until 
the equilibrium state is restored. The longitudinal relaxation time is a measurement of the 
amount of time it takes for the nuclei to return to their equilibrium state (in the Z-direction) 
after the system is excited by a 90° RF pulse. 
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Figure 16: Mo Vector Rotation into the Transverse Plan following 90° Pulse 
The nuclei dissipate the acquired energy with the surrounding environment, commonly 
known as the lattice, which is where the name spin-lattice relaxation originates. While the 
longitudinal MZ magnetization returns to equilibrium, the transverse MXY magnetization created 
following the 90° RF pulse returns to zero, its equilibrium value. The mathematical equation 
representing the behavior of the longitudinal magnetization as a function of time, i.e., MZ (t), is 
given in the following equation:  
MZ (t) = M0 (1 - e
-t/T1) 
Equation 2: The Change in Transverse Magnetization as a Funtion of Time [29] 
where t represents time, and T1 is the time constant associated with the rate of recovery of 
longitudinal magnetization, which is different for each different kind of tissue. The time scale is 
equal to zero immediately after the RF pulse is turned off. The T1 parameter is typically defined 
as the amount of time that it takes for the magnetization to recover to 63% of its equilibrium 
value after the RF pulse is applied.[37]  Figure 17 shows a plot of Equation 2 using the T1 
relaxation times of 898 ms and 382 ms for muscle and fat, respectively.  At a RF pulse repetition 
time (TR) of approximately 650 ms, the curve shows the relative difference in signal intensity 
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between the two different tissues is based on differences in their intrinsic T1 relaxation time 
values. This is the fundamental basis of T1-weighted MRI as a means of distinguishing between 
different tissue types.  
 
 
 
 
 
 
 
Figure 17: T1 Recovery of Muscle vs. Fat 
2.8.2 Transverse Relaxation 
Transverse relaxation is another parameter that can be used to distinguish tissues. 
Transverse relaxation, unlike its counterpart, longitudinal relaxation, is a much faster process. 
Instead of this relaxation occurring in the longitudinal direction, it occurs within the transverse 
plane. This can also be commonly referred to as spin-spin relaxation, because the energy 
exchange that is measured between the various spins within the system itself.  Immediately 
after the initial 90° RF pulse, all of the nuclear magnetic moments are aligned in the transverse 
plane. The spins then begin to separate, or un-align,  because of the variations within the local 
magnetic field; which lead to variations in the precessional frequencies of the nuclei.  These 
frequency variations, as shown in Figure 18, tend to cause the spins to “fan out”.  
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Figure 18: Un-alignment of Nuclear Spins Over Time 
This reduces the overall net magnetization in the transverse (XY) plane. [15] This 
ultimately results in the overall sum of all transverse components converging to zero. The 
mathematical equation that shows the behavior of the transverse magnetization as a function 
of time, i.e., MXY (t), is given by:  
Mxy (t) = M0 e
-t/T2 
Equation 3: Change in Transverse Magnetization as a Function of Time [29] 
where t represents time, and T2 is the time constant associated with the rate of decay of 
transverse magnetization, which is different for each different kind of tissue. Just like the 
longitudinal magnetization, the time scale is equal to zero immediately after the 90° RF pulse is 
turned off. The T2 variable is defined as the amount of time that it takes for the transverse 
magnetization to decay to 37% of its initial value. [37] In comparison to the longitudinal 
equation, the T2 relaxation time is always less than or equal to the T1 relaxation time. Figure 19 
shows the plot of Equation 3 using the T2 relaxation times of 29 ms and 68 ms of muscle and 
fat, respectively. At an echo time (TE) of approximately 45 ms, this curve shows the relative 
difference in signal intensity between the two different tissues. This is the fundamental basis of 
T2-weighted MRI as a means of distinguishing between different tissue types. 
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Figure 19: T2 Decay of Muscle and Fat 
2.8.3 Image Acquisition 
When attempting to acquire an MR image, there are electrical signals being detected 
from the protons at different locations within the specimen being imaged. These signals are 
then mapped back to their spatial locations when reconstructing the image. Each picture is 
made up of multiple pixels. An image is typically thought of as having x and y coordinates. This 
allows each pixel to have its own defined location using a specific set of x and y coordinates. 
The data recorded is primarily thought of as the amount of current induced within the RF coil 
from that location in space. This data has to be mapped from its location within the specimen, 
back to a specified location within the image itself. This is done with slice selection techniques, 
frequency-encoding magnetic field gradients, and phase-encoding magnetic field gradients. 
These techniques are able to encode the spatial position of the protons within the sample. 
A magnetic field gradient varies the magnetic field strength with respect to position. For 
example, a one-dimensional linear magnetic field gradient along the x axis in a magnetic field 
increases the magnetic field linearly in the x direction. These gradients can be applied in the x, 
y, and z directions are denoted Gx, Gy, and Gz respectively. This creates a range of MR 
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frequencies, with the acquired signal amplitude proportional to the number of nuclei at each 
location along the direction of the magnetic field gradient. This technique is called frequency 
encoding and causes the resonance frequency to be proportional to the spatial position of the 
nuclei giving rise to the signal. [21] 
Slice selection in MRI is the selective excitation of nuclei in a particular plane via a one-
dimensional, linear magnetic field gradient during the period that the RF pulse is applied. As 
depicted in Figure 20, a 90o pulse applied in conjunction with a magnetic field gradient will 
rotate spins which are located in a slice or plane. Slice selection is the first process applied to 
encode the spatial signal location, followed by a phase encoding gradient and the 
previously mentioned frequency encoding gradient. Each pixel corresponds to a specific slice 
in the specimen, based upon the phase and frequency of the data collected. The signal is 
processed and separated into its different components through the application of the Fourier 
transform. [15]  
 
Figure 20: Slice Selection via Field Gradients and a 90⁰ RF Pulse  [21] 
 The phase encoding gradient determines the spatial signal location along a second 
dimension by variations in the phase of the transverse magnetization. The phase encoding 
gradient assigns a specific phase angle to a transverse magnetization vector which is dependent 
on the location of the transverse magnetization vector along the direction of the phase 
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encoding field magnetic gradient. A gradient in the magnetic field when applied along the X 
direction will result in vector precession about the direction of the applied magnetic field 
(Figure 21). While the phase encoding gradient is on, each transverse magnetization vector has 
its own unique Larmor frequency according to the vector location along the gradient. If the 
gradient in the X direction is turned off, the external magnetic field and thus the Lamor 
frequency of each spin vector will again be identical. As depicted in Figure 22, the phase angle 
of each vector however is not identical because of the previously applied phase encoding 
gradient. This difference uniquely defines the spatial location of the nuclei along the phase 
encoding gradient direction.  
 
Figure 21: Vector Phase prior to Phase Encoding Gradient 
 
Figure 22: Vector Phases after Phase Encoding Gradient 
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2.8.4 Image Weighting 
Each of the relaxation processes, longitudinal and transverse relaxation, occurs 
simultaneously. Therefore, the resulting signal contains contributions from both relaxation 
rates. Individual relaxation data can however be differentiated through a process known as 
image weighting. Image weighting can be achieved by varying the pulse sequences applied to 
the RF coil to select which relaxation process dominates the image. [29]  
There are two basic timings regarding RF pulse sequence, which when altered 
correspond to a different type and strength of weighting; TE interval, or echo time, which is the 
time at which the signal is measured after the pulse happens, and TR interval, which is the time 
between excitation repetitions of the RF pulse.[21] 
When creating a T1-weighted image, short TR and TE intervals are used. This is used to 
enhance T1 contrast and to minimize T2 contrast. When creating a T2-weighted image, long TR 
and TE intervals are used. These ultimately enhance T2 contrast and minimize T1 contrast. 
Another type of image-weighting is known as proton-density weighting. This is obtained by 
using long TR and short TE intervals. This reduces both T1 and T2 contrast, which can be 
extremely useful in determining the water content in a given specimen. [29] 
2.9 Contrast Enhanced Imaging 
Relaxation times of water protons can be manipulated by using MRI contrast agents. 
The principles of how these agents work is beyond the scope of this project. When introduced 
at minimal, non-toxic concentrations, these agents interact with the 1H protons to reduce their 
T1 and T2 relaxation times. This then enhances the image contrast and allows for better analysis 
of targeted areas. Negative contrast agents are typically small, coated microcrystalline 
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magnetite particles often called superparamagnetic iron oxide (SPIO). These agents produce 
local field inhomogeneities via spin-spin relaxation effects, resulting in shorter T2 relaxation times. 
Positive contrast agents cause a reduction in the T1 relaxation time. The active element is typically 
gadolinium, manganese, or iron; which have unpaired electron spins in their outer shells. The 
ability of contrast agents to cause an increase in proton spin energy or decrease in proton spin 
energy will result in the targeted medium to either brighten or darken, depending on whether 
T1- or T2-weighting is being used, respectively. [29, 63] 
Gadolinium chelates have been commonly used as MRI contrast agents to essentially 
highlight certain tissues of interest. Superparamagnetic iron oxide (SPIO) particles were 
introduced after gadolinium-based agents and are often used to facilitate in differentiating 
between healthy and damaged tissues. [62] Due to their numerous advantages, they are now 
recognized as the preferred MRI contrast agent for certain applications. These particles provide 
the most change in signal intensity, especially in T2 weighted images, and they mitigate the low 
contrast agent sensitivity of MRI since they are composed of thousands of iron atoms. Unlike 
gadolinium-based agents, SPIO particles are biocompatible since they are composed of 
biodegradable iron which could potentially be reused by cells for iron metabolism. Some other 
advantages of SPIO particles are: (1) that their surface is usually coated with dextran, which 
allows for straightforward chemical linkage of functional groups and ligands; (2) they can be 
easily distinguished by electron and light microscopy; (3) and they can be magnetically 
manipulated according to size. [63]    
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3.0 Project Strategy 
 Preliminary efforts to create a logical and effective approach to the project were 
concentrated on understanding and building upon the initial client statement. Through 
feedback and consistent communication with the clients and potential users, project objectives, 
functions, and constraints were defined, helping to provide clearly defined project goals and 
establish direction. A final revised client statement was written following this process and 
consistently referenced to gauge the compliance of each decision and procedure.      
3.1 Initial Client Statement 
 To design and develop an in vitro model system using MRI technology to non-invasively 
evaluate the position of tissue-embedded microthreads that are used as cell-delivery systems 
to promote the regeneration of cardiac muscle. 
3.2 Objectives Functions & Specifications 
3.2.1 Objectives: 
 Based on meetings with clients and potential users of the final product(Appendix 1: 
Client Meeting Minutes), as well as a review of relevant literature, design objectives were 
produced for the experimental procedure and structures involved via an objective tree. These 
objectives were based upon the qualities and functions that stakeholder’s ‘want’ the device to 
possess. Often apparently interchangeable, objectives were clarified and separated from goals, 
following the definition that objective statements claim what the design will be. Using a 
pairwise comparison chart, objectives were weighted in accordance to their importance to the 
stakeholders and considered in the design process. The implemented pairwise comparison 
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chart and objective tree can be found in Appendix 2: Objectives. A summary of these objectives 
are organized and defined below: 
Phantom Modeling System 
1. Cardiac phantom representation should be accurate.  
 
1.1. Material strength in comparison to native and ischemic cardiac tissue. 
1.2. MR relaxation parameters in comparison to native and ischemic cardiac tissue. 
1.3. Anatomically accurate shape and volume in comparison to a normal heart. 
1.4. Anatomically accurate volume of infarct area. 
 
1.4.1.  Shape of tissue. 
1.4.2.  Positioning of tissue. 
 
2. Cardiac modeling system should be stable and reproducible. 
 
2.1. Cardiac phantom composition should be consistent during subsequent tests. 
 
2.1.1.  Normal tissue representation. 
2.1.2.  Ischemic tissue representation. 
2.1.3.  Embedded microthread. 
2.1.4.  Applied contrast agent(s). 
 
2.2. Phantom component locations should be stable and reproducible during 
 subsequent tests. 
 
2.2.1. Normal tissue representation. 
2.2.2.  Ischemic tissue representation. 
2.2.3.  Embedded microthread. 
2.2.4.  Applied contrast agent(s) – minimal diffusion. 
 
3. Tissue component representations and microthread should be easily differentiated. 
 
3.1. Native and ischemic relaxation rates should be altered via contrast agents to 
obtain desirable differentiation. 
3.2. Microthread relaxation rate should be altered via contrast agents to obtain 
desirable differentiation. 
 
4.  Modeling system should be easy to use. 
 
4.1. Construction should be simple and directions complete. 
46 
 
4.2. Microthread placement and stabilization is easily achieved and maintained 
4.3. Cardiac phantom placement and stabilization in the MRI is easily achieved and     
maintained. 
4.4.  System alterations can be easily calculated and implemented. 
 
5.  Modeling system should be cost effective. 
 
Data Acquisition- Image Parameters 
1. Image parameters should be similar to those used in vivo. 
 
1.1. TE or echo time should be consistent with in vivo cardiac acquisition timing. 
1.2. TR time should be consistent with in vivo cardiac acquisition timing. 
1.3. Coil size in relation to the phantom should aim to achieve similar resolution. 
1.4. Spatial resolution (Field of view/ # Digital points) should be considered to 
 sufficiently view and accurately locate the embedded thread. 
 
2. Safety considerations should be defined and applied to design and procedures. 
 
2.1.  Usage of ferromagnetic material. 
2.2.  Usage of protective hearing equipment. 
2.3.  Local RF power disposition. 
 
3. Data acquisition should be easily obtainable and implementable. 
 
3.1. MR parameters can be easily altered via provided calculations. 
3.2. Acquisition of image is in a time efficient manner. 
 
4. Utilization of MR machine should be done in a time and cost effective manner. 
 
Data Analysis 
1. Analysis procedure should be applicable to images acquired in vivo. 
2. Software should allow for easy image analysis. 
3. Imaging software should display areas of differentiation accurately. 
 
3.1. Microthread location, size, and shape. 
3.2. Infarct location, size, and shape. 
 
4. Software analysis should be time and cost effective. 
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 When establishing the objectives of this particular project, desired design functions and 
attributes were organized into distinct categories as illustrated above. In conjunction, each 
category serves to address the defined goals in the most comprehensive manner possible. The 
first category, the phantom modeling system, serves to address and define all objectives 
encompassed in the in vitro modeling system. This included not only the cardiac phantom but 
microthread and contrast agent design and integration within the phantom. Objectives within 
the category were weighted according to their importance via input from our clients and 
potential users. Accuracy, precision, and reproducibility were considered to be the most 
important primary objectives for the modeling system, as they are directly correlated with the 
production of plausible and applicable results. The relative ease of use and cost effectiveness, 
although objectives, were considered important only after plausible results were achieved. The 
pairwise comparison charts and final weights for each level of objectives can be found in 
Appendix 2: Objectives 
 The next category of objectives defined and weighted included those relevant to data 
acquisition of the designed in vitro modeling system. The determination and design of how 
valuable data will be acquired via MRI is equally important in the fulfillment of the project 
goals. The aim of in vitro experimentation was to model in vivo conditions to establish proof of 
concept and refine methodology and safety procedures prior to preclinical or clinical trials. Any 
experimental parameters that are not applicable in vivo should immediately be discarded. In 
light of this information, using MR parameters that will be applicable in vivo was determined to 
be the objective of utmost importance. Safety when using MR equipment is, in relation to the 
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other two categories, a high priority. The usage of ferromagnetic material in and around MRI 
machinery can be particularly dangerous because of their attraction to the powerful magnets.   
 The analysis of the acquired data was the final category designed to more easily define 
project objectives in a complete and logical organization. Data analysis will utilize software and 
designed code to achieve desired analysis options and results. Accuracy and in vivo applicability 
were considered to be the most important primary objectives for data analysis, as they are 
again most directly correlated with the production of plausible and applicable results, and the 
achievement of defined goals.   
3.2.2 Constraints: 
 Similar to design functions, identified constraints of our project must be met in all 
aspects of design considerations. It is important to note that each component and procedure of 
the design process must be fully integratable with each object. Failure or incompatibility of 
components or procedures in any instance must be considered a project constraint. Identified 
constraints will ultimately be used to develop and define project specifications. Listed below 
are the primary constraints defined for this project: 
1. All materials and/or methods must be: 
a. Considered safe and non-detrimental to health of users and test subjects. 
b. Biocompatible within the experiment. 
c. Applicable to in vivo experimentation(s). 
d. Within the project budget. 
2. Excluding the cardiac phantom, all materials must be biocompatible with regards to in 
vivo experiments.  
3. Phantom size parameters must not exceed MRI machine parameters. 
4. Spatial resolution must be the same order of magnitude as the microthread. 
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5. The phantom modeling system and internal components must remain in a static 
position in the MRI machine during testing. 
6. The project must be completed within the allotted time frame. 
Constraints via Limitations 
1. Limitations of image noise reduction and contrast via image construction software and 
 contrast agents respectively.  
2. The ability of the tissue phantom and applied contrast agents to mimic the physiological 
 conditions found in normal and infarcted myocardium.  
3. The ability of the contrast agent(s) to remain in the area of intended delivery. 
3.2.3 Functions: 
 Objectives by definition are desired attributes that describe what the object will be, 
while a function is a task the designed device should do. In principle there are five primary 
objects that must be considered when establishing design functions: the microthread, tissue 
phantom, contrast agents, data acquisition, and data analysis. All objects or processes that do 
not directly agree with any of the defined functions should immediately be disregarded or 
reengineered. Listed below is a brief summary of the primary functions derived from the 
complete list found in Appendix 3: Functions 
1. Phantom modeling system should accurately and precisely mimic the corresponding in   
 vivo system.  
2. Application of contrast agent(s) should allow for differentiation of relaxation times of 
 the embedded microthread and phantom modeling system. 
3. Resulting image (via the phantom modeling system, data acquisition parameters, and 
 analysis tools) should display the desired differences in signal intensity between the 
 microthread and the surrounding tissue phantom. 
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4. Data acquisition and analysis tools should allow for 3D reconstruction of the cardiac       
phantom and embedded microthread. 
5.  Applied software should allow for microthread analysis.  
6. Resulting image (via the phantom modeling system, data acquisition parameters, and 
analysis tools) should accurately and precisely display microthread location. 
 
As stated above, the phantom modeling system should accurately and precisely mimic 
corresponding in vivo systems. The development of a model that represents an in vivo system is 
crucial to the eventual application of test parameters in vivo and relevance of collected 
experimental data. The application of contrast agent(s) will be the primary tool utilized to 
differentiate the embedded microthread. Doping (treating) the thread and targeted areas of 
the in vitro system should allow for sufficient differentiation via different relaxation times. The 
resulting image acquired given the experiment design and parameters should also display 
differences in signal intensity corresponding to differences in set relaxation times. It is 
important that the acquired images and designed analysis of them are accurate relative to in 
vitro experimental results.  
3.3 Specifications 
Following the definition of the project objectives, constraints, and functions; design 
specifications were defined. Specifications aim to denote the various standards that the design 
system must fulfill. There are certain specifications that must be met by individual components 
in order for the total design system to function properly. Similar to the defined objectives, 
project specifications were categorized into the phantom modeling system, the MR data 
acquisition, and the software image analysis tools. Categorization of specifications was utilized 
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in hopes to address project specifications to the fullest extent possible as well as evaluate the 
efficacy of the device after experimental analysis. The evidence base for defined specifications 
and calculations can be found in Appendix 4: Calculations for Specifications 
General 
1. Project must stay within budget, $156/person and $468 in total. 
2. Project must be completed by April 21, 2010. 
Phantom Modeling System 
1. Phantom must mimic the relaxation rates of both normal and ischemic heart tissue at 3T 
which are 31.9 ms and 44.1 ms, respectively (see Appendix 4: Calculations for 
Specifications). 
2. Phantom size must be no larger than 38 mm in diameter in order to fit inside the RF coil. 
3. Normal cardiac and ischemic cardiac representations must have MR contrast differences 
of at least 20% in order to accurately represent the differences expected in actual 
normal and ischemic heart tissue.  
Data Acquisition   
1. The field strength of the MRI machine is 3T. (Original field strength was to be 4.7T) 
2. Rate of change of the magnetic field must not exceed 60 dB/dt. 
3. Spatial resolution of the MR image must be the same order of magnitude as the micro 
thread for viewing purposes.  Resolution should be approximately 30 μm to account for 
2-3 pixels of the thread size. 
4. Image acquisition must mirror the heart rate of the patient (approximately 80 bpm).  
Data Analysis 
1. Microthread and tissue phantom must differ in signal intensity by at least 20%. 
2. Image size should be a 256 x 256 x 128 image.   
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3. Repetition times (TR) must be a minimum of 50 ms and a maximum of 800 ms and the 
echo time (TE) must be static, for T1 weighted image.    
4. Repetition times (TR) must be static, and the echo time (TE) must be a minimum of 10 
ms and a maximum of 200 ms For a T2-weighted image.    
3.4 Revised Client Statement 
The objective is to address the current constraints regarding the accurate and dynamic 
monitoring of cardiac regeneration using human mesenchymal stem cells (hMSCs). The design 
and development of an in vitro modeling system will consider safety, reproducibility, size and 
physiological specifications, and ease of use among other factors. Embedded microthreads 
utilized must be biocompatible and able to support hMSC growth, migration, and 
differentiation. Magnetic Resonance Imaging (MRI) will be used as the primary non-invasive 
modality to optimize the differentiation of normal and ischemic cardiac tissue and the 
embedded microthreads.  Introduction of MR contrast agents to increase differentiation should 
be safe, biocompatible, and contained within the intended area of delivery. Software analysis 
will facilitate in the acquisition of quantitative data concerning the microthread and infarct 
region, specifically its location and dimensions within the phantom. 
3.5 Project Approach 
3.5.1    Project Assumptions 
When developing a project approach several initial project assumptions in regards to the 
implementation of crucial design components were defined. These assumptions aim to 
rationalize the usage of materials and methodologies provided by the clients in their initial 
project statement. 
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 Implementation of MRI technology and contrast agents on an in vitro cardiac model 
representation is the best choice for non-invasive differentiation and analysis. 
 
 Microthread technology is among the most promising forms of cellular therapy and will 
aid in the progression of myocardial regeneration and cardiac functionality.  
 
 Completion of experimentation and analysis is achievable given project constraints, with 
the most notable being time, budget, and resource constraints. 
 
3.5.2 Project Goals 
Defined in the initial client statement, the primary goal of the project was to develop an in vitro 
cardiac modeling system and utilize MR technology in such a way as to evaluate and confirm 
the position of tissue-embedded microthreads. Primary users specializing in cellular therapy, 
specifically through implementation of biomaterials, have the need for an improved material 
evaluation method that is quick, easy, and accurate in comparison to current techniques. To 
fulfill the project goal a list of specific aims was defined: 
1. Design experimental parameters to increase accuracy and ease of thread location. 
a. Determine optimal MR settings applicable for phantom tissue differentiation. 
b. Explore contrast agent possibilities and agent concentrations as a technique to 
enhance microthread and tissue differentiation.  
 
i. Determine the best agent application methodology on the microthread.   
ii. Determine the best agent application methodology on the tissue 
phantom. 
 
c. Enhance software parameters for image analysis and thread differentiation.  
d. Design an image mapping system to enhance location confirmation.  
 
2. Design and develop an in vitro cardiac modeling system that mimics in vivo physiological 
parameters necessary for tissue differentiation via MR imaging. 
 
3. Develop an accurate 3D modeling system. 
a. Explore software and compilation possibilities to optimize microthread/tissue 
differentiation and thread location accuracy.  
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b. Explore the possibility of designing and implementing various 3D image analysis 
tools. 
3.6 Project Hypotheses 
In addition to the revised client statement, project hypotheses and specific aims were 
formulated in accordance with the defined project goals. The provided literature review was 
utilized to rationalize the various hypotheses made regarding MR imaging, cardiac phantom 
accuracy, and contrast agent differentiation.    
3.6.1 Hypothesis #1 
In comparison to current techniques, magnetic resonance imaging will allow for accurate, non-
invasive, and less time consuming detection and differentiation of infarct and normal tissue. 
Rationale: Magnetic Resonance technology is a noninvasive imaging tool that is able to 
noninvasively deduce the nuclear magnetic resonance (NMR) properties of tissue and 
interstitial space within the body. When MR parameters are properly defined and applied, 
variations in water proton MR relaxation times give rise to varying spatial signal intensities that 
create contrast that depicts functional anatomy and physiological processes. Studies have 
shown that the mature scar tissue resulting from an infarction is comprised primarily of 
collagen and has significantly less water concentration in comparison to native cardiac tissue. 
[47] These differences produce significant contrast between representative scar and native 
tissue signal intensities on T1- and T2-weighted images, allowing for visual differentiation. With 
an accurate model of tissue locations and boundaries, the placement of the microthread can be 
determined pre-operation in such a way as to maximize effectiveness.  
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In theory, histological techniques have been noted to produce superior spatial resolution in 
comparison to magnetic resonance imaging, but are ultimately limited by artifacts accumulated 
during the preparation and compilation processes. MR technology also has advantages in 
regards to its non-invasiveness and constant monitoring capabilities. 
Specific Aim: Develop optimal MR parameters that maximize tissue differentiation and image 
quality. (Noise, blurring, contrast factors must be analyzed and set for optimization) 
3.6.2 Hypothesis #2 
A cardiac tissue phantom designed within the constraints of the project can accurately mimic 
attributes crucial to tissue differentiation and thread location in vivo. 
Rationale: In regards to the scope of this project, the parameter essential for tissue 
differentiation and accurate thread location via MR imaging is the variation in water proton MR 
relaxation times as a function of tissue water concentration.  Average concentrations of H2O in 
native cardiac and fibrous scar tissue have been calculated in numerous studies resulting in 
representative approximations to incorporate in tissue phantom design. Representative solid 
state and containable viscous models of native tissue have been developed commercially and 
independently for experimental purposes within the defined constraints of this project. [64] 
Incorporation of tissue representative of the scarred region of infarct is hypothesized to be 
achieved via contrast agents or through alterations in the water concentration of a defined and 
containable area. 
Specific Aim: To design an accurate working model representative of native and ischemic tissue 
within the designated objectives, functions, and constraints.   
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3.6.3 Hypothesis #3 
Contrast agents when properly chosen will aid in optimization of differentiation and thread 
location accuracy. 
Rationale: MR relaxation times have the ability to be manipulated through the application of 
contrast agents. When introduced these agents interact with targeted 1H protons, affecting the 
relative spin energy and energy transfer rate, resulting in the decrease in MR relaxation times. 
Positive contrast agents alter signal intensity via reduction in T1 and T2 relaxation times while 
negative contrast agents result in altered signal intensity via a reduction in T2 relaxation times. 
Proper application of image contrast agents can greatly enhance tissue and thread contrast and 
the relative ease of differentiation. 
Specific Aim: Experiment and determine optimal agent concentrations for differentiation and 
application for tissue and microthread containment. 
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4.0 Design Alternatives 
Developing and analyzing design alternatives were utilized to select the best possible 
design given project objectives, functions, and limitations. In order to commence the design 
phase, the project team first had to understand the wants and needs of both the clients and 
potential users. Although we were able to accomplish much of this with the completion of the 
revised client statement, we needed to assure that our clients and users agreed with our 
methodology and progression. To do this, a series of pairwise comparison charts (PWCC) were 
implemented to prioritize the upper and lower level objectives as defined in the revised client 
statement.  
4.0.1 Pairwise Comparison Charts 
 Table 1 (shown below) is an example of the pairwise comparison charts (PWCC) 
designed by our project team for first order of objectives. Using these tables, input from the 
client and users, and information from the conducted literature review, we were able to rank 
the objective in each row against the objective in each column. If it was decided that the 
objective in the corresponding row was more important than that of the corresponding column 
the objective was assigned a “1.” The total score and objective importance was then calculated 
by adding up each objective row.  The opinion of objective importance increased with the 
increase in the collective total. Complete ranking of the objectives in each section of the 
experimental design can be found in Appendix 2: Objectives.  
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Table 2 depicted below is an example of the weighted objectives for the first order of 
objectives as completed by our clients (Professor Pins and Sotak), the project team, as well as a 
potential user (Professor Gaudette, a cardiac tissue engineering and cardiovascular 
biomechanics specialist). Objectives were ranked from 0 – 4 by each noted person or group 
according to the objective’s importance in the final design. The opinion of objective importance 
increased with the increase in the corresponding number assigned. It is important to also note 
that each number could only be used once by each person or group. Once the initial ratings 
were collected they were averaged and weighted, resulting in the final rating of objective 
importance. The objectives with the highest weighted totals were considered the most 
important during the experimental design process as they were crucial to accomplish project 
goals and objectives. Complete ranking of the objectives in each section of the experimental 
design can be found in Appendix 2: Objectives. 
 
Table 1: Objective Pairwise Comparison Chart Example 
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4.0.2 Needs Analysis 
 Although prioritizing the project goals and objectives provides a good basis for the 
experimental design phase, it is equally important to determine and separate client/user wants 
and needs. While omitting design parameters and attributes that the user wants can often 
affect the relative performance and success of the design, omitting design needs can result in 
the immediate failure of the design. A needs analysis was completed in order to determine the 
functional needs of the final product (properties that the results must have), as well as the 
physical limitations. During this step of the design process, the defined project functions, 
specifications, constraints, and weighted objectives were all taken into account to conduct a 
proper need vs. wants analysis: 
Client/User Needs  
1. Cardiac Phantom must: 
 
a. Be smaller than 38 mm in diameter due to the RF coil size. 
b. Contain microthread in a static position. 
c. Contain a contrast agent adhered to the embedded microthread with minimal 
diffusion into the surrounding medium. 
d. Contain a microthread with evenly applied concentration of contrast agent. 
 
2. Data Acquisition: 
Table 2: Weighted Objectives from Project Stakeholders Example 
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a. Parameters must produce at least 20% grayscale contrast between the 
phantom and microthread.  
b. Signal-to-noise ratio must be much greater than 20. 
c. Spatial resolution must be the same order of magnitude as the micro thread for 
viewing purposes.   
 
3. Data Analysis must allow for: 
a. Accurate healthy and infarcted tissue volume/shape/location measurements. 
b. Accurate microthread volume/shape/location measurements. 
 
Client/User Wants 
1. Cardiac Phantom 
 
a. Signal intensity of healthy and infarcted areas of the phantom should mimic 
calculated in vivo values.  
b. Shape, including location and relative size of infarction should be representative 
of typical in vivo measurements. 
c. Should possess the ability to contract/expand, similar to an in vivo system. 
d. Should produce minimal resistance when delivering the microthread. 
 
2. Data Acquisition 
a. Acquire 3D images since they have larger SNR than and are superior in image 
analysis potential than 2D images. 
b. Contrast-to-noise ratio should be calculated to optimize contrast. 
c. Use advanced techniques to mimic in vivo parameters and enhance image 
quality and data analysis. 
 
3. Data Analysis 
a. Software should be easy to use and inexpensive. 
b. Allow for further analysis via processing functions, including contrast 
enhancement, density profiling, smoothing, sharpening, edge detection, median 
filtering, and spatial convolution. 
 
4.1 Conceptual Designs 
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 The completion of the needs analysis and objective prioritization transitioned the design 
process into the conceptual design phase. This stage began by identifying various means to 
execute the previously defined project functions. These means were then considered to be 
conceptual designs and were critiqued via evaluation matrices based on their potential ability 
to fulfill the project objectives and constraints. The morphological chart, shown in Appendix 3: 
Functions lists the defined functions along with the possible means that were produced via 
brainstorming. To devise design alternatives, combinations of feasible and compatible means 
were paired. The compiled design alternatives were organized and evaluated via a numerical 
matrix. The following list briefly describes a number of the possible alternatives for each 
category of the design. A more thorough description of each alternative design, including 
means weighting and 3D CAD modeling can be found in Appendix 5: Design Alternatives. 
4.1.1 Cardiac Phantom Modeling System  
Cardiac Mold 
 Conceptual designs of the material representing and mimicking normal and ischemic 
cardiac tissue were limited, primarily because of the unique and numerous characteristics 
needed. In total tissue models comprised of gelatin, various vegetation, and synthetic water-
based polymers were conceptualized, determined to be viable, and analyzed via evaluation 
matrices. The following list briefly describes each conceptual design: 
 An In vitro WP phantom model comprising of one type of vegetation will be doped with 
a varying degree of a contrast agent to model approximate normal/infarct myocardial 
tissue relaxation rates and rate differences. A non-metallic divider will be placed in 
between the differing representative tissue to restrict the diffusion of contrast agents  
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 An In vitro VF phantom model comprising of two different types of vegetation doped 
with a varying degree of a contrast agent to model approximate normal/infarct 
myocardial tissue relaxation rates and rate differences. Each component will be 
sectioned off via a non-metallic divider to restrict the diffusion of contrast agents.  
 An In vitro Gelatin Model. The inside of a compartmental mold would contain gelatin of 
varying concentration used to mimic the differing relaxation rates of normal/infarct 
myocardial tissue.  
 Numerous cardiac phantoms designed specifically for imaging purposes were discovered 
on the web, most notably an MRI specific phantom composed of a synthetic water-
based polymer called zerdine. The signal intensity created from the material was stated 
to be consistent with that of normal cardiac tissue.    
Contrast Agent Application 
In addition to the design of viable cardiac material the application of a contrast agent is a vital 
component to the final phantom modeling system. A contrast agent will be applied to the 
embedded microthread and possibly the cardiac material itself to ultimately increase image 
contrast and phantom component differentiation. As stated in the literature review, contrast 
agents can be either negative or positive, affecting the spin-spin relaxation and spin-lattice 
relaxation, respectively. The numerous positive and negative contrast agents researched can be 
found in Appendix 5: Design Alternatives.  
 A calculated concentration of Superparamagnetic Iron oxide (SPIO) particles, a negative 
contrast agent, will dope the microthread and/or cardiac phantom to produce a 
variation in relaxation and thus signal intensity.  
 A calculated concentration of a positive contrast agent will dope the microthread and/or 
cardiac phantom to produce a variation in relaxation and thus signal intensity.  
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4.1.2 Data Acquisition 
 Conceptual designs for data acquisition parameters revolved around review of relevant 
material, specifically the MR portion of the literature review and utilized scholarly articles. 
Given the countless number of imaging techniques and parameter combinations proposed 
designs were kept relatively simplified, with limited cardiac specific applications.     
 Delayed enhancement MRI (DE-MRI) utilizing ECG-gating, inversion recovery (IR), and 
rewound (fast) gradient echo sequencing (FGE). IR time will be chosen to null the normal 
myocardium making areas of infarction appear hyper-enhanced.   
 
 Fast Spin Echo MRI (FSE-MRI) utilizing ECG-gating and blood suppression preparation 
(BSP). The FSE technique can acquire multiple lines of data per repetition limiting the 
effect of image artifacts due to movement of thoracic cavity during pulse sequences. 
 
 Spin Echo MRI (SE-MRI).  The SE technique is similar to the FSE described in the previous 
design however this technique will be simplified. All techniques and preparations 
regarding cardiac imaging will be ignored limiting this technique to stationary objects.   
 
4.1.3 Data Analysis 
Similar to data acquisition, numerous programs were found to be applicable to fulfill the 
goals of the project. The analysis techniques below were chosen on their ability to analyze the 
compiled data in a efficient and effective manner.      
 ImageJ [70] software with 3D analysis plug-in. ImageJ is a public domain, Java-based 
image processing program developed to display, edit, analyze, and process a variety of 
image formats. ImageJ can calculate area and pixel value statistics, measure distances 
and angles, and supports standard image processing functions.  
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 Matlab program is a high-level language and interactive environment that enables 
computationally intensive tasks to be performed, such as 3D image reconstruction, or 
even image analysis, faster than with traditional programming languages such as C, C++, 
and Fortran. 
 
 Segment is a free image analysis tool for Windows developed specifically for 
cardiovascular MR image analysis. This program has the ability to acquire and analyze 
2D, as well as 3D MRI and CT images. Some analyses that can be done in the program 
are length, volume, and area measurements in the regions of interest.  
 
4.1.4 Design Evaluation 
As the excerpt of the matrix in Table 3 below shows, each alternative was weighted 
according to how well they fulfilled relevant objectives and constraints. The top column lists 
design alternatives, while the left column and its corresponding rows list the design objectives 
and constraints. The second column denotes the objective weights that were established earlier 
via the weighted objective trees. Each objective was categorized in regards to how promising 
they were to fulfill defined objectives, with 0 being the least promising and 2 being the most 
promising. To gauge the objective promise, discussions within the group were conducted, 
noting the pros, cons, and limitations of each design to fulfill the objective. The designs were 
then rated by multiplying the design promise (from 0 - 2), by its corresponding objective 
weight. The final weighted score for each design was obtained by adding the weighted metric 
score for each objective, as shown in Table 4.  Constraints were given a score of Y or N based on 
the designs ability to fulfill the constraint. A complete list of evaluated designs and comparison 
scores can be found in Appendix 5: Design Alternatives. 
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Table 3: Example Evaluation Table 
Example   Design       
Objectives & Constraints Weight D1 D2 D3 D4 
O: Objective 1      0.325         
C: Constraint 1 Y/N         
  
Table 4: Design Alternatives 
Phantom Design Alternatives Total Score 
WP phantom w/ corresponding relaxation and tissue differentiation 2 
VF phantom w/ corresponding tissue differentiation 1.675 
Gelatin phantom w/ corresponding relaxation and tissue differentiation 1.8 
    
DAQ Design Alternatives Total Score 
Delayed enhancement MRI (DE-MRI) utilizing ECG-gating,IR, and FGE 1.624 (-) 
Fast Spin Echo MRI (FSE-MRI) utilizing ECG-gating and BSP 1.624 (+) 
Simple Spin Echo MRI with limited cardiac monitoring techniques 1.082 
    
Image Analysis Design Alternatives Total Score 
ImageJ software with 3D analysis plug-in (NIH) 1.833 
Matlab data visualization and analysis (Mathworks) 1.833 
Segment software for Windows (Cardiac MR group & Medviso AB) 2 
 
After the fundamental methodology was determined it was necessary to further devise 
and weight detailed alternative design components within the cardiac modeling system. 
Methodology including microthread placement, contrast administration, and contrast type 
among others were all crucial in the achievement of a phantom compliant with defined 
functions and specifications. Designs were evaluated against the design objectives using 
another numerical matrix utilizing the same process described above. Depicted below is first an 
example of the matrix structure, Table 5, followed by the resulting scores associated with each 
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design candidate, Table 6. Complete calculations and tables can be found in Appendix 5: Design 
Alternatives.  
Table 5: Example Sub-objective Table 
Static placement of Phantom   Method     
Objectives  Weight M1 M2 M3 
O: Objective 1         0.375    
O: Objective 2           0.325    
Table 6: Design Alternatives Sub-objectives 
Candidate Methods to: Subcategories Total 
Statically place phantom in RF coil     
  Secured containment 1.9 
  Phantom pinning 1.325 
  
Flat bottom 
phantom 
0.725 
  Clamp 1.525 
  Velcro 1.675 
  Double sided tape 1.675 
Deliver phantom contrast agent    
  Injection 1.625 
  Static Saturation 1.625 
  Dynamic Saturation 2 
Deliver microthread contrast agent    
  Adhesion 1.9 
  Static Saturation 1.425 
  Dynamic Saturation 1.6 
Aid in relaxation differentiation    
  Gadolinium based 1.1 
  Iron Oxide based 2 
4.2 Feasibility Study for Alternative Designs 
4.2.1 Feasibility for Cardiac Phantom 
 We performed feasibility tests for each of our four initial cardiac phantom designs in 
order to determine which could suffice for future MRI testing. For each model feasibility testing 
consisted of attempting to insert a thread, which mimicked a microthread, into the 
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representative tissue, using a surgical needle (3/8 circle cutting edge). Observations and notes 
were then taken regarding the ease of delivery and the ability of the material to statically 
contain the thread. We were not able to test the contrast agent application or undergo any MRI 
testing for these models, due to material availability at the time, but research was done to 
determine if the proposed methods were plausible.   
Design 1 – Single Vegetation Model 
 In order to test the single vegetation phantom model, we used a regular store bought 
white potato in an attempt to replicate cardiac tissue. This model was cost effective and could 
easily be reproduced since there is an ample supply of vegetation. We then tried to place a 
thread into the potato using a surgical needle (3/8 circle cutting edge). Unfortunately, we were 
not able to effectively pierce the potato using the surgical needle. The stiffness of the potato 
limited insertion of the needle and the amount of microthread encased in the material. 
Design 2 – Dual Vegetation Model  
 We performed feasibility studies on the dual vegetation model (design 2), which 
comprised of a white potato and carrot. The white potato represented healthy myocardium, 
while the carrot characterized infarcted myocardium. Once again, although it was slightly more 
expensive than the previous model due to the fact that it requires two different types of 
vegetation, it was still extremely cost effective and reproducible. After properly placing these 
two components, we administered a thread using a surgical needle (3/8 circle cutting edge). As 
depicted in Figure 23, with significant effort the needle was successfully able to pierce into the 
carrot and remained in place. 
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Figure 23: WPC Model 
Design 3 - Gelatin Model  
 To test the gelatin phantom, Jell-O® gelatin was created in a plastic Easter egg 
container. Before we placed the Jello-O® mixture into the egg, we drilled two holes, one at each 
end of the bottom portion of the egg to eventually use for microthread placement. This design 
was not as cost effective as the other two models, but it was still fairly cheap and easily 
reproducible. The bottom portion of the egg would potentially represent the infarcted 
myocardium while the top would represent the healthy myocardium. The gelatin mixture was 
placed in the two portions of the Easter egg as shown in Figure 24, in order to prevent the 
mixture from leaking out of the drilled holes. The gelatin mixture was refrigerated overnight for 
it to gel. 
  
 
Figure 24: Gelatin Formation in Phantom 
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After the gelatin was formed we took a surgical needle (3/8 circle cutting edge) and a 
thread and placed it inside the gelatin phantom through the drilled holes. This is shown in 
Figure 25 The needle was easily able to pierce into the gelatin phantom, and the thread was 
able to follow the needle tract and remained in position inside it.  
 
 
Design 4 – Commercial CIRS Model 
 
                No feasibility studies were conducted on the commercial CIRS cardiac phantom [64], as 
shown in Figure 26 due to an inability to obtain a sample of the synthetic zerdine based 
material. To determine if this model was feasible the product information, particularly the 
specifications, were analyzed. Ultimately the design was deemed unfit as a model for this 
project for several other reasons. This product is not cost effective or within the project budget 
as it costs $2000.  
Figure 25: Initial Gelatin Cardiac Phantom 
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Figure 26: CIRS Synthetic Phantom Model 
These cardiac phantom feasibility tests led us to believe that the gelatin model (design 
3) was the best cardiac phantom. Although it was not as time efficient as the other models, in 
regards to the project budget it was cost effective and could further sustain and deliver the 
thread the easiest. 
4.2.2 Feasibility for Data Acquisition  
With the limited time and budget available for imaging, the project team was unable to 
test the feasibility of the conceptual MR parameter designs. Based upon the research compiled 
regarding basic and cardiac imaging techniques and consultation with of our project advisor 
Professor Christopher Sotak, an expert in the field, it was determined that the proposed 
methods were all reasonable. When deciding what particular data acquisition design to utilize, 
previous design evaluations and advisor recommendations were taken into account. 
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4.2.3 Feasibility for Data Analysis  
Feasibility analysis for the chosen possible image analysis tools consisted of testing the 
capabilities applicable to our analysis project goals. Using a synthetic data set and multiple 2-D 
cranial MRI images, Segment, ImageJ, and MatLab were tested, analyzing the effectiveness and 
efficiency at which the data could be analyzed. Among the most important tests performed was 
the ability to calculate the volume and signal intensity of a chosen area.  In Figure 27 and Figure 
28 below, image analysis was performed of the signal intensity and the area of the highlighted 
portion, respectively. 
 
Figure 27: Signal Intensity Measurements using ImageJ 
 
 
Figure 28: Area Measurements using Segment 
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4.3 Preliminary Experiments 
4.3.1 Phosphate Buffered Saline Preparation 
 The purpose of utilizing a phosphate buffered saline (PBS) was to ensure pH neutrality 
for the gelatin and ferumoxtran samples. The PBS was prepared using de-ionized (DI) water, 
1.06 mM of potassium phosphate monobasic (KH2PO4), 155.17 mM sodium chloride (NaCl), and 
2.97 mM of sodium phosphate dibasic (Na2HPO4 – 7H2O). One liter of the PBS solution was 
prepared using 0.144 g of KH2PO4, 9.000 g of NaCl, and 0.794 g of Na2HPO4 – 7H2O in 1000 mL 
of DI water. The DI water was heated until warm in order to dissolve the other three 
ingredients in the water. The other three ingredients were then added and the mixture was 
stirred until there were no visible particles. The cooled solution was stored in two 500 mL 
sterile glass bottles to be used to buffer the gelatin.  
4.3.2 Gelatin Formation Analysis 
 The gelatin used in our experiments was unflavored, unsweetened Knox® Gelatin, 
packaged in individual 8-ounce packages. Preliminary experiments aimed to determine the 
minimal concentration at which the gelatin/PBS mixture would become gelatinous. The gelatin 
concentrations (grams/mL) which were originally chosen were ¼%, ½%, 1%, 2%, 4%, and 10%. 
Each concentration was prepared by first measuring the appropriate volume and weight of PBS 
and gelatin powder, respectively. The components were then added into a 200 mL beaker and 
dynamically mixed at 200 °F until dissolved. Table 7 below notes the exact measurements used 
to prepare each concentration. 
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Table 7: Actual Gelatin and PBS Measurements 
Volume PBS Weight Gelatin Percent Gelatin 
99.75mL 0.252g 0.25% 
99.5mL 0.506g 0.50% 
99mL 1.002g 1% 
98mL 2.009g 2% 
96mL 4.001g 4% 
90mL 10.002g 10% 
 
After the gelatin was fully dissolved, 15 mL of each sample was then measured out using a 
motorize pipette and transferred into a 12-well plastic plate, as shown in Figure 29. Each 
sample was duplicated to ensure efficiency, so there were 2 samples of each gelatin sample in 
the 12 well plate container. The plate was then covered, and placed in a refrigerator at 37°C 
overnight to solidify. 
 
Figure 29: 12-Well Plate 
 The prepared gelatin was removed from the refrigerator after 24 hours and observed.   
The minimal gelatin concentration needed to form a gelatinous solid structure was 
approximately 1%. Each concentration greater than 0.5% solidified to a varying degree and was 
noted to increase in stiffness with increasing concentration.  
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4.3.3 Gelatin Reconstruction 
 From the previous observations, the minimum concentration which could be used in 
gelatin testing was 1%. In order to achieve a good concentration curve after imaging, a series of 
4 concentrations were then chosen, 1%, 3%, 6%, and 10%. These percentages were prepared in 
a similar fashion to the previously prepared gelatin, however, instead of a 12-well plate, 4 
separate 35-mm culture dishes were used. Table 8 below notes the exact measurements used 
to prepare each concentration. 
 
Table 8: Actual Gelatin Concentration for Preliminary Imaging 
Volume PBS Weight Gelatin Percent Gelatin 
49.5 mL 0.5004 g 1% 
48.5 mL 1.5007 g 3% 
47 mL 3.003 g 6% 
45 mL 5.004 g 10% 
 
4.3.4 Ferumoxtran (AMI 227) Preparation 
 Ferumoxtran is an iron oxide based contrast agent, which was determined through 
analysis and its availability to be the best contrast agent to administer. The original sample that 
was received contained 17.8 mg of Ferumotrax iron oxide nanoparticles per mL of PBS. In order 
to conduct meaningful relaxation experiments as a function of agent concentration, solutions 
were choosen in increasing concentration increments.  Concentrations of 5 µg/mL, 10 µg/mL, 
20 µg/mL, 30 µg/mL, and 50 µg/mL were made by first diluting 10 µL of the original sample to 
of Fe to make the solution concentration more manageable to work with. After completion of 
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the process the samples were ready to be imaged and analyzed. The calculations below list the 
concentration determination process.  
10 µL + 35.56mL of PBS = 5 µg/mL 
10 µL + 17.9mL of PBS = 10 µg/mL 
10 µL + 8.89mL of PBS = 20 µg/mL 
10 µL + 5.92mL of PBS = 30 µg/mL 
10 µL + 3.55mL of PBS = 50 µg/mL 
 
4.3.5 Imaging Process and Parameters 
 The gelatin phantom and contrast agent imaging process was performed on the Philips 
Achieva 3.0T X-Series MRI, using a homemade 38 mm x 127 mm copper, birdcage RF-coil seated 
within a plexiglas tube. The software used, which was provided, was the Philips MRI SmartExam 
software. All of the testing was performed at the UMASS medical school, with the assistance of 
Mohammed Shazeeb, a PhD student at Worcester Polytechnic Institute. The Larmor Frequency 
for the samples was determined by multiplying the magnetic field (3.0T) by the gyromagnetic 
ratio of 42.56 MHz/T to give 127.5 MHz. Proper safety precautions were followed when 
performing all of the tests. 
 During this preliminary imaging session there were three gelatin samples that were 
measured, 3%, 6%, and 10% gelatin by concentration along with 5 samples of Ferumoxtran 
(AMI 227) 5 µg/mL, 10 µg/mL, 20 µg/mL, 30 µg/mL, and 50 µg/mL by concentration. The gelatin 
samples had been previously prepared in individual sterile polystyrene 35mm x 10mm cell 
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culture dish (Corning Inc., Corning, N.Y.). The ferumoxtran samples were previous prepared and 
housed in 20 mL teardrop containers. Prior to imaging, each gelatin sample was individually 
seated inside the RF coil, aligned within the magnet itself, and the Larmor frequency set. The 
fermuxotran samples followed the same process, individually seated on top of plastic block and 
secured using electrical tape.  
The first image of each sample taken was a survey image to verify proper placement and 
MR functionality. The sample was then run through various adjustable tests, with the purpose 
of figuring out roughly what TR and TE values to use for T1 data and T2 data, respectively. 
Finally, a magnetic resonance spectrum of each sample was taken in order to examine the 
frequency spectrum of the sample inside the RF coil. The following Table 9 shows the TR and TE 
values use for the different gelatin samples, as well as Table 10 shows the TR and TE values for 
the different AMI 227 sample scans. 
Table 9: TR and TE Scan Values for Gelatin Samples 
Gelatin 
Concentration 
(%) 
Start TR 
(ms) 
TR Interval 
(ms) 
End TR 
(ms) 
Start TE 
(ms) 
TE Interval 
(ms) 
End TE 
(ms) 
3% 25 (ms) 400 ms 5625 ms 50 ms 100 ms 2350 ms 
6% 25 (ms) 400 ms 5625 ms 50 ms 100 ms 2350 ms 
10% 25 (ms) 800 ms 11225 ms 50 ms 100 ms 2350 ms 
 
Table 10: TR and TE Scan Values for AMI 227 Concentration 
Ferumoxtran 
Concentration 
(µg/mL) 
Start TR 
(ms) 
TR Interval 
(ms) 
End TR 
(ms) 
Start TE 
(ms) 
TE Interval 
(ms) 
End TE 
(ms) 
5 µg/mL 25 ms 300 ms 4225 ms 25 ms 50 ms 1175 ms 
10 µg/mL 25 ms 200 ms 2825 ms 25 ms 25 ms 600 ms 
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20 µg/mL 25 ms 200 ms 2825 ms 15 ms 15 ms 195 ms 
30 µg/mL 25 ms 100 ms 1425 ms 11 ms 10 ms 191 ms 
50 µg/mL 25 ms 50 ms 725 ms 11 ms 20 ms 371 ms 
 
 Each of the previous scans were performed consecutively starting with the 10% gelatin 
concentration and ending with the 3%, then again starting with the 5 µg/mL and ending with 
the 50 µg/mL. The first scans that were performed were the T1-weighted scans, followed by the 
T2-weighted scans. 
4.3.6 Curve Fitting and Data Analysis 
  The program which was used to analyze our preliminary data was Matlab. Matlab 
provides a curve fitting tool that was used to plot and determine the T1 and T2 relaxivities of 
each set of samples. The data collected from the MRI was stored in a .xls extension documents 
and consisted of two data columns for each sample; one was the time and the other the signal 
intensity value. Two arrays were created from the two data columns and then plotted using 
the cftool(Time, Signal_Intensity) function in Matlab (a careful note is that the x-axis always 
comes first, where as the y-axis comes second).  
 After each graph was created for each sample, the curve fitting tool provided by Matlab 
was used. This tool fit a curve for the T1 and T2 relaxation curves for each data set and provided 
T1 and T2 values. The curve that we used to fit to the T1 data was, y = (1 - 2 * exp ((-x) / t), where 
y is the signal intensity and the x is the time. The t is then determined through this curve fitting 
tool and is the T1 relaxivity time for that data set. The curve in which we attempted to fit to the 
T2 data was, y = (2 * exp ((-x) / t), where y is the signal intensity and the x is the time. The t is 
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then determined through this curve fitting tool and is the T2 relaxivity time for that data set. 
The following two figures, Figure 30 and Figure 31, are two examples of the concentration 
curves that were received. The remainder of the concentration Curves can be found in 
Appendix 6: Preliminary Data 
 
Figure 30: T1 Signal Intensity vs. Time at 10% Gelatin Concentration 
 
Figure 31: T2 Signal Intensity vs. Time at 10% Gelatin Concentration 
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4.3.7 Preliminary Data Results and Conclusions 
4.3.7.1 Gelatin Initial Results 
The following set of graphs, Figure 32 and Figure 33, provide results of the entire data 
set for each gelatin concentration, both for T1 and T2 weighting. The following Table 11 has 
each T1 and T2 value for each initial gelatin. 
Table 11: Gelatin Concentration Initial Results 
Concentration (%) T1 (ms) T2 (ms) R1 (1/s) R2 (1/s) 
0.10 1320 271 0.76 3.68 
0.06 1520 363 0.66 2.75 
0.03 1800 294 0.56 3.39 
 
 
Figure 32: 1/T1 vs. Gelatin Concentration 
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Figure 33: 1/T2 vs. Gelatin Concentration 
 
4.3.7.2 Ferumoxtran Initial Results 
 
The following set of graphs, Figure 34 and Figure 35, provide results of the entire data 
set for each Ferumoxtran concentration, both for T1 and T2 weighting. The following Table 12 
has each T1 and T2 value for each initial Ferumoxtran sample. 
Table 12: Ferumoxtran Concentration Initial Results 
Concentration (ug/mL) T1 (ms) T2 (ms) R1 (1/s) R2 (1/s) 
5 1033 143 0.968 0.699 
10 640 70.5 0.156 1.41 
20 401 29.7 0.249 3.36 
30 244 20.8 0.409 4.79 
50 157 12.9 0.634 7.73 
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Figure 34: 1/T1 vs. Ferumoxtran Concentration 
 
Figure 35: 1/T2 vs. Ferumoxtran Concentration 
4.3.7.3 Preliminary Conclusions 
 Utilizing the data from preliminary results, the components of the phantom modeling 
system were calculated. The T1 Gelatin curve, Figure 32, worked extremely well given the 
known value for T1 relaxation of normal myocardium, approximately 1450 ms. To determine 
the percent concentration of gelatin needed to replicate native myocardial tissue 1450 ms was 
plugged into the concentration curve equation, y = 2.84x + 0.48, yielding a value of 7.1%. This 
value fits inside the range of data that was collected from the analysis of relaxivity (R1) as a 
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function of gelatin concentration and help to confirm the feasibility of our results. The 
concentration of gelatin needed to replicate in vivo infarct tissue was determined in a similar 
fashion, plugging in the known T1 relaxation time, 1700 ms, into the concentration curve 
equation, y = 2.84x + 0.48. The resulting value was determined to be 3.1% gelatin by 
concentration.   
Unfortunately, at the gelatin concentration needed to reproduce the cardiac T1 value 
(7.1%) the estimated in vivo T2 relaxation time of approximately 40 ms could not be accurately 
mimicked. Following the T2 concentration curve, at 7.1% gelatin concentration, the T2 
relaxation time would be approximately 320 ms, a factor of 8 longer than the in vivo value. In 
light of this information it was decided to focus on producing accurate T1 values, as altering the 
concentration of gelatin to mimic in vivo T2 relaxation times would subsequently affect the T1 
value. Although T2 relaxation times could not be mimicked, it was determined that the 
phantom could reproduce T2-weighted contrast difference between the microthread and tissue 
itself. An analysis was performed to determine what value of TE would produce a 20% 
difference in cardiac signal intensity. At that TE value the concentration of Ferumoxtran that 
would produce a 60% reduction in signal intensity was determined, ultimately resulting in a 3:1 
signal intensity ratio between the infarct tissue representation and thread doped with 
Ferumoxtran. Similarly this TE analysis can be done to produce the exact same signal intensity 
ratio imaging in vivo, the only difference being the TE value and Ferumoxtran concentration. It 
was concluded through the analysis that a TR of 1600ms, TE’s ranging from 25 ms to 100 ms, 
and concentration of 10 ug/mL of Ferumoxtran would most closely produce the resulting signal 
intensity ratios described above. The preliminary parameter results are found in Figure 36. 
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Figure 36: T2 Contrast Agent Study - Final Parameter Results 
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5.0 Design Verification 
The final design and verification section of this report encompasses the techniques used 
to produce and conduct the selected methods to, via MRI, analyze MR-contrast-agent-doped 
tissue-embedded microthreads in a cardiac phantom. The construction of the cardiac phantom 
and microthreads, doping of the microthread, construction of the final phantom system, 
imaging of the system, and usage of the imaging analysis tool is discussed in detail.  
5.1 Collagen Microthread Production 
 The proceeding section describing the production of self-assembling collagen 
microthreads is comprised of numerous detailed and sequential procedures adapted from 
Cornwell and Pins [67]. For simplicity, the production of collagen microthreads is organized into 
two distinct processes, the extraction and preparation of acid-soluble collagen and collagen 
thread extrusion. In total 8 – 2.0 cm bundles of 12 collagen microthreads were formed and 
utilized in the final design modeling system. 
5.1.1 Preparation of acid-soluble collagen 
Using hemostatic clamps, acid-soluble type I collagen was extracted from tendon fibers 
in Sprague-Dawley rat tails. Following the dissection, the tendon fibers were rinsed twice in 
phosphate buffered saline (PBS) and dissolved in 1600 mL of a 3% acetic acid solution 
overnight. The solution was then refrigerated and centrifuged for 2 hours at 4˚C and 8000g, 
after which the resulting components, supernatant and precipitate, were retained. To isolate 
the collagen within the solution, 320 mL of 30% NaCl was slowly added, forming a collagen 
precipitate. The precipitate and solution was once again centrifuged for 30 minutes at 4˚C, 
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discarding the resulting supernatant. The collagen precipitate was re-suspended in 400 mL of a 
0.6% acetic acid solution and stirred at 4˚C until completely dissolved (typically overnight). The 
solution was dialyzed five times, each for at least four hours, against 4 L of 1 mM HCl and then 
lyophilized and stored at 4˚C.  
5.1.2 Collagen thread Extrusion 
Before the threads were extruded, the lyophilized collagen was dissolved at 4˚C 
overnight in a rotating vessel with 5 mM HCl, with a final concentration of 10 mg/mL. Air 
bubbles that were in the collagen solution were also removed by centrifugation. 
 
Figure 37: Collagen Microthread Extrusion Process 
As depicted above in Figure 37, thread extrusion was driven by a syringe pump 
connected to 0.86-mm-diameter polyethylene tubing.  The threads were extruded at a flow 
rate of 0.7 mL/min into a fiber formation buffer bath (pH of 7.42 at 37˚C) consisting of 135 mM 
NaCl, 30 mM TrizmaBase, and 5 mM NaPO4. After 24 hours, the buffer was replaced with 
distilled water, and the microthreads were incubated for another 24 hours at 37˚C. The threads 
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were then taken out of the distilled water bath, air dried, and stored at room temperature in a 
desiccator.  
5.2 Gelatin Production 
5.2.1 Phosphate Buffered Saline (PBS) Production 
The construction of the final gelatin phantom design involved dynamically mixing gelatin 
powder with a phosphate buffered saline (PBS). In regards to the scope of this project using PBS 
as a buffer has numerous advantages over distilled (DI) water. The osmolarity and ion 
concentrations of PBS are similar to those found in the body, keeping the gelatin isotonic and 
limiting its effects on the seeded stem cells. The utilized PBS formula consisted of DI water, 
1.06mM KH2PO4, 155.17 mM NaCl, and 2.97 mM Na2HPO4 – 7H2O) (Invitrogen Corp., San Diego, 
CA). The solution components were dynamically mixed for approximately 5 minutes at 200 F° 
using a ceramic hot plate stirrer (VWR, West Chester, PA) and stored in sterile glass media 
bottles for future usage. Upon cooling, the pH of the solution was recorded with Baker-pHIX (J.T 
Baker, Phillipsburg, USA) and visually approximated to be consistent with the expected pH of 
7.4 ± 0.1 (Figure 38). 
 
Figure 38: pH approximation of the PBS solution 
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5.2.2 Gelatin Concentration & PBS Integration   
Gelatin is a protein produced by partial hydrolysis of collagen and, with water, forms a 
semi-solid colloid gel.  The percent concentration of Knox Original Unflavored Gelatin (Knox, 
Johnstown, N.Y.) required in the phosphate buffered saline to mimic the T1 relaxation rates of 
both normal and ischemic myocardial tissue were determined via initial magnetic resonance 
testing and referenced literature and found to be 7.1% and 3.7%, respectively. Calculated 
concentrations of gelatin were constructed based on these findings via percent weight of 
gelatin powder (grams) per volume of PBS (milliliter) and are 7.1 g gelatin and 93.9 mL PBS for 
normal tissue and 8.3 g gelatin and 91.7 mL PBS for infracted tissue. The gelatin powder was 
weighed using a Mettler Toledo Classic Plus, AB-S/Fact analytical balance (Mettler-Toledo 
International Inc., Columbus, OH)  and transferred using Fisherbrand 3” x 3” weighing paper 
(Fisher Scientific, Hampton, N.H) into a 200 mL beaker containing the calculated volume of PBS. 
Once introduced into the PBS solution,  the gelatin was dynamically mixed at 400 rotations/min 
for approximately 5 minutes at 200 °F with a ceramic hot plate stirrer (VWR, West Chester, PA). 
As depicted in Figure 39 and Figure 40, approximately 30 mL of the liquefied gelatin was then 
immediately transferred from the mixing beaker into a sterile polystyrene 35 mm x 10 mm cell 
culture dish (Corning Inc., Corning, N.Y.) using a motorized Fisherbrand pipette dispenser 
(Fisher Scientific, Hampton, N.H) and 10 mL serological pipette (Becton-Dickinson Labware, 
Franklin Lakes, NJ). The cell culture dish was then sealed, taped closed, marked to indicate the 
concentration, and placed inside a 37 °C refrigeration unit for three hours.  
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Figure 40: Gelatin Delivery into 35mm Petri Dish 
5.3 Microthread Contrast Agent Application 
As previously stated, a total of 8, 2.0 cm bundles of 12 collagen microthreads were 
formed for delivery into the gelatinous cardiac phantom. To determine optimal agent 
application, a variety of thread preparation techniques were conducted. The microthread 
bundles were divided into two groups of four, with thread preparation prior to implantation 
varying for and within each group. To determine if microthread MR differentiation varied as a 
function of agent exposure time, each thread bundle within each group was placed in 10 ug/mL 
of Ferumoxtran, the chosen contrast agent, for differing time increments. Table 13 below 
illustrates the time of agent exposure for each thread in their respective group. Figure 41 
depicts the location and agent exposure time of each thread in the cardiac modeling system. 
Table 13: Contrast Agent Application 
Figure 39: Sterile 35mm Petri Dish w/ Gelatin 
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  Group 1 - "Air-dried Threads" Group 2 - "Hydrated Threads" 
Thread #     
1 60 min. Exposure in Ferumoxtran 60 min. Exposure in Ferumoxtran 
2 30 min. Exposure in Ferumoxtran 30 min. Exposure in Ferumoxtran 
3 5 min. Exposure in Ferumoxtran 5 min. Exposure in Ferumoxtran 
4 60 min. Exposure in PBS 60 min. Exposure in PBS 
 
 
 
 
 
 
 
 
 
 
Figure 41: Thread Location and Agent Exposure Time 
 
The second variation in microthread preparation consisted of differences between each 
group, and would examine the effects of thread hydration on MR differentiation. The 
microthreads in group 1, called the “Air-dried Group”, were exposed in the varying time 
increments described above, rinsed 3 times in distilled water, and then air dried prior to 
implantation in the cardiac phantom. Group 2, called the “Hydrated Group”, was similarly 
exposed in the time variant manner to Ferumoxtran and PBS solutions, but then directly 
inserted into the phantom. 
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5.4 Cardiac Phantom Construction 
 
Construction of the final cardiac modeling phantom comprised of integrating the 
phantom gelatin components and the doped collagen microthread. As previously stated the 
percent concentration of Knox Original Unflavored Gelatin (Knox, Johnstown, N.Y.) required in 
the phosphate buffered saline to mimic the relaxation rates of both normal and ischemic 
myocardial tissue were determined to be 7.1% and 3.7%, respectively. Using the same 
techniques and materials as previously described, 30 mL mixtures consisting of 7.1% and 3.7% 
gelatin will prepared, placed into separate sterile 35 mm culture dish, and allowed to solidify 
overnight. In total 2 phantom modeling systems were constructed and tested, one containing 
the 4 microthreads in Group 1- “Air-Dried Threads” and the other containing the remain 4 
microthreads in Group 2 – “Hydrated Threads”. Each microthread within the 2 phantom 
modeling systems was placed approximately 5mm apart on top of the solidified gelatin 
representative of normal tissue. The gelatin mold representing the infarct tissue was then 
extracted from the culture dish, making sure to keep the gelatin in one piece, and then placed 
on top of the threads and “infarct gelatin”, effectively “sandwiching” the threads between the 2 
gelatin concentrations. Figure 42 and Figure 43 below depict gelatin placement housed within 
the 35-mm culture dish and the microthread bundles sandwiched in between these layers. 
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Figure 43: Microthread Placement in between Gelatin Layers of Varying Concentration 
 
5.5 Imaging Process and Parameters 
 
The gelatin phantom and contrast agent imaging process was performed on the Philips 
Achieva 3.0T X-Series MRI, using a homemade 38mm x 127mm copper, birdcage RF-coil seated 
within a plexiglas tube. The software used, which was provided, was the Philips MRI SmartExam 
software. All of the testing was performed at the UMASS medical school, with the assistance of 
Mohammed Shazeeb, a PhD student at Worcester Polytechnic Institute. Proper safety 
precautions were followed when performing all of the tests. 
Infarct Gelatin [3.7%] 
Healthy Gelatin [7.1%] 
Figure 42: Gelatin Concentration and Placement 
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  After the cardiac phantom process with the microthreads introduced, the image testing 
could occur. The phantom was placed within the birdcage coil aligned parallel to the xy-plane, 
as accurately as possible. This allowed the cross sectioning of the phantom slices during imaging 
to be as ideally perpendicular to the phantom bottom. The birdcage was then hooked up to the 
MRI machine, then properly aligned and placed within the bore of the magnet. This then 
allowed the setup for the imaging parameters in order to perform our image testing.  
The entire sets of imaging parameters are shown in Table 14. In all of the experiments 
the number of slices which were acquired were 15 slices per experiment. The T1-weighted 
imaging experiments were acquired using a multi-slice, single-echo technique. The T2-weighted 
imaging experiments were performed using a multi-echo, multi-slice technique, in order to 
allow the acquisition of separate echo times in a shorter amount of time. Each echo time 
produces a separate set of images. The TR was determined by finding the maximum difference 
in signal intensity between the healthy and normal gelatin, and determined using our 
concentration analysis curves. The sets of images that were acquired were saved as a DICOM 
format, and were also converted to .tiff format for use in image analysees. 
Table 14: TR and TE Times for Imaging Experiment 
Phantom Experiment Repetition 
Time (TR) 
Echo Time (TE) Image Matrix Size  
Air- Dried T1 Weighted Image 700 ms 8.7 ms 256 x 256 pixels 
Air- Dried T2 Weighted Image 1600 ms 25,50,75,100 ms 384 x 384 pixels 
Hydrated T1 Weighted Image 700 ms 8.7 ms 256 x 256 pixels 
Hydrated T2 Weighted Image 1600 ms 25,50,75,100 ms 384 x 384 pixels 
Phantom Field of View Slice Thickness Slice Gap Voxel Size  
Air- Dried 10 x 35 x 25 mm 1.5mm .15mm .09 x.09 x 1.5mm 
Air- Dried 10 x 35 x 25 mm 1.5mm .15mm .14 x .14 x 1.5mm 
Hydrated 10 x 35 x 25 mm 1.5mm .15mm .09 x.09 x 1.5mm 
Hydrated 10 x 35 x 25 mm 1.5mm .15mm .14 x .14 x 1.5mm 
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5.5.1 Air-Dried Phantom Imaging 
The first experiment was performed on the air-dried thread phantom. There were two 
image acquisitions that were performed, the first was a T1-weighted image and the second was 
a T2-weighted image. The T1-weighted image was performed with the imaging parameters of a 
TR of 700 ms and a TE of 8.7 ms, with a field of view of 10 x 35 x 25 mm, a slice thickness of 1.5 
mm and a slice gap of .15 mm, which produced a voxel size of .09 x .09 x 1.5 mm per pixel. The 
images that were acquired were 256 x 256 pixel size images. The T2-weighted images were 
performed using a TR of 1600 ms the TE acquisition times were 25, 50, 75, 100 ms, the field of 
view of 10 x 35 x 25 mm, a slice thickness of 1.5 mm and a slice gap of .15 mm, which produced 
a voxel size of .14 x .14 x 1.5 mm per pixel. 
5.5.2 Hydrated Phantom Imaging 
The second experiment was performed on our hydrated thread phantom. There were 
two image acquisitions that were performed, the first was a T1-weighted image and the second 
was a T2-weighted image. The T1-weighted image was acquired with a TR of 700 ms and a TE of 
8.7 ms, with a field of view of 10 x 35 x 25 mm, a slice thickness of 1.5 mm, and a slice gap of 
.15 mm, which produced a voxel size of .09 x .09 x 1.5 mm per pixel. The images that were 
acquired were 256 x 256 pixel-size images. The T2-weighted images were acquired using a TR of 
1600 ms, the TE acquisition times were 25, 50, 75, 100 ms, the field of view of 10 x 35 x 25 mm, 
a slice thickness of 1.5 mm and a slice gap of .15 mm, which produced a voxel size of .14 x .14 x 
1.5 mm per pixel.  
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5.5.3 T1-Weighted Image Acquisition 
 One slice of a T1-weighted image that we acquired through the cardiac phantom 
containing the hydrated microthreads are shown in Figure 44 and Figure 45 shows a T1-
weighted slice of the phantom containing the air-dried microthreads. Both of these images 
represent one out of the 15 slices that were obtained from each phantom. The entire set of 15 
T1-weighted images for both phantoms can be seen in an attached document under the 
directory D:\MQP Final Submittal\Imaging Experiment\Original data or D:\MQP Final 
Submittal\Imaging Experiment\T1 Data. The microthreads were poorly depicted in the T1-
weighted scan as shown by the small holes in the middle of each image. From left to right in 
both Figure 44 and Figure 45, the microthreads align as 60 minutes, 30 minutes, and 5 minutes 
contrast agent exposure and finally one without any contrast agent but just a PBS exposure. 
The fact that the microthreads are oriented in the middle of the images shows that they 
remained stable after being sandwiched in between the “infarcted” and “healthy” gelatin.  The 
top half of the images correspond to the infarcted gelatin comprised of 3.7% gelatin and the 
bottom half correspond to the healthy, which is 7.1% gelatin. It is important to note that some 
of the T1-weighted images in the separate document contain more than four holes. Any extra 
holes in the images can be explained by air bubbles that may have occurred while sandwiching 
the microthreads in between the infarcted and healthy gelatin.  
 
Figure 44: T1-Weighted Image of Cardiac Phantom with Hydrated Microthreads 
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Figure 45: T1-Weighted Image of Cardiac Phantom with Air-Dried Microthreads 
 
5.5.3 T2-Weighted Images Acquisition 
One T2-weighted slice of the phantom containing the hydrated microthreads at a TE of 
100 ms is shown in Figure 46. Another T2-weighted slice at 100 ms TE, displaying the phantom 
containing the air-dried microthreads is shown in Figure 47. The entire set of T2-weighted 
images of both phantoms at all four echo times (TE = 25, 50, 75, and 100ms) can be seen in an 
attached document under the directory D:\MQP Final Submittal\Imaging Experiment\Original 
data or D:\MQP Final Submittal\Imaging Experiment\T2 Data. Just as with the T1-weighted 
images, the black holes were oriented in the middle of each T2-weighted image. Some images 
contained more than four holes which once again can be explained by air bubbles created while 
inserting the microthreads inside the phantoms. The top half of the image corresponds to the 
infarcted gelatin comprised of 3.7% gelatin and the bottom half corresponds to the healthy 
which is 7.1% gelatin. 
 
Figure 46: T2-Weighted Image of Cardiac Phantom with Hydrated Microthreads at 100ms TE 
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Figure 47: T2-Weighted Image of Cardiac Phantom with Air-Dried Microthreads at 100ms TE 
5.6 Data Analysis Procedure 
The program that was chosen was ImageJ in order to perform our thread diameter and 
location analysis along with our signal intensity and contrast measurements. A set of 
programming macros were developed in order to reproduce the results across all of the images, 
these are shown in a separate set of documents, which are labeled and stored on the final DVD 
in directory D:\MQP Final Submittal\Image Analysis\Imaging Macros.  
These analysis macros performed a diameter analysis of what were determined as the 
microthreads in the images. Each line of the macro required a “;” at the end of it for syntax 
purposes. These macros took and opened the given image file, using the open(“file_name”) 
command. This file was then ran in 8 bit by using the run("8-bit") command. The correct tool 
was then selected using the //setTool(4). A line was then made across the middle point of what 
was determined to be each thread. This line was then plotted on a graph using the run("Plot 
Profile"). Then there was a full width half maximum height (FWHMH) measurement taken , 
which is explained in the a later paragraph, taken on it. This was done using the run("Measure") 
command.  
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There were 4 threads per single slice, 15 slices per image, however we only used 10 
slices to perform measurements on, and there were 8 images analyzed. So there were 320 
measurements made in total. Each echo time had a set of 10 images for each sample that were 
analyzed. So after each macro run, this produced 40 measurements for each image set. These 
measurements were to scale because previously the image pixel size was set to our scale of .14 
x .14 1.5mm per pixel for hydrated threads and .09 x .09 x 1.5 mm for the air-dried threads. 
These measurements were then exported to an excel document and separated, with every 
fourth measurement separated into a different column making it so that measurements for 
each thread (60, 30, 5, and control threads) were separated into their own column. This gave 
the entire data set, once each of the 8 macros were performed. The results are found in 
Appendix 7: Results. 
The analysis which we performed was a full width half maximum height analysis. This is 
an analysis where the maximum full width of the depression is evaluated, then the maximum 
height is evaluated, and the diameter is taken at half of this height. (As shown in Figure 48)  
 
Figure 48: Image Analysis, Full-Width Half-Maximum-Height 
A separate analysis of our actual phantom was performed as well. An optical picture of 
our phantom was taken next to a ruler in order for to provide a scale tool to analyze the optical 
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thread width. The scale for the image was set by taking the line tool making it read 10 mm on 
the ruler, and using a Set Scale command to our known scale of 10 mm. This allowed the scale 
to be applied to every measurement that was taken. Then 10 sections were analyzed in line 
with the slices from the MR images. These results are shown in Appendix 7: Results. 
5.6.1 Hydrated Microthread Diameter Measurements 
 
 Figure 49 displays the average hydrated microthread diameters from the T2-weighted 
images at each separate contrast agent application time. It also displays the average hydrated 
microthread diameters of the optical image of the cardiac phantom. In order to determine each 
microthread diameter for the MRI slices, we utilized the full width at half maximum height 
(FWHMH) method which is discussed in 5.6 Data Analysis Procedure. A detailed methodology 
for optical image microthread measurements are also discussed in 5.6 Data Analysis Procedure.  
The fact that the standard deviations overlap suggests that there is no statistical difference 
between the microthread size and the contrast agent exposure time. It also suggests that there 
is no statistical difference between the microthread diameter in the T2-weighted MR images 
and the optical image containing hydrated microthreads. This same analysis was done at each 
echo times, and yielded similar results. There was no significant difference between contrast 
agent exposure time as well as imaging type and microthread diameter. Each measurement 
was done at every echo time and the graphs that correspond to these data are shown in 
Appendix 7: Results.  
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Figure 49: Average Hydrated Microthread Diameter Measurements 
5.6.2 Air-Dried Microthread Diameter Measurements 
 Figure 50 shows the average air-dried microthread diameters for the T2-weighted 
images at each different contrast agent exposure time. This bar graph also displays the air-dried 
microthread diameters from the optical image. The overlap in standard deviations shows that 
once again there is no statistical difference between the microthread diameter and contrast 
agent exposure time. It also suggests that there is so significant difference in the measurements 
between the MR images and the optical image containing the air-dried microthreads. All of the 
measurements taken at different echo times and their corresponding graphs can be seen in 
Appendix 7: Results. Just as with the hydrated microthreads, all of the air-dried analyses 
showed that there was no significant difference in diameter at different contrast agent 
exposure times, echo times, or with different imaging types.   
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Figure 50: Average Air-Dried Microthread Diameter Measurements 
5.6.3 Contrast as a Function of TE 
 Figure 51 depicts close up images of the highlighted region for the 4 applied MR echo 
times of 25, 50, 75, and 100 ms, respectively. Upon visual analysis the magnitude of contrast 
between the microthread and surrounding gelatinous medium appeared to increase as a 
function of increasing TE. To verify this observation a signal intensity analysis was performed on 
the hydrated and air dried MR images via ImageJ software.  Starting with an image slice with TE 
= 25 ms, a straight line segment was drawn across the apparent center of a selected 
microthread, making sure to encompass the diameter of the thread in its entirety. With the line 
segment remaining stationary signal intensity profiles of the same imaged location with TE = 50, 
75, and 100 ms were collected. All signal intensity profiles were then imported into an Excel 
spreadsheet and analyzed. A total of 10 separate signal intensity profiles were conducted 
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across varying threads and image slices, with 5 being air dried thread images and the remaining 
5 hydrated thread images.  
 
 
Figure 51: Image Contrast as a Function of Increasing TE 
 Figure 52 depicts an example of the resulting signal intensity across a line segment as a 
function of data points taken. The maximum signal intensity difference of each SI profile for the 
range of echo times were collected, averaged, and finally compared. Table 15 displays the 
average maximum signal intensity difference for each applied echo time, which increases as a 
function of increasing TE as expected by previous microthread MR image visualization.   
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Figure 52: Signal Intensity as a Function of Echo Time 
Table 15: Average Maximum SI Difference as a Function of TE 
  TE 25ms TE 50ms TE 75ms TE 100ms 
Hydrated          
Thread 1 56 67 70 78 
Thread 2 65 80 81 89 
Thread 3 73 89 90 92 
Thread 4 70 82 85 90 
Thread 5 81 90 93 90 
          
Air Dried TE 25ms TE 50ms TE 75ms TE 100ms 
Thread 1 54 66 70 81 
Thread 2 61 70 75 79 
Thread 3 58 62 76 78 
Thread 4 58 69 69 85 
Thread 5 68 73 82 88 
          
Average: 64.4 74.8 79.1 85 
 
5.6.4 Image Artifacts 
 As expected, image artifacts were scattered throughout the acquired T1 and T2 image 
slices. Two recurring artifacts observed were areas of increased signal intensity or 
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“hyperintensity” around the perimeter of the microthread and arrowhead shape distortion of 
the thread itself. Figure 53 below depicts two areas of signal hyperintensity highlighted in red. 
Similar to previous methods numerous signal intensity profiles across the thread diameter and 
into the gelatinous medium were taken and compared. On average the signal intensity of these 
locations highlighted were 1.6 times that of the gelatin. 
 
Figure 53: Hyperintensity Artifact 
 As depicted in Figure 54 the circular area of decreased signal intensity representing the 
microthreads were occasionally misshapen. Through a visual analysis, the majority of these 
distortions were “arrowhead” shaped, as shown by the region highlighted in red. The direction 
in which the distortion occurred was also noted to be strictly vertical. 
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Figure 54: Microthread Shape Distortion 
5.7 3D- Reconstruction Design 
 The idea of three dimensional reconstruction is to be able to see the MR images in 
another dimension and visually analyze the phantom. This reconstruction was again done using 
ImageJ. A plugin for ImageJ was required in order to perform this reconstruction called “ImageJ 
3D Viewer”. This tool allowed each slice to be imported as a separate entity. The scale was then 
set for the image size of .14 x .14 x 1.5mm per pixel for hydrated threads and .09 x .09 x 1.5 mm 
for the air-dried threads. Each of the 15 images has the same size, and each of these images for 
each separate echo time was oriented in the same place on the xyz plane. The bottom left pixel 
of each image was oriented in the +x,+y,+z quadrant. This location provided a reference point 
for the image assembly. The image stack then aligned along from this reference point and the 
grey scale images were then assembled as a three dimensional figure. This programming plugin 
then provided an ability to shade the signal intensities of the individual slices of each image 
together. Doing this performed a three dimensional reconstruction of our cardiac phantom 
model.  
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5.7.1 3-D Reconstruction Results 
 The idea of the 3-D reconstruction was to be able to visualize the microthreads and the 
phantom using a computer generated image set. However, measurements were not able to be 
made in three dimensions on these images. Figure 55 and Figure 56 show a three dimensional 
reconstruction of our phantoms using the ImageJ 3D viewer. These were compiled and the 
smoothing surfaces were removed in order to view the slices individually. 
 
Figure 55: 3-D Air-Dried Phantom Reconstruction 
 
Figure 56: 3-D Hydrated Phantom Reconstruction 
 Figure 57 shows a box cut-out of our microthreads. This was done in order to show the 
thread tracks by themselves without the phantom surrounding it. This image was achieved by 
reversing the contrast of the images then using a box cut-out and then compiling the images in 
three dimensions. Figure 58 gives a very effective visualization of the thread track through the 
106 
 
phantom itself. Figure 59 provides a cross section in order to compre to the optical images. The 
methodology on how the 3-D reconstruction was conducted is depicted in 5.7 3D- 
Reconstruction Design. 
 
Figure 57: 3-D Reconstruction of Microthreads 
 
Figure 58: 3-D Montage of Individual Slices 
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Figure 59: Orthagonal Phantom View 
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6.0 Discussion 
6.1 T1-Weighted Images 
 The T1-weighted images showed some slight contrast between the infarcted and healthy 
regions of the cardiac phantom. The top portion of the images is somewhat darker than the 
bottom half, which is what we expected since the infarcted region was constructed to have a 
longer T1-relaxation than the healthy region. However, we expected a much greater contrast in 
between these two locations. These images also seemed to have differences in signal 
intensities moving from left to right, which was not expected. In all of the T1-weighted images, 
the signal intensities get lighter as you view them from left to right. This phenomenon may be 
explained by the phantom placement and alignment within the RF-coil. The main problem with 
the T1 acquisition which we performed was that the images do not effectively show the 
microthreads. Thus, the microthread diameter or contrast measurements were not able to be 
performed using these images. 
6.2 T2-Weighted Images 
 As expected, the T2-weighted images did not show contrast between the region of 
infarct and the healthy portion of the phantom. The reason why this was expected is explained 
in detail in 4.3.7.3 Preliminary Conclusions. The signal intensity of each phantom became 
brighter moving from left to right just as in the T1-weighted images. Once again, this can be 
explained by positioning and alignment of the cardiac phantom in the RF-coil. In comparison to 
T1-weighted images, the microthreads and their boundaries were more prominent in T2-
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weighted images allowing for accurate microthread diameter and contrast measurements, a 
primary objective of the experiment.   
6.3 Image Artifacts 
As expected, image artifacts were scattered throughout the acquired T1 and T2 image 
slices. Although there were no significant differences regarding thread diameter between the 
optical and MR images, these artifacts ultimately aided in the deviation of apparent thread 
diameter. The occurrence of susceptibility artifacts were expected due to the response of 
ferromagnetic-iron-based contrast agents and resulting susceptibility gradient. Magnetic 
susceptibility is a measure of a material’s tendency to interact and distort an applied magnetic 
field. The large susceptibility of the iron particles map signals from spins near the object to the 
same image location as distant spins, resulting in areas of double exposure, thus producing 
hyperintensity. The spherical shape of the microthreads could have also aided in the production 
of hyperintense areas. The magnetic field around the perimeter of a sphere, if transverse to the 
applied field, is intensified, producing increased signal intensity. The magnitude of this 
magnetic field intensity is a function of the radius, applied magnetic field, and susceptibility 
gradient.  
The shape distortion of imaged microthreads is typical. Spins just outside of an 
ellipsoid’s surface do not map in a continuous fashion with those just inside. As shown in Figure 
60, the image produced is an elongated v-shaped sphere. It is important to note that the 
severity of distortion is a function of the radius of the imaged sphere, with the degree of 
distortion increasing with decreasing sphere radius. [68] 
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Figure 60: Arrowhead Distortion as a Function of Radius 
6.4 Effectiveness of Contrast Agent 
 The microthreads were exposed to the contrast agent in order to increase the contrast 
in signal intensities between the microthread, infarcted gelatin, and healthy gelatin of the 
cardiac phantom. The microthreads were exposed to the contrast agent in a time variant 
manner in order to demonstrate whether exposure time had any significant effect on the 
contrast in the acquired images. Qualitatively, the T2-weighted images show that the contrast 
agent exposure time had no significant effect on contrast between these areas of interest, 
meaning that contrast neither increased nor decreased significantly as exposure time was 
increased. Another interesting finding was that the control microthread had just as much 
contrast as those which were exposed to contrast agent, which questions the necessity of 
contrast agents in visualizing these microthreads via MRI. 
6.5 Effect of Microthread Preparation Type 
 The microthreads were prepared in two different ways to determine whether 
preparation type played a significant role in contrast between areas of interest within the 
cardiac phantom. One set of four microthreads were simply exposed to the contrast agent in 
the time variant manner previously discussed and placed inside one cardiac phantom. Another 
set of four microthreads were exposed to the contrast agent in a time variant manner, air-
111 
 
dried, and then placed inside a separate cardiac phantom. During the experiment it was 
apparent that the microthreads which were not air-dried were clearly thicker in diameter. 
However, Figures 40 and 41 show that the microthread preparation had no significant effect on 
the microthread diameter. Qualitatively it was apparent that the microthread preparation type 
did not have an effect on contrast in the T2-weighted images. 
 6.6 Contrast as a Function of TE 
Based upon knowledge of magnetic resonance imaging the results suggesting an 
increase in image contrast as a function of TE can be rationalized. The echo time is the time at 
which the image signal is acquired after the RF pulse. Increasing TE allows for increasing time 
for nucleic relaxation, thus reducing the intensity of the signal acquired by the RF coil in the 
transverse plane.The resulting intensity of the microthread is reduced to near zero, making the 
thread more apparent. The increase in maximum difference in signal intensity as TE increases is 
most likely due the variation in relaxation rates between the microthread and the gelatin. 
Allowing for longer periods of relaxation also allows for a greater difference between the 
relaxation curves, thus producing more contrast.      
6.7 Project Applications 
 
6.7.1 Economics 
 
 The system design would influence the economy and everyday living by creating job 
opportunities for chemists, MRI technicians, and biomedical as well as electrical engineers. The 
contrast agent (ferumoxtran iron-oxide nanoparticles) production requires chemists while the 
tissue-embedded microthread production and contrast agent application requires biomedical 
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engineers. MRI technicians and electrical engineers can benefit from the fact that MRI 
machines will be needed to function properly to provide accurate analysis of cardiac 
regeneration. Government funding may also be needed for clinical and pre-clinical trials in MRI 
cardiac regeneration monitoring.  If cardiac regeneration is then deemed effective and brought 
into the market, such expensive treatments would be available for MI survivors.  
6.7.2 Environmental Impact 
 
 There may be a decrease in the amount of waste products when monitoring cardiac 
regeneration via MRI than with a histological approach because there will be no need to 
manually create hundreds to thousands of slices to view under a microscope. The MRI machine 
is capable to creating the slices of an in vivo heart itself, which can be stored on a computer, 
which negates the need for creating slices in a lab and then throwing them away after the 
analyses are performed.  
6.7.3 Societal Influence 
 
 As previously mentioned, the design could generate job opportunities for many 
individuals in society, as well as help save lives of those who have suffered from MI. Since 
current treatments only suppress the increase in stress on the ailing heart post MI, determining 
the effectiveness of delivering stem cells with microthreads via MRI can one day stimulate 
cardiac regeneration. Cardiac regeneration can potentially restore the heart back to full health 
and functionality, providing the survivors of a myocardial infarction with longer, healthier, and 
more productive lives. 
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6.7.4 Political Ramifications 
 
The system design involves the use of stem cells for cardiac regeneration, which is an 
extremely controversial topic. The support of the federal government is needed for such 
research to continue. If MRI is able to demonstrate that cardiac regeneration is effective, such 
treatments may introduce new clauses in health insurance packages. Private health insurance 
companies or the federal government (with the passage of Barack Obama’s global health 
insurance plan) may have to offer different types of health insurance packages to cover the 
expensive costs of these treatments to MI survivors. Such success may also influence other 
countries to adopt stem cell therapy which may not have been accepted in the past. This would 
in turn affect the global economy since more job opportunities would stem in foreign countries 
as well as the influence of foreign governments on their countries.  
 
6.7.5 Ethics 
 
 The ethical implications concerning this particular project are limited. Potential false 
concerns are expected to most likely revolve around the usage of human mesenchymal stem 
cells (hMSCs). HMSCs, unlike embryonic stem cells, are found in adult tissues, including bone 
marrow, periosteum, trabecular bone, adipose tissue, synovium, skeletal muscle, and 
deciduous teeth. Although embryonic stem cells have numerous advantages, harvesting them 
has been known to destroy the embryo, an effect that has been met with great opposition. 
Adult hMSCs however can be harvested from tissue with minimal moral or ethical ramifications, 
and have demonstrated the ability to divide indefinitely and differentiate into other types of 
cells.  
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6.7.6 Health and Safety  
 
The administration of iron based contrast agents into the body – specifically the 
circulatory system – were considered prior to their implementation, as further studies would 
potential aim to utilize the design parameters in vivo. Iron is found normally in the body and is 
an essential component of hemoglobin, the oxygen carrying pigment in the body. Numerous 
clinical tested have determined that iron based agents are well tolerated. No acute or toxic 
effects were detected by studies in rats or beagle dogs who received 150 times the dose 
proposed for MR imaging of the liver. [69] The ability to process and expel excess iron has also 
been demonstrated, as iron based agents’ intravenously injection have been noted to cleared 
from the body within 7 days. [69] 
The magnitude of the magnet utilized by the MR machine itself posses’ further health 
and safety related issues. Prior to imaging there are noted safety related protocols that must be 
addressed. The greatest safety issue when imaging includes the magnets’ attraction to 
ferromagnetic material. Introduction of ferromagnetic materials around the machine can result 
in them becoming harmful projectiles. For similar reasons, patients with magnetic implants 
such as a cardiac pacemaker are also put under increased risk.  
6.7.7 Manufacturability 
 The manufacturability or reproducibility of the final design was considered extensively 
in the design process.  The compliance of our final design with our objectives, functions, and 
constraints aided in the viability of the design being manufactured. All design goals were met, 
producing a low cost, easy to use, bio- and MRI-compatible, and reproducible experiment to 
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locate tissue embedded microthreads in cardiac muscle. The necessary design components to 
be manufactured including the development of collagen or fibrin microthreads, gelatinous 
phantom, and contrast agent concentration and application, are simple enough to be 
accurately replicated when following the provided design parameters.        
6.7.8 Sustainability 
 
 The sustainability of the in vitro modeling system is subject to questions that have yet to 
have been examined. The most important question to be looked into would most likely be the 
viability of collagen and fibrin microthreads as a function of time. When delivered in vivo the 
threads have been noted to degrade overtime, limiting the ability to locate them. It would be 
interesting to see if the microthreads experience the same effects in the gelatinous phantom, 
therefore limiting the potential time that MRI could be used to locate the microthreads. 
Another potential issue could be the ability of the gelatin to sustain the designed water 
concentration over time. Water diffusion or evaporation over time could severely affect the 
spatial water concentration and produce unrepresentative image contrast.  
 Although instances of potential sustainability are apparent, sustainability in general is 
not particularly relevant to the ultimate goals of the project. The ability to locate embedded 
microthread shortly after implantation is crucial to maximizing the effectiveness of stem cell 
and myocardial regeneration, however, once the placement is confirmed there more concern 
on the positioning of the cell overtime then the microthreads, thus eliminating the need for 
sustainability.    
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7.0 Final Design and Validation 
In order to produce a successful end product, it is important to conduct extensive 
background research encompassing the full spectrum of project components. Proper 
background research allows for a clear understanding of what exactly the problem is and how 
to potentially solve it. It also provides information on the history behind the problem at hand 
and how solutions to the problem have previously been attempted. A clear and thorough 
definition of the problem then permits for plausible goals and objectives to produce a 
successful outcome. 
 Before the objectives and goals can be defined however, it is essential to create an 
interim project schedule with tasks designated to specific group members in order to efficiently 
begin the engineering design process. This can be accomplished using a Gantt chart, which 
helps in assigning specific duties of the project to group members, aids in the visualization of 
project progression, and establishes deadlines for important milestones in the project. If tasks 
are not divided up in the group, then the project may not comply with its time constraints. It is 
vital to realize that a Gantt chart is never concrete and that it is subject to change throughout 
the timeline of the project as obstacles and constraints are often encountered during the 
design process. 
 Once the objectives and constraints are defined, the focus of the project can once again 
be more thoroughly redefined with more specific needs, wants, functions, specifications, and 
constraints. Based upon the thorough need analysis it was determined that the location of 
embedded microthreads is crucial to the success of myocardial regeneration and restoration of 
cardiac functionality. Currently there lacks an effective and efficient method to determine the 
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location and performance of these embedded threads, a problem that potentially can be 
addressed via magnetic resonance imaging.  
Once the objectives, functions, and constraints were clarified the client statement was 
revisited and redefined using the new information at hand. This statement was more concise in 
addressing the overall goals of the project and the means by which they would be met. Creating 
a revised project statement also aids in establishing the direction of the design and credibility 
with the client. Utilizing the final project goals and direction alternative designs were created 
via brainstorming. To simplify the process the design was divided into three distinct 
components, the cardiac modeling system, data acquisition, and data analysis. Making sure that 
each chosen component was compatible with one another, the “best” design of each 
component was chosen via feasibility testing and weighted comparisons. 
Ultimately the cardiac modeling system consisted of a simple and inexpensive gelatin-
based medium, with gelatin concentrations and MR parameters designed to mimic the contrast 
of actual cardiac tissue. Collagen microthreads were soaked in Ferumoxtran, a 
superparamagnetic iron oxide and negative contrast agent, to produce more contrast between 
the threads and surrounding tissue, effectively increasing the ability to locate the threads and 
differentiate their boundaries. To produce results consisted with project goals, gelatin and 
contrast agent concentrations were determined via initial MR relaxivity measurements as a 
function concentration. Utilizing the preliminary data and the knowledge of MR imaging, 
appropriate parameters for the final design could be determined. With the project team 
confident the modeling system would mimic in vivo results and embedded microthreads would 
be easily distinguishable design variables were altered, specifically contrast agent application, 
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to further optimize results. Thread exposure time and hydration were both examined to 
determine if they had an effect on resulting thread signal intensity and thus differentiation.  
Results and conclusion from the experiment verified the calculations made regarding 
properly design cardiac phantom and MR parameters. The microthread location in the cardiac 
phantom was apparent and statistically similar in diameter regardless of the agent application 
process. Apparent microthread diameter of the MR image in comparison to the actual diameter 
measured via an optical image was statistically similar, suggesting that the current design and 
procedure is highly accurate. Accurate in vivo thread location and measurements utilizing 
imaging compilation techniques that takes fractions of the time when compared to previous 
methods offer the client and all potential users a significantly improved method for not only 
thread visualization, but also stem cell delivery and myocardial regeneration.            
 
 
 
 
 
 
 
 
 
119 
 
8.0 Conclusions and Future Recommendations 
The development of MRI as an enabling technology for tissue science and engineering 
has proven to be highly effective. Through background research the problem was able to be 
identified, objectified, and put through the design process. A preliminary design was able to be 
drawn up, then a  series of preliminary gelatin and contrast agent concentration experiments 
were made to provide proper contrast for the images, then a careful image analysis procedure 
was performed. A thread diameter data analysis protocol was designed, this is key due to the 
fact that without it there would be no way to actually determine the thread diameter. The 
three dimensional reconstruction and cross sectioning provided the means to match up the 
actual phantom to the re-rendered phantom proving it to be ideally one and the same. There 
were some image artifacts that occurred, but through the design of the experiment, were able 
to be almost eliminated using the data analysis tools.  
There are a series of conclusions that are able to be drawn from our project. The first, of 
which is the ability to visualize bundles of microthreads that are impregnated with Ferumoxtran 
iron-oxide nanoparticles.This visualization was done using our preliminary concentration 
analysis of our concentration curves in order to provide proper contrast for our images, along 
with our designed image analaysis protocol.  The second, is the ability to determine the 
microthread size and location in both our MR images and our optical images. This size and 
location was determined using our thread diameter analyzis protocol along with the three 
dimensional reconstruction and cross sectioning. The last conclusion, and the overall complete 
goal of the project, is the ability to take the microthreads introduce them into the gelatin 
phantom, design a set of imaging parameters in order to aquire images with proper contrast, 
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then the ability to take these images and assemble them, then to take this data and analyze it 
and come up with demonstrated results. 
Of course there are possible changes that can be made to this overall project. The first 
of which is the ability to design and develop a means to be able to accurately be able to take 
measurements once the 3-D reconstruction is compiled. This allows better visualization along 
with the same measurement accuracy which was received with the normal data analysis. The 
second goal is to be able to determine the necessity and viability of the use of contrast agents, 
in order to actually visualize the microthreads inside an MRI machine. The third future goal is 
the validation of the actual iron-oxide nanoparticle uptake of the microthreads. The idea of this 
is to ensure that the microthreads that were exposed to constrast agent actually soaked up the 
constrast agent. Of course the ultimate and final goal is to be able to take microthreads, treated 
with human mesenchymal stem cells, and be able to visualize them inside a living heart using 
magnetic resonance imaging. 
 
 
 
 
 
121 
 
Table of Figures 
Figure 1: Cross Section and Blood Flow of Heart [18] .................................................................. 13 
Figure 2: Increase in LV Pressure (B) in an attempt to Maintain Efficient Stroke Volume [23] ... 16 
Figure 3: Endoventricular Patch Plasty or Dor Procedure ............................................................ 18 
Figure 4: Intravenous Infusion Method for Stem Cell Delivery [42] ............................................. 21 
Figure 5: Intracoronary Infusion Method for Stem Cell Delivery [42] .......................................... 22 
Figure 6: Transepicardial Injection Method for Stem Cell Delivery [42] ...................................... 23 
Figure 7: Transendocardial Injection with Cardiac Mapping System for Stem Cell Delivery [42] 24 
Figure 8: Microthread Size ............................................................................................................ 28 
Figure 9: Site Specific Placement Tissue Embedded Microthread ............................................... 29 
Figure 10: 3D Construct Via Histological Sectioning [26] ............................................................. 30 
Figure 11: Magnetic Moment of a Nuclear Dipole ....................................................................... 32 
Figure 12: Parallel and Anti-Parallel Orientation .......................................................................... 32 
Figure 13: M0 Vector ..................................................................................................................... 33 
Figure 14: Nuclear Precession and Angle ..................................................................................... 34 
Figure 15: NMRI Coordinate System ............................................................................................. 34 
Figure 16: Mo Vector Rotation into the Transverse Plan following 90° Pulse .............................. 36 
Figure 17: T1 Recovery of Muscle vs. Fat ...................................................................................... 37 
Figure 18: Un-alignment of Nuclear Spins Over Time .................................................................. 38 
Figure 19: T2 Decay of Muscle and Fat ......................................................................................... 39 
Figure 20: Slice Selection via Field Gradients and a 90: RF Pulse  *21+ ........................................ 40 
Figure 21: Vector Phase prior to Phase Encoding Gradient ......................................................... 41 
Figure 22: Vector Phases after Phase Encoding Gradient ............................................................ 41 
Figure 23: WPC Model .................................................................................................................. 68 
Figure 24: Gelatin Formation in Phantom .................................................................................... 68 
Figure 25: Initial Gelatin Cardiac Phantom ................................................................................... 69 
Figure 26: CIRS Synthetic Phantom Model ................................................................................... 70 
Figure 27: Signal Intensity Measurements using ImageJ .............................................................. 71 
Figure 28: Area Measurements using Segment ............................................................................ 71 
Figure 29: 12-Well Plate ................................................................................................................ 73 
Figure 30: T1 Signal Intensity vs. Time at 10% Gelatin Concentration ......................................... 78 
Figure 31: T2 Signal Intensity vs. Time at 10% Gelatin Concentration ......................................... 78 
Figure 32: 1/T1 vs. Gelatin Concentration .................................................................................... 79 
Figure 33: 1/T2 vs. Gelatin Concentration .................................................................................... 80 
Figure 34: 1/T1 vs. Ferumoxtran Concentration .......................................................................... 81 
Figure 35: 1/T2 vs. Ferumoxtran Concentration .......................................................................... 81 
122 
 
Figure 36: T2 Contrast Agent Study - Final Parameter Results ..................................................... 83 
Figure 37: Collagen Microthread Extrusion Process ..................................................................... 85 
Figure 38: pH approximation of the PBS solution ........................................................................ 86 
Figure 40: Gelatin Delivery into 35mm Petri Dish ........................................................................ 88 
Figure 39: Sterile 35mm Petri Dish w/ Gelatin ............................................................................. 88 
Figure 41: Thread Location and Agent Exposure Time ................................................................. 89 
Figure 43: Microthread Placement in between Gelatin Layers of Varying Concentration .......... 91 
Figure 42: Gelatin Concentration and Placement ........................................................................ 91 
Figure 44: T1-Weighted Image of Cardiac Phantom with Hydrated Microthreads ...................... 94 
Figure 45: T1-Weighted Image of Cardiac Phantom with Air-Dried Microthreads ....................... 95 
Figure 46: T2-Weighted Image of Cardiac Phantom with Hydrated Microthreads at 100ms TE . 95 
Figure 47: T2-Weighted Image of Cardiac Phantom with Air-Dried Microthreads at 100ms TE .. 96 
Figure 48: Image Analysis, Full-Width Half-Maximum-Height ..................................................... 97 
Figure 49: Average Hydrated Microthread Diameter Measurements ......................................... 99 
Figure 50: Average Air-Dried Microthread Diameter Measurements ........................................ 100 
Figure 51: Image Contrast as a Function of Increasing TE .......................................................... 101 
Figure 52: Signal Intensity as a Function of Echo Time............................................................... 102 
Figure 53: Hyperintensity Artifact ............................................................................................... 103 
Figure 54: Microthread Shape Distortion ................................................................................... 104 
Figure 55: 3-D Air-Dried Phantom Reconstruction ..................................................................... 105 
Figure 56: 3-D Hydrated Phantom Reconstruction .................................................................... 105 
Figure 57: 3-D Reconstruction of Microthreads ......................................................................... 106 
Figure 58: 3-D Montage of Individual Slices ............................................................................... 106 
Figure 59: Orthagonal Phantom View ........................................................................................ 107 
Figure 60: Arrowhead Distortion as a Function of Radius .......................................................... 110 
Figure 61: Data Analysis Objective Tree ..................................................................................... 133 
Figure 62: Phantom Modeling System Objective Tree ............................................................... 134 
Figure 63: Data Acquisition Objective Tree ................................................................................ 134 
Figure 64: Average T1 Relaxation Rates vs. Magnet Strength .................................................... 139 
Figure 65: Average T2 Relaxation Rates vs. Magnet Strength .................................................... 139 
Figure 66: Normal (yellow) v Infarct (blue) trend lines .............................................................. 141 
Figure 67: White Potato Phantom .............................................................................................. 144 
Figure 68: Potato and Carrot Phantom ....................................................................................... 144 
Figure 69: Separated Gelatin Phantom....................................................................................... 145 
Figure 70: Gelatin Phantom ........................................................................................................ 145 
Figure 71: T1 of 10% Gelatin Concentration ............................................................................... 151 
Figure 72: T1 of 6% Gelatin Concentration ................................................................................. 151 
Figure 73: T1 of 3% Gelatin Concentration ................................................................................. 152 
123 
 
Figure 74: T2 of 10% Gelatin Concentration ............................................................................... 152 
Figure 75: T2 of 6% Gelatin Concentration ................................................................................. 153 
Figure 76: T2 of 3% Gelatin Concentration ................................................................................. 153 
Figure 77: T1 of 5ug/mL Contrast Agent ..................................................................................... 154 
Figure 78: T1 of 10ug/mL Contrast Agent ................................................................................... 154 
Figure 79: T1 of 20 ug/mL Contrast Agent .................................................................................. 155 
Figure 80: T1 of 30ug/mL Contrast Agent ................................................................................... 155 
Figure 81: T1 of 50 ug/mL Contrast Agent .................................................................................. 156 
Figure 82: T2 of 5 ug/mL Contrast Agent .................................................................................... 156 
Figure 83: T2 of 10 ug/mL Contrast Agent .................................................................................. 157 
Figure 84: T2 of 20 ug/mLContrast Agent................................................................................... 157 
Figure 85: T2 of 30 ug/mL Contrast Agent .................................................................................. 158 
Figure 86: T2 of 50 ug/mL Contrast Agent .................................................................................. 158 
Figure 87: Signal Intensity vs Time for all AMI and Gelatin at TR of 1600.................................. 159 
Figure 88: Signal Intensity vs Time for all AMI and Gelatin at TR of  1400 ................................. 159 
Figure 89: Intensity vs Time for all AMI and Gelatin at TR of  1200 ........................................... 159 
Figure 90: Intensity vs Time for all AMI and Gelatin at TR of  1000 ........................................... 160 
Figure 91: Intensity vs Time for all AMI and Gelatin at TR of  800 ............................................. 160 
Figure 92: Intensity vs Time for all AMI and Gelatin at TR of  600 ............................................. 160 
Figure 93: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1400 .......................... 161 
Figure 94: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1400 Zoomed ............ 161 
Figure 95: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1300 .......................... 161 
Figure 96: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1300 Zoomed ............ 162 
Figure 97: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1200 .......................... 162 
Figure 98: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1200 Zoomed ............ 162 
Figure 99: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1100 .......................... 163 
Figure 100: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1100 Zoomed .......... 163 
Figure 101: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1000 ........................ 163 
Figure 102: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1000 Zoomed .......... 164 
 
 
 
 
 
 
124 
 
Table of Tables 
 
Table 1: Objective Pairwise Comparison Chart Example .............................................................. 58 
Table 2: Weighted Objectives from Project Stakeholders Example ............................................. 59 
Table 3: Example Evaluation Table ............................................................................................... 65 
Table 4: Design Alternatives ......................................................................................................... 65 
Table 5: Example Sub-objective Table .......................................................................................... 66 
Table 6: Design Alternatives Sub-objectives ................................................................................. 66 
Table 7: Actual Gelatin and PBS Measurements .......................................................................... 73 
Table 8: Actual Gelatin Concentration for Preliminary Imaging ................................................... 74 
Table 9: TR and TE Scan Values for Gelatin Samples .................................................................... 76 
Table 10: TR and TE Scan Values for AMI 227 Concentration ...................................................... 76 
Table 11: Gelatin Concentration Initial Results ............................................................................ 79 
Table 12: Ferumoxtran Concentration Initial Results ................................................................... 80 
Table 13: Contrast Agent Application ........................................................................................... 88 
Table 14: TR and TE Times for Imaging Experiment ..................................................................... 92 
Table 15: Average Maximum SI Difference as a Function of TE ................................................. 102 
Table 16: Objective Pairwise Comparison Chart......................................................................... 132 
Table 17: Weighted Objectives from Project Stakeholders ........................................................ 133 
Table 18: Morphological Table ................................................................................................... 135 
Table 19: Heart Rate Statistics & Calculations ............................................................................ 137 
Table 20: Relaxation Rate Variation............................................................................................ 138 
Table 21: Case Study References ................................................................................................ 138 
Table 22: T2 Normal v Infarcted relaxation ................................................................................ 141 
Table 23: MQP reference particle data [65] ............................................................................... 142 
Table 24: Objectives and Constraints for Phantom .................................................................... 146 
Table 25: Objectives and Constraints for Data Acquisition ........................................................ 147 
Table 26: Objectives and Constraints for Data Analysis ............................................................. 149 
Table 27: Sub-Objective Weighting for Phantom ....................................................................... 149 
Table 28: Sub-Objective Weighting for Phantom Contrast Agent Delivery ............................... 149 
Table 29: Sub-Objective Weighting for Microthread Contrast Agent Delivery .......................... 150 
Table 30: Sub-Objective Weighting for Contrast Agent Use ...................................................... 150 
  
125 
 
Works Cited 
1. Antunes, P. (2005). Left Ventricular aneurysms: early and long-term results of two types 
of repair. European Journal of Cardiothoracic Surgery , 27(2):210-215. 
2. Athanasuleas, C. L., Buckberg, G. D., Stanley, A., Siler, W., Dor, V., Di Donato, M., et al. 
(2004). Surgical ventricular restoration in the treatment of congestive heart failure due 
to post-infarction ventricular dilation. Journal of the American College of Cariology , 
47(7):1439-1445. 
3. Barry, F. P., & Murphy, M. J. (2004). Mesenchymal stem cells: clinical applications and 
biological characterization. The International Journal of Biochemistry & Cell Biology , 
36(4):568-84. 
4. Burton, R. (2006). Three-Dimensional Models of Individual Cardiac Histo-Anatomy: Tools 
and Challenges. Annals of the New York Academy of Sciences , 1080:301-19. 
5. Chevallay, B., & Herbage, D. (2000). Collagen-based biomaterials as 3D scaffold for cell 
cultures:applications for tissue engineering. Institut de Biologie et Chimie des Proteins.  
38(2):211-8. 
6. Christman, K. L., Vardanian, A. J., Fang, Q., Sievers, R. E., Fok, H. H., & Lee, R. J. (2004). 
Injectable Fibrin Scaffold Improves Cell Transplant Survival, Reduces Infarct expansion, 
and Induces Neovasculature Formation in Ischemic Myocardium. Journal of the 
American College of Cardiology , 44(3):654-60. 
7. Christman, K., & Lee, R. (2006). Biomaterials for the Treatment of Mycardial Infarction. 
Journal of American College , 48:907-913. 
8. Cornwall, K. (n.d.). Collagen and Fibrin Biopolymer Microthreads for Bioengineered 
ligament Generation: a Dissertation. University of Massachusetts Medical School . 
9. Cornwall, K., & Pins, G. (2007). Discrete crosslinked fibrin microthread scaffolds for 
tissue regeneration. J Biomed Mater Res A , 82A(1):104-112. 
10. Davis, M., Hsieh, P., Grodzinsky, A., & Lee, R. (2005). Custom Design of the Cardiac 
Microenvironment with Biomaterials. Circulation , 97:8-15. 
11. Decision Resources, I. (2003). Total Market Value for Post Myocardial Infarction 
Therapeutics Will Exceed $13 Billion in 2012. PR Newswire . 
12. Eghbali, M., & Weber, K. (1990). Collagen and the myocardium: fibrillat structure, 
biosynthesis and degredation in relation to hypertrophy and its regression. Molecular 
and Cellular Biochemistry , 96(1):1-14. 
13. Ferrero, J. M. (2006). Wiley Encyclopedia of Biomedical Engineering. John Wiley & Sons . 
14. Gabe, M. (1976). Histological Techniques. New York: Springer-Verlag. 
15. Haacke, E. M. (New York). Magnetic Resonance Imaging : Physical Principles and 
Sequence Design. J Wiley & Sons: 1999. 
16. Health, C. (2003). Datasheet, Diagnostic Imaging PDF. Retrieved from Multipurpose 
Tissue/Cyst Ultrasound Phantom. 
17. Heart Disease andStroke Statistics. (2009). American Heart Association . 
18. Heart and Stroke Facts. (2003). American Heart Association . 
19. Heber-Katz, E., Leferovich, J., Bedelbaeva, K., Gourevitch, D., & Clark, L. (2004). The 
scarless heart and the MRL mouse. Trans R Soc , 359(1445): 785–793. 
126 
 
20. Ho, W. (2006). The Behavior of Human Mesenchymal Stem Cells in 3D fibrin Clots: 
Dependence on Fibrin Clots: Dependence on Fibrinogen Concentration and Clot 
Structure. Tissue Engineering , 12(6):1587-95. 
21. Hornak, J. P. (2008). The Basics of MRI. Retrieved October 10, 2009, from The Basics of 
MRI: http://www.cis.rit.edu/htbooks/mri/  
22. Huang, N., Yu, J., Sievers, R., Li, S., & Lee, R. J. (2005). Injectable Biopolymers Enhance 
Angiogenesis after Myocardial Infarction. Tissue Engineering , 11(11-12):1860-6. 
23. Klabunde, R. (2004). Cardiovascular Pharmacology Concepts. Lippincott, Williams & 
Wilkins. 
24. Kloner, R. A., & Jennings, R. B. (2001). Consequences of Brief Ischemia: Stunning, 
Preconditioning,and TheirClinical Implications. Circulation , 104:2981-89.  
25. Kocupura, P., Azeloglu, E., Kelly, D., Doronin, S., & Badylak, S. (2005). Tissue Engineered 
Myocardial Patch Derived from Extracellular Matrix Regional Mechanical Function. 
Circulation , 112:I-144 – I-149. 
26. Leeson, T., & Leeson, R. (1970). Histology. Philadephia: Saunder. 
27. Leor, J., Aboulafia-Etzion, S., Dar, A., Shapiro, L., Barbash, I. M., & Battler, A. (2000). 
Bioengineering Cardiac Grafts: A New Approach to Repair the Infarcted Myocardium. 
Circulation , 102:III-56-III-61. 
28. McRobbie, D. W., Moore, E. A., Graves, M. J., & Prince, M. R. (2006). MRI : Prom Picture 
to Proton. UK, Cambridge: Cambridge University Press. Pg 155. 
29. McRobbie, D. W., Moore, E. A., Graves, M. J., & Prince, M. R. (2006). MRI : Prom Picture 
to Proton. UK, Cambridge: Cambridge University Press. 
30. O'Connor, M., & Caiati, T. (1995). Effects of Scatter Correction on the Measurement of 
Infarct Size from the SPECT Cardiac Phantom Studies. The Journal of Nuclear Medicine , 
36 (11) 2080-2086. 
31. Opie, L. H. (2004). Heart Physiology: From Cell to Circulation. Philidephia: Lippincott 
Williams & Wilkins. 
32. Pittenger, M. F. (2004). Mesenchymal stem cells and their potential as cardiac 
therapeutics. Circulation Research , 95:9-20. 
33. Ponticiello, M. (2000). Gelatin based resorbable spounge as a carrier matrix for human 
mesenchymal stem cells in cartilage regeneration therapy. Journal of Biomedical 
Materials Research , 52(2):246-55. 
34. Rowley, J. A., Madlambayan, G., & Mooney, D. J. (199). Alginate hydrogels as synthetic 
extracellular matrix materials. Biomaterials , 20(1):45-53. 
35. Ruszczak, Z. Effect of collagen matrices on dermal wound healing. Advanced Drug 
Delivery Reviews , 55(12):1595-611. 
36. Sherwood, L. (2007). Human Physiology, from Cells to Systems 6th Edition. Thomson 
Brooks/Cole. 
37. Smith, R. C. (1997). Understanding Magnetic Resonance Imaging. Boca Raton: CRC Press 
LLC. 
38. Stevens, M. (2004). A rapid-curing alginate gel system:utility in periosteum-
derivedcartilage tissue engineering. Biomaterials , 25 (5):887-894. 
39. Sutton, M., & Sharpe, N. (2000). Left Ventricular Remodeling After Myocardial 
Infarction: Pathophysiology and Therapy. Circulation , 101:2981-88. 
127 
 
40. Tang, J., & e. a. (2006). Mesenchymal stem cells participate in angiogenesis and improve 
heart function in rat model of mycardial ischemia with reperfusion. Eupropean Journal 
of Cario-Thoracic Surgery . 30(2):353-61. 
41. Tonnessen, T., & Knudsen, C. W. (2005). Surgical Left Ventricular Remodeling in Heart 
Failure. The European Journal of Heart Failure , 7 (5):704-707. 
42. Wei, H. (2009). Cell Delivery and tracking in post-myocardial infarction cardiac stem cell 
therapy: an introduction for clinical researchers. Circulation . (DOI: 10.1007/s10741-009-
9134-1) 
43. Wesbey, G., Higgins, C., Lanzer, P., & Botcinick, E. (1984). Imaging and characterization 
of acute mycardial infarction in vivo by gated nuclear magnetic resonance. Circulation , 
69:125-130. 
44. Williams, M., Knaut, M., & Be'rube, D. (2002). Application of Microwave Energy in 
Cardiac Tissue Ablation: From In Vitro Analyses to Clinical Use. Annal of Thoracic Surgery 
, 74:1500-1505. 
45. Wollert, K. C., & Drexler, H. M. (2005). Mesechymal Stem Cells for Myocardial Infarction: 
Promises and Pitfalls. Circulation , 112:151-3.  
46. Zimmermann, W. H., Melnychenko, I., & Exchenhagen, T. (2004). Engineered heart 
tissue for regeneration of diseased hearts. Biomaterials , 25 (9):1639-1647. 
47. Lee K.T., Joseph MD & Glazer S. Harvey MD. (1990). Controversy in the MR Imaging 
Appearance of Fibrosis. Radiology. 177(1):21-2 
48. Wenzhen, Z. et al. (2007) Superparamagnetic Iron Oxide Labeling of Neural Stem Cells 
and 4.7T MRI Tracking in vivo and in vitro. Journal of Huazhong University of Science and 
Technology. 27 (1): 107-110. 
49. J. Krejčí , et al. (2008).  In vitro labeling of mouse embryonic stem cells with SPIO 
nanoparticles. Physiol. Biophys. 27, 160–169. 
50. Cobb J, et al. (2009) Improved In Vivo Measurement of Myocardial Transverse 
Relaxation with 3 Tesla Magnetic Resonance Imaging. Journal of Magnetic Resonance 
Imaging. 30: 684–689.  
51. Boxt M, Lawrence, et al. (1993) Estimation of myocardial water content using transverse 
relaxation time from dual spin-echo magnetic resonance imaging. Magnetic Resonance 
Imaging. 11(3): 375-383.  
52. Hosch W, et al. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 
relaxation times in cardiac amyloidosis. Invest Radiol. 2007 Sep; 42(9):636-42. 
53. Allmann KH, Horch R, Uhl M, Gufler H, Altehoefer C, Stark GB, Langer M. (1997) MR 
imaging of the carpal tunnel. Eur J Radiology. 25:141–145. 
54. Imbriaco M, et al. (2007) MRI Characterization of Myocardial Tissue in Patients with 
Fabry’s Disease. AJR . 188:850–853 
55. Maris T, Mavrogeni S. (1998) Myocardial iron deposition in Beta-Thalassemia studied by 
magnetic resonance imaging. International Journal of Cardiac Imaging.  14: 117–122. 
56. Marie P, Carteaux J, et al. (1998) Detection and prediction of acute heart transplant 
rejection: preliminary results on the clinical use of a “black blood” magnetic resonance 
imaging sequence. Transplantation Proceedings. 30, 1933–1935  
128 
 
57. Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF. (1992) Quantitative 
Dependence of MR Signal Intensity on Tissue Concentration of Gd(HP-DO3A) in the 
Nephrectomized Rat. Magnetic Resonance Imaging. 10:97-108 
58. Gold G, Han E. (2004) Musculoskeletal MRI at 3.0 T: Relaxation Times and Image 
Contrast. AJR.  183:343–351 
59. Duewell S, et al. (1995) Musculoskeletal MR Imaging at 4T and 1.5T: Comparison of 
Relaxation Times and Image Contrast. Radiology. 196: 551-555. 
60. Sharma P, et al. Post-Contrast T1 Measurements of Blood, Infarct and Normal 
Myocardium at 1.5T and 3T. Proceedings of the 13th Annual Meeting of ISMRM, Miami 
Beach, FL, USA, 2005. 
61. Babes, L , et al. (1999). Synthesis of Iron Oxide Nanoparticles Used as MRI Contrast 
Agents A Parametric Study. Journal of Colloid and Interface Science. 212: 474-482. 
62. Bulte, J and Kraitchman, D . (2004). Iron oxide MR contrast agents for molecular and 
cellular imaging. NMR Biomed. 17, 484-499. 
63. Howes, S . Design of a Noninvasive System for the Evaluation of Collagen Scaffolds Using 
MRI. Worcester Polytechnic Institute . May 2007. 
64. CIRS. (2009). Ultrasound Phantoms. Retrieved December 16, 2009. 
http://www.cirsinc.com/067_ultra.html  
65. Gribouski E, Jaimes R. (2009) The Use of Iron-oxide Nanoparticles for Hyperthermia 
Cancer Treatment and Simultaneous MRI Monitoring. Worcester Polytechnic Institute.  
66. Zhang H, et al. (2007) Injection of bone marrow mesenchymal stem cells in the 
borderline area of infracted myocardium: Heart status and cell distribution. J Thorac 
Cardiovasc Surg 2007;134 
67. Cornwell, K. (2006) Crosslinking of discrete self-assembled collagen threads: Effects on     
mechanical strength and cell–matrix interactions. Journal of Biomedical Materials 
Research Part A DOI 10.1002/jbm.a. 
68. Schenck,JF. The role of magnetic susceptibility in magnetic resonance imaging: MRI 
magnetic compatibility of the first and second kinds. American Association of Physicists 
in Medicine. 23:6, 839. June 2006 http://mrel.usc.edu/class/591/library/Schenck-
Suscept.pdf  
69. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis 
J. Superparamagnetic iron oxide: Pharmacokinetics and toxicity. AJR. American Journal 
of Roentgenology 1989 Jan-1;152(1):167-73. 
70. Image Processing and Analysis in Java. NIH. http://rsbweb.nih.gov/ij/ Version 1.43u 24 
April 2010. 
  
129 
 
Glossary 
Artifacts – distortion of pixels in an image created by susceptibility effects such as water 
diffusion or contrast agents 
Contrast agent – chemical which allows extra contrast to occur when performing an image 
aquisition 
Echo time (TE) – the time in which the actual imaging of the subject is performed after 
excitation of the RF pulse 
Ferumoxtran – AMI-227, superparamagnetic iron-oxide nanoparticle. SPIO contrast agent 
Full width half maximum height – analysis of depth of a hole, take the full width of the 
depression, then take the maximum height, and then perform the measurement at half that 
height 
Human mesenchymal stem cells – (hMSCs) stem cells that are derived from humans, non-
embryonic, provide the ability to differentiate into surrounding cell types 
ImageJ – designed by the NIH, program to import, examine, manipulate, analyze, and export 
images. 
in vitro – outside of the living body 
in vivo – inside of the living body 
Infarcted – damaged area of the heart, dead cells 
Longitudinal relaxation – relaxation of nucleic energy within surrounding nuclei, spin-spin 
relaxation 
Macro – programming language type inside the ImageJ program 
Matlab – designed by Mathworks, very complex utility program, has its own script and 
programming involved. 
Microthread – made up of collagen or fibrin, multiple are put together to form bundles, these 
threads are a housing and administering unit for human mesenchymal stem cells 
Myocardial Infarction – usually occurs after a heart attack, blood clot or plaque build up is 
usuallythe cause.  
Pairwise Comparison Chart – objective analysis chart, in order to provide a ranking of 
objectives, functions, specifications 
Phantom – in vitro model that mimics relaxation properties of the tissue you are mimicing 
Phosphate buffed saline (PBS) – sterile solution, purpose is to provide neutrality in mixtures 
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Relaxation rate – inate time period unique to each type of tissue or subject that has relaxivity 
properties 
Relaxivity – time at which it takes for a tissue or subject to relax back to its equilibrium state 
Repetition Time (TR) – time at which the rf pulse is applied 
Signal Intensity – grey scale intensity used in order to provide contrast in an MRI image 
T1-Weighted – designed in order to provide/show more anatomical differences 
T2-Weighted – designed in order to provide/show more pathological differences 
Transverse relaxation – relaxation of nucleic energy into the transverse plane, spin-laticce 
relaxation 
RF Pulse – magnetic field that is applied to a subject in order to agitate or excite the nuclei, to 
generate signal intensity 
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Appendix 1: Client Meeting Minutes 
Meeting:  Professor Glenn Gaudette - Ph.D. Biomedical Engineering. 
     September 22nd, 2009 – 11:00am Goddard Hall 
  
  
Background: Professor Gaudette's research is focused on cardiac tissue engineering and 
cardiovascular biomechanics. In particular, he has developed a novel method to regenerate 
heart muscle (embedded microthreads).  
Notes:  During our meeting with Professor Gaudette the project group listened in on a brief 
overview of a presentation he had given at the University of Akron entitled, “Biological 
Microthreads for the Delivery of Stem Cells”. Included in this presentation was an overview of 
current delivery techniques, the new base for new and improved methods, and an in depth 
description on the development and promise of biological microthreads. This information 
played a crucial role in the compilation of an accurate and fulfilling literature review. 
                Also obtained from the meeting was an understanding of the “wants” of Professor 
Gaudette in relation to our project. Insertion of microthreads into the intended area of delivery 
is a somewhat uncertain process, as there are no means of correct placement verification. 
Improper placement of microthreads can potentially affect the thread’s efficacy and result in 
numerous unnecessary reapplications. Thread location confirmation in the area of infarction is 
the first step in maximizing thread effectiveness. Utilizing MR technology and contrast agents 
can aid in the thread visualization process and potentially be used for further thread analysis 
including thread parameters (volume, length, etc.) and stem cell induced myocardial 
proliferation.  
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Appendix 2: Objectives 
Pairwise Comparison Chart 
Table 16: Objective Pairwise Comparison Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phantom Modeling System 
1. Cardiac phantom representation should be accurate.  
2. Cardiac modeling system should be stable and reproducible. 
3. Tissue component representations and microthread should be easily differentiated. 
4. Modeling system should be easy to use. 
5. Modeling system should be cost effective. 
Data Acquisition- Image Parameters 
1. Image parameters should be similar to those used in vivo. 
2. Safety considerations should be defined and applied to design and procedures. 
3. Data acquisition should be easily obtainable and implementable. 
4. Utilization of MR machine should be done in a time and cost effective manner. 
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Data Analysis
Procedures applicable in 
vivo
Display differentiation 
accurately
Microthread location, size, 
and shape
Infarct location, size, and 
shape
Easy
Time and cost Effective
Data Analysis 
1. Analysis procedure should be applicable to images acquired in vivo. 
2. Software should allow for easy image analysis. 
3. Imaging software should display areas of differentiation accurately. 
4. Software analysis should time and cost effective. 
Weighted Objectives 
Table 17: Weighted Objectives from Project Stakeholders 
 
 
 
 
Figure 61: Data Analysis Objective Tree 
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Data Acquisition 
Safety 
considerations
Usage of 
ferromagnetic 
material
Usage of protective 
hearing equipment
Local RF power 
disposition
Image parameters 
similar to those 
used in vivo.
TE or echo time
TR or repetition 
time
Resolution – coil 
size in relation to 
phantom
Spatial resolution        
(FOV/# Digital 
points)
Easily obtainable 
and implementable
Parameters easily 
altered
Image acquisition 
is time efficient
Time and Cost 
effective
Phantom 
Modeling System
Accurate
Resistivity 
Relaxation rates
Infarct volume
Shape of tissue
Positioning of 
tissue
Shape
Stable and 
Reproducible
Consistent 
Composition
Normal tissue 
representation
Ischemic tissue 
representation
Embedded 
microthread
Applied contrast 
agents
Component 
locations
Normal tissue 
representation
Ischemic tissue 
representation
Embedded 
microthread
Applied contrast 
agents
Cost Effective
Easy 
Differentiation
Native & ischemic 
relaxation altered 
Microthread 
relaxation altered 
Easy to Use
Simple 
construction and 
directions
Microthread 
stabilization 
Phantom 
stabilization  
System 
altercations and 
calculations
Figure 62: Phantom Modeling System Objective Tree 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 63: Data Acquisition Objective Tree 
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Appendix 3: Functions 
Table 18: Morphological Table 
FUNCTION POSSIBLE MEANS 
Phantom modeling system 
should accurately/precisely 
mimic an in vivo system. 
Water content 
should be about the 
same in different 
tissues 
Water content 
should have the 
same percent 
difference in 
different tissues 
Apply electrical 
stimulation to 
give phantom 
ability to 
contract/expand 
like a real heart 
Use same 
dimensions for 
phantom as of a 
real rat heart 
Contrast agent(s) should aid in 
differentiation of relaxation 
times of microthread/phantom 
system. 
Higher 
concentrations of 
negative agents 
lead to decreases in 
T1 and T2 
relaxation rates 
Higher 
concentrations of 
postive agents 
lead to increases 
in T1 relaxation 
rates 
  
Image should display the desired 
differences in SI between the 
microthread/tissue phantom. 
T1- use positive 
agents to create 
brighter signal in 
microthread than in 
tissue phantom 
T1- use negative 
agents to create 
darker signal in 
microthread than 
in tissue 
phantom 
T2- use positive 
agents to create 
darker signal in 
microthread 
than in tissue 
phantom 
T2- use negative 
agents to create 
brighter signal 
in microthread 
than in tissue 
phantom 
DAQ and analysis tools should 
allow for phantom/microthread. 
3D reconstruction 
Acquire 3D images 
from MRI 
Acquire multiple 
2D images from 
MRI and 
reconstruct on 
computer using 
software 
  
Applied software should allow 
for microthread analysis. 
Create program 
which allow for 
healthy and 
infarcted tissue 
volume/location 
measurements 
Create program 
which allow for 
microthread 
volume/orientati
on 
measurements 
  
Resulting image should 
accurately/precisely display 
microthread location. 
Acquire 3D images 
which have higher 
SNR than 2D images 
Image should be 
displayed in an 
xy plane for 2D 
images 
Image should be 
displayed in an 
xyz plane for 3D 
images 
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Function Enumeration 
1) Mimic corresponding in vitro system. 
a) Native tissue model should relax with identical rates as in vitro native tissue. 
b) Infarct tissue model should relax with identical rates as in vitro infarct tissue. 
2) Contrast agent relaxation differentiation. 
3) Display desired differences 
a) MR parameters should capture modeling components (tissue/microthread) at 
sufficient relaxation differentiation time points. 
b)  Software will convert relaxation rates into corresponding signal intensities.  
4) 3D construction of cardiac phantom and microthread. 
5) Software microthread analysis. 
a) Quantitative measurements should be used to analyze microthread 
success/failure. 
b) Determine physical parameters including size, shape, and volume. 
c) Confirm proper location in area of infarction 
6) Display location of microthread. 
a) Tissue and microthread contrast (via applied agents and image acquisition 
parameters) should be as large as possible. 
b)  Image acquisition and analysis should result in optimal signal to noise ratio. 
c)  Image acquisition and analysis should result in optimal resolution. 
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Appendix 4: Calculations for Specifications 
Minimal signal intensity difference calculations 
 Grayscale image contains 256 possible grayscale values. 
 Desired signal intensity difference = 20 percent. 
(256 x 0.20) ≈ Minimum 50 grayscale value difference 
Average heart rate statistics & calculations 
 Over 83 percent of people who die of coronary heart disease are 65 or older.  
 In men, the risk for heart attack increases significantly after the age of 45.  
 In women, heart attacks are more likely to occur in the years after the age of 50. 
Table 19: Heart Rate Statistics & Calculations 
 
 
 
 
 
 
* Statistics courtesy of the American Heart Association, Inc. 2005 © 
 Using Table 14 and the associated statistics above, average heart rate 
approximations of the subjects imaged can be made. This information could be used to 
set proper MR parameters for limiting the effects of image artifacts and noise due to the 
beating of the heart. Heart rate will reflect the average from the data in yellow with the 
rationale being that 83% of people who die from CAD are 65 and older, and 
men/women over the age of 50 have significantly greater risks of MI. HR used will be 
the 50% HR target zone statistics from the table above, as it represents the mid-point of 
cardiac output performance. This technique is applicable to numerous species as long as 
statistical data regarding cardiac performance is available. 
Average HR of patient = [(85+83+80+78+75) / 5] ≈ 80 bpm 
Age Target HR 50-85% Age Target HR 50-85% 
20 yrs 100 - 170 bpm 50 yrs 85 - 145 bpm 
25 yrs 98 - 166 bpm 55 yrs 83 - 140 bpm 
30 yrs 95 - 162 bpm 60 yrs 80 - 136 bpm 
35 yrs 93 - 157 bpm 65 yrs 78 - 132 bpm 
40 yrs 90 - 153 bpm 70 yrs 75 - 128 bpm 
45 yrs 88 - 149 bpm     
138 
 
Spatial resolution calculation 
Hydrated microthreads are average 100μm in diameter. Spatial resolution should be 
small enough for the doped microthread to represent 2-3 pixel widths. 
(100μm/ 3)  ≈ 30μm = Largest image spatial resolution 
Normal and ischemic relaxation rate calculations 
Table 20: Relaxation Rate Variation 
0.5Tesla           2.0Tesla          
  T1 STD T2 STD    T1 STD T2 STD 
Normal Myocardium - Case Study 7     48.3 5.5  Normal Myocardium - Case Study 9 1060   37   
Normal Myocardium - Case study 3     54.6 5.7  Avg. 1060.0 - 37 - 
Normal Myocardium - Case study 8     50 5       
Avg.  - - 51.0 9  3.0Tesla          
        T1 STD T2 STD 
      Normal Myocardium - Case Study 1     31.6 5.8 
1.5Tesla           Normal Myocardium - Case Study 10     31.7 1.9 
  T1 STD T2 STD  Normal Myocardium - Case Study 12 1260 60     
Normal Myocardium - Case Study 5     44 6  Normal Myocardium – Case Study 13 1471 31   
Normal Musculoskeletal - Case Study 2 1075   33    Avg. 1365 45 32 6.1 
Normal Myocardium - Case Study 4 1146 71           
Normal Myocardium - Case Study 6     52    4.0Tesla          
Normal Musculoskeletal - Case Study 10     35.3 3.9    T1 STD T2 STD 
Normal Myocardium - Case Study 12 1150 60      Normal Musculoskeletal - Case Study 11 1830 170 26 1 
Avg. 1124 93 41.1  7.2  Avg. 1830.0 170 26.0 1 
 
We were able to determine the average relaxation rates, along with the uncertainties of the 
average value by propagating the given standard deviations with the following equation:  
 
(xy)/2  σaverage = √(σx
2+ σy
2) 
Equation 4 
Table 21: Case Study References 
Case Study 1 
Cobb J, et al. Improved In Vivo Measurement of Myocardial Transverse Relaxation with 3 Tesla Magnetic Resonance 
Imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING. 2009 30: 684–689.  
 Case Study 2 McRobbie W, Donald, et al. MRI: From Picture to Proton. 2nd ed. Cambridge: Cambridge University Press, 2006. 155. 
 Case Study 3 
Boxt M, Lawrence, et al. Estimation of myocardial water content using transverse relaxation time from dual spin-echo 
magnetic resonance imaging. Magnetic Resonance Imaging. Elsevier Inc. 11(3): 375-383. 1993. 
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 Case Study 4 
Hosch W, et al. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac 
amyloidosis. Invest Radiol. 2007 Sep; 42(9):636-42. 
 Case Study 5 
Allmann KH, Horch R, Uhl M, Gufler H, Altehoefer C, Stark GB, Langer M. MR imaging of the carpal tunnel. Eur J Radiology 
1997; 25:141–145. 
 Case Study 6 
Imbriaco M,Spinelli L, et al. MRI Characterization of Myocardial Tissue in Patients with Fabry’s Disease. AJR 2007; 
188:850–853 
 Case Study 7 
Maris T, Mavrogeni S,Myocardial iron deposition in Beta-Thalassemia studied by magnetic resonance imaging. 
International Journal of Cardiac Imaging 14: 117–122, 1998. 117 
 Case Study 8 
Marie P, Carteaux J, et al. Detection and prediction of acute heart transplant rejection: preliminary results on the clinical 
use of a “black blood” magnetic resonance imaging sequence Transplantation Proceedings, 30, 1933–1935 (1998) 
 Case Study 9 
Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF. (1992) Quantitative Dependence of MR Signal Intensity 
on Tissue Concentration of Gd(HP-DO3A) in the Nephrectomized Rat. Magnetic Resonance Imaging. 10:97-108 
 Case Study 10 Gold G, Han E. Musculoskeletal MRI at 3.0 T: Relaxation Times and Image Contrast. AJR 2004; 183:343–351 
 Case Study 11 
Duewell S, et al. Musculoskeletal MR Imaging at 4T and 1.5T: Comparison of Relaxation Times and Image Contrast. 
Radiology 1995; 196: 551-555. 
 Case Study 12 
Sharma P, et al. Post-Contrast T1 Measurements of Blood, Infarct and Normal Myocardium at 1.5T and 3T. Proceedings 
of the 13th Annual Meeting of ISMRM, Miami Beach, FL, USA, 2005.  
Case Study 13 
Stanisz, Greg J, et al.  T1, T2 Relaxation and Magnetization Transfer in Tissue at 3T. Magnetic Resonance in Medicine. 
August 2005. 54(3) p.507-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: Average T1 Relaxation Rates vs. Magnet Strength 
Figure 65: Average T2 Relaxation Rates vs. Magnet Strength 
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y =0.2879x + 0.5627 
Equation 5: T1 Trend line equation 
y = -6.9137x + 52.63 
Equation 6: T2 Trend line equation 
 
* Prior to switching to 3.T, trend lines were extended using the derived formula to approximate 4.7 Tesla T1 and T2 
relaxation rates. 4.7T T1 relaxation was found to be approximately 1.98 seconds while T2 relaxation was 20.1 
milliseconds.  
 
 The relationship between water content and T2 relaxation of left ventricular 
myocardium was used to approximate relaxation rates of infarcted myocardium with known 
water content percentages. Using 0.5T dual spin echo MR imaging Case Study 4 estimated 
myocardial water content to be: 
WCLV = 62.1 + (0.29 * T2LV) 
Equation 7: Water Content of Left Ventricle as a function of T2 
 
 Water content is approximated to be 75.9% +/- 0.7 in normal myocardium and 79.0% 
+/- 0.9 in ischemic tissue 1 week post infarct. These values were entered into the water content 
equation to verify the equation’s accuracy. The resulting data when enter in to equation 3 was 
0.2% outside of the given standard deviation of water content (76.8%). To account for the error 
in the normal T2 water content percentage and make the most accurate approximation of 
infarct relaxation via equation 3, the maximum value (within one standard deviation) of infarct 
water content was used (79.9%). Using this information the T2 trend line was adjusted to 
estimate T2 infarction relaxation time versus magnet field strength. The new y intercept and 
the resulting values are calculated below. 
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T2 infarct relaxation time calculation 
79.9 = 62.1 + (0.29 * T2LV) 
T2LV = (79.9 – 62.1) / 0.29 
T2LV = 61.4 ms 
T2 infarct trend line equation 
61.4 = -6.9137(0.5T) + X 
X = 64.85 
y = -6.9137x + 64.85 
 
Table 22: T2 Normal v Infarcted relaxation 
 Tesla (T) 0.5 T 1.5 T 2 T 3 T 4 T 4.7 T 
Normal Myocardium  48.9 ms 42.3 ms 38.8 ms 31.9 ms 25.9 ms 20.1 ms 
Infarcted Myocardium  61.4 ms 54.5 ms 51.0 ms 44.1 ms 38.2 ms 32.4 ms 
 
Infarct relaxation calculations 
0.5T = -6.9137 (0.5) + 64.85 = 61.4 ms 1.5T = -6.9137 (1.5) + 64.85 = 54.5 ms 
2.0T = -6.9137 (2.0) + 64.85 = 51.0 ms 3.0T = -6.9137 (3.0) + 64.85 = 44.1 ms 
4.0T = -6.9137 (4.0) + 64.85 = 38.2 ms 4.7T = -6.9137 (4.7) + 64.85 = 32.4 ms 
 
 
 
 
 
 
 
 
Figure 66: Normal (yellow) v Infarct (blue) trend lines 
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Contrast agent differentiation calculations 
Contrast agent relaxation can be defined as R’ = R + rC  
 Where: R = the relaxation rate = [(1/Tx) = inverse of relaxation time] 
   r = specific concentration relaxivity 
   C = agent concentration  
 
Table 23: MQP reference particle data [65] 
Iron Oxides Contrast Effect Administration Target  Concentration 
Feridex 
T2 negative 
enhancement 
intravenous Liver 11.2mg Fe/ml 
Lumirem T2* enhancement oral intestinal 
52.5mg 
Fe/300ml 
Resovist 
T2/T1 negative 
enhancement 
intravenous Liver 0.5 mol Fe/L 
Sinerem 
T1/T2 negative 
enhancement 
intravenous 
infusion 
lymph nodes ?? 
SPIOM 
T1/T2 negative 
enhancement 
intravenous Heart ?? 
Gadolinium      
Eovist 
T1 positive 
enhancement 
intravenous Liver 181.43mg Fe/L 
Dotarem 
T1 positive 
enhancement 
intravenous intracranial 0.5 mol/L 
Gadovist 
T1 positive 
enhancement 
intravenous CNS 0.5 mol/L 
MultHance 
T1 positive 
enhancement 
intravenous liver/ CNS 0.05 mg/ml 
Omniscan 
T1 positive 
enhancement 
intravenous intracranial 287mg/ml 
 
SPIO particle relaxation error analysis 
Knowing that the size of iron nanoparticles plays a large role in their effect on T1 and T2 
relaxation as small analysis was done to determine the relationship between particle size and 
R2 values. If the size of the particles that are utilized is unknown, similar analyses can be 
conducted to make an approximation. Endorem SPIO nanoparticles are 80-150nm in diameter 
and the iron oxide crystal is 4.8 - 5.6nm in size coated with dextran. Looking at a prior MQP, it 
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was found that SPIO particle size and concentration directly affect the resulting relaxation time. 
The ratio of particle size to slope of the R2 values is [(32.4nm ÷ 14.4nm) ÷ (2.21 ÷ 1.22)] = (2.25 
÷ 1.8) or approximately 1.25. Thus to find the particle slope of Endorem (5.2nm): 
 
(14.4nm ÷ 5.2nm) = 2.77           (2.77 ÷ x) = 1.25           x = 2.22 = additional slope 
[2.22 (additional) * 2.21 (previous)] = 4.91 = total slope 
 
Next we can make approximations as to the y-intercept of the linear regression. The 
ratio of particle size to y-intercept of the R2 values is [(32.4nm ÷ 14.4nm) ÷ (1.765 ÷ 22.63)] = 
2.25 ÷ 0.78 or approximately 2.88. Thus to find the y-intercept of Endorem (5.2nm) 
 
(2.77 ÷ x) = 2.88          x = 0.962 = y-intercept of linear regression. 
 
It was noted that 25ug Fe/mL of Endorem when labeling neural stem cells decreased the 
T2 signal intensity by 50.7% compared to unlabeled cells. The calculation of T2 relaxation time 
indicated T2 relaxation time of labeled cells and unlabeled cells was 516 ms and 77 ms 
respectively, relaxation rates R2 (1/T2) were 1.94/s and 12.98/s. [49] 
 
(516ms ÷ 77ms) = 6.7x normal values [48] 
R2         (1 ÷ 516ms) = 12.98 and (1 ÷ 77ms) = 1.94 
Equation formulated = 4.91x + 0.962 
[(4.91 * 12.98) + 0.962] = 64.7 
[(4.91 * 1.95) + 0.962] = 10.5 
(64.7 ÷ 10.5) = 6.2x normal values 
Percent Error = [(6.7 – 6.2) ÷ 6.7] * 100 = 7.5%   
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Appendix 5: Design Alternatives 
Potential Designs: Phantom Modeling System 
Design 1: In vitro single vegetation phantom model comprising only one type of vegetation, 
such as a potato. The surrounding area will represent healthy myocardium and will be doped 
with positive contrast agents to possess relaxation times corresponding to real cardiac tissue. 
The microthread will also be doped with contrast agents. The area of infarction will be 
represented by the white potato itself, as they will be doped to possess such MRI properties.  
 
Figure 67: White Potato Phantom 
Design 2: In vitro dual vegetation phantom model comprising of two different types of 
vegetation such as a potato and a carrot. These components will be doped with different types 
and concentrations of contrast agents to create relaxation times which correspond to real 
cardiac tissue. A non-metallic divider will be utilized to restrict the diffusion and mixing of the 
contrast agents.   
 
Figure 68: Potato and Carrot Phantom 
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Design 3: In vitro Gelatin Model. This model helps to establish a differentiation of normal and 
infarcted regions of the heart, by representing each part of the heart as a separate 
compartment. This would be encased in a plastic mold. The inside of the mold would be filled 
with a gelatin, each doped to mimic each part of the heart based on their relaxation rate, 
normal and infarcted. The microthread would be doped in order to distinguish it from the 
infarcted area.   
 
Figure 69: Separated Gelatin Phantom 
 
Figure 70: Gelatin Phantom 
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Table 24: Objectives and Constraints for Phantom 
Cardiac Modeling System Design      
Objectives & Constraints Weight D1 D2 D3 D4 
C: Within size limitations Y/N Y Y Y N 
C: Static microthread placement Y/N Y Y Y Y 
O: Representation should be accurate         0.325 2(.325) 1(.325) 2(.325) 2(.325) 
O: Should be stable and reproducible           0.2 1(.20) 1(.20) 2(.20) 1(0.2) 
O: Tissue & microthread easily differentiated 0.375 1(.375) 1(.375) 2(.375) 2(.375) 
O: Should be easy to use                                    0.1 2(.10) 2(.10) 1(.10) 1(.10) 
O: Should be cost effective                                  0 2(0) 2(0) 1(0) 0(0) 
Total  1.425 1.1 1.9 1.7 
 
Potential Designs: Data Acquisition 
Design 1: Delayed enhancement MRI (DE-MRI). Ischemic tissue has significantly greater 
amounts of interstitial space than viable tissue. Presumably because these processes are 
diffusion mediated, gadolinium-chelate accumulates in greater concentrations in ischemic 
myocardium within minutes following contrast administration. MR parameters include: ECG-
gating, inversion recovery (IR), and rewound (fast) gradient echo sequencing (FGE). IR time will 
be chosen to null the normal myocardium making areas of infarction appear hyper-enhanced.   
 
Design 2: Fast Spin Echo MRI (FSE-MRI). The FSE technique can acquire multiple lines of data 
per repetition and thus an entire cardiac image can be taken within one breath hold. This limits 
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the effect of image artifacts due to movement of thoracic cavity during pulse sequences. MR 
parameters include: ECG-gating, blood suppression preparation (BSP), and FSE. BSP will reduce 
the signal from blood taken during acquisition (during diastole). It involves a double inversion 
preparation scheme applied at TI prior to FSE acquisition.  
 
Design 3: Spin Echo MRI (SE-MRI).  The SE technique is similar to the FSE described in the 
previous design however this technique will be simplified. This will not include any ECG-Gating 
nor blood suppression preparation. All techniques and preparations regarding cardiac imaging 
will be ignored limiting this technique to stationary objects.  This technique is typically taken 
setting TR and TE values only. The TR and TE time is calculated based upon the relaxation time 
of the stationary phantom that will be imaged.  
Table 25: Objectives and Constraints for Data Acquisition 
Data Acquistition  Design     
Objectives & Constraints Weight D1 D2 D3 
C: Applicable spatial resolution Y/N Y Y Y 
O: Parameters similar to those in vivo 0.375 2(.375) 2(.375) 1(.375) 
O: Safety considered and defined 0.333 2(.333) 2(.333) 2(.333) 
O: Easily obtainable & implementable 0.208 0(.208) 0(.208) 2(.208) 
O: Time and cost effective 0 1(0) 2(0) 1(0) 
Total  1.416(-) 1.416(+) 1.457 
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Potential Designs: Data Analysis 
 
Design 1: ImageJ software with 3D analysis plug-in. ImageJ is a public domain, Java-based image 
processing program developed to display, edit, analyze, and process a variety of image formats 
including TIFF, PNG, GIF, JPEG, and BMP. ImageJ can calculate area and pixel value statistics, 
measure distances and angles, and create density histograms and line profile plots. It supports 
standard image processing functions including logical and arithmetical operations between 
images, contrast manipulation, convolution, Fourier analysis, sharpening, smoothing, edge 
detection and median filtering. Custom acquisition, analysis and processing plug-ins can be 
developed using a built-in editor and a Java compiler.  
 
Design 2:  Matlab program is a high-level language and interactive environment produced by 
Mathworks. Inc.  It enables you to perform computationally intensive tasks, such as 3D image 
reconstruction, or even image analysis, faster than with traditional programming languages 
such as C, C++, and Fortran. You can use MATLAB in a wide range of applications, including 
signal and image processing, communications, control design, test and measurement, and 
financial modeling and analysis. 
 
 Design 3: Segment is a free image analysis tool for Windows, which was originally constructed 
by Einar Heiberg at the Cardiac MR Group at Lund University and Medviso AB. It was developed 
specifically for cardiovascular MR image analysis. This program has the ability to acquire and 
analyze 2D, as well as 3D MRI and CT images. Some analyses that can be done in the program 
are length, volume, and area measurements in the regions of interest. The program allows the 
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user to highlight a specific region of interest in order to easily display the significant portions of 
the image. An image can also be manipulated by changing its light and contrast, its color-map 
settings (grayscale, hot, HSV, Jet, or SPECT), and by adding Gaussian white noise.       
 
Table 26: Objectives and Constraints for Data Analysis 
Data Analysis Design     
Objectives & Constraints Weight D1 D2 D3 
C: Allow for 3-D image analysis Y/N Y Y Y 
O: Applicable to images acquired in vivo 0.375 2(.375) 2(.375) 2(.375) 
O: Allow easy image analysis 0.167 1(.167) 1(.167) 2(.167) 
O: Display areas of differentiation accurately 0.375 2(.375) 2(.375) 2(.375) 
O: Time and cost effective 0.083 2(.083) 2(.083) 2(.083) 
Total  1.833 1.833 2.0 
 
Table 27: Sub-Objective Weighting for Phantom 
Static placement of Phantom   Method     
Objectives  Weight Secured containment Phantom pining Flat bottom phantom 
O: Should be accurate         0.375 2(0.375) = .75 1(0.375) = .375 0(0.375) = 0 
O: Should be reproducible           0.325 2(0.325) = .650 2(0.325) = .650 1(0.325) = .325 
O: Should be easy to use                                    0.2 2(0.2) = .40 1(0.2) = .20 1(0.2)  = .20 
O: Should be cost effective                                  0.1 1(0.1) = .10 1(0.1) = .10 2(0.1) = .20 
Total   1.9 1.325 0.725 
     
Static placement of Phantom   Method     
Objectives  Weight Clamp down Velcro Double sided tape 
O: Should be accurate         0.375 1(0.375) = .375 2(0.375) = .75 2(0.375) = .75 
O: Should be reproducible           0.325 2(0.325) = .650 1(0.325) = .325 1(0.325) = .325 
O: Should be easy to use                                    0.2 2(0.2) = .40 2(0.2) = .40 2(0.2) = .40 
O: Should be cost effective                                  0.1 1(0.1) = .10 2(0.1) = .20 2(0.1) = .20 
Total   1.525 1.675 1.675 
 
Table 28: Sub-Objective Weighting for Phantom Contrast Agent Delivery 
Phantom contrast agent delivery   Method     
Objectives  Weight Injection Static Saturation Dynamic Saturation 
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O: Should be accurate         0.375 1(0.375) = .375 1(0.375) = .375 2(0.375) = .75 
O: Should be reproducible           0.2 2(0.2) = .4 2(0.2) = .4 2(0.2) = .4 
O: Tissue representation & 
microthread should be easily 
differentiated 
0.325 
2(0.325) = .650 2(0.325) = .650 2(0.325) = .650 
O: Should be easy to use                                    0.1 2(0.1) = .2 2(0.1) = .2 2(0.1) = .2 
O: Should be cost effective    0 2(0) = 0 2(0) = 0 2(0) = 0 
Total   1.625 1.625 2 
 
Table 29: Sub-Objective Weighting for Microthread Contrast Agent Delivery 
Microthread contrast agent delivery   Method     
Objectives  Weight Adhesion Static Saturation Dynamic Saturation 
O: Should be accurate         0.375 2(0.375) = .75 1(0.375) = .375 1(0.375) = .375 
O: Should be reproducible           0.2 2(0.2) = .4 1(0.2) = .2 1(0.375) = .375 
O: Tissue representation & microthread 
should be easily differentiated 
0.325 
2(0.325) = .650 2(0.325) = .650 2(0.325) = .650 
O: Should be easy to use                                    0.1 1(0.1) = .1 2(0.1) = .2 2(0.1) = .2 
O: Should be cost effective    0 2(0) = 0 2(0) = 0 2(0) = 0 
Total   1.9 1.425 1.6 
 
Table 30: Sub-Objective Weighting for Contrast Agent Use 
Contrast agent applied   Method   
Objectives  Weight Gadolinium based Iron Oxide based 
O: Should be accurate         0.375 1(0.375) = .375 2(0.375) = .75 
O: Should be reproducible           0.2 1(0.2) = .2 2(0.2) = .4 
O: Tissue representation & microthread 
should be easily differentiated 
0.325 
1(0.325) = .325 2(.325) = .65 
O: Should be easy to use                                    0.1 2(0.1) = .2 2(0.1) = .2 
O: Should be cost effective    0 2(0) = 0 2(0) = 0 
Total   1.1   2 
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Appendix 6: Preliminary Data 
 
Figure 71: T1 of 10% Gelatin Concentration 
 
 
 
Figure 72: T1 of 6% Gelatin Concentration 
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Figure 73: T1 of 3% Gelatin Concentration 
 
Figure 74: T2 of 10% Gelatin Concentration 
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Figure 75: T2 of 6% Gelatin Concentration 
 
Figure 76: T2 of 3% Gelatin Concentration 
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Figure 77: T1 of 5ug/mL Contrast Agent 
 
Figure 78: T1 of 10ug/mL Contrast Agent 
155 
 
 
Figure 79: T1 of 20 ug/mL Contrast Agent 
 
Figure 80: T1 of 30ug/mL Contrast Agent 
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Figure 81: T1 of 50 ug/mL Contrast Agent 
 
Figure 82: T2 of 5 ug/mL Contrast Agent 
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Figure 83: T2 of 10 ug/mL Contrast Agent 
 
Figure 84: T2 of 20 ug/mLContrast Agent 
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Figure 85: T2 of 30 ug/mL Contrast Agent 
 
Figure 86: T2 of 50 ug/mL Contrast Agent 
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Figure 87: Signal Intensity vs Time for all AMI and Gelatin at TR of 1600 
 
Figure 88: Signal Intensity vs Time for all AMI and Gelatin at TR of  1400 
 
Figure 89: Intensity vs Time for all AMI and Gelatin at TR of  1200 
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Figure 90: Intensity vs Time for all AMI and Gelatin at TR of  1000 
 
Figure 91: Intensity vs Time for all AMI and Gelatin at TR of  800 
 
Figure 92: Intensity vs Time for all AMI and Gelatin at TR of  600 
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Figure 93: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1400 
 
Figure 94: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1400 Zoomed 
 
 
Figure 95: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1300 
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Figure 96: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1300 Zoomed 
 
Figure 97: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1200 
 
Figure 98: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1200 Zoomed 
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Figure 99: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1100 
 
Figure 100: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1100 Zoomed 
 
Figure 101: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1000 
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Figure 102: Signal Intensity vs Time for all 10ug/mL and Gelatin at TR of 1000 Zoomed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 
 
Appendix 7: Results 
Magnetic Resonance Images 
TE 25 Air- Dried 
  
Hydrated 
   Thread 60 min 30 min 5 min Control 60 min 30 min 5 min Control 
Slice 
        1 0.58 0.53 0.88 0.44 0.37 0.52 0.60 0.48 
2 0.42 0.41 0.69 0.48 0.29 0.48 0.71 0.48 
3 0.44 0.33 0.46 0.32 0.44 0.51 0.49 0.32 
4 0.57 0.44 0.40 0.47 0.37 0.26 0.26 0.35 
5 0.68 0.40 0.40 0.37 0.45 0.63 0.37 0.51 
6 0.53 0.62 0.39 0.70 0.36 0.39 0.32 0.26 
7 0.54 0.66 0.37 0.74 0.28 0.46 0.42 0.43 
8 0.61 0.50 0.39 0.81 0.35 0.63 0.32 0.35 
9 0.48 0.47 0.48 0.58 0.76 0.57 0.40 0.38 
10 0.76 0.60 0.47 0.42 0.65 0.41 0.32 0.52 
Average 0.56 0.49 0.49 0.53 0.43 0.48 0.42 0.41 
Std Dev 0.11 0.11 0.17 0.17 0.16 0.11 0.14 0.09 
P-value 
    
0.047257 0.836571 0.319865 0.052344 
         TE 50 Air- Dried 
  
Hydrated 
   Thread 60 min 30 min 5 min Control 60 min 30 min 5 min Control 
Slice 
        1 0.64 0.55 0.61 0.60 0.37 0.50 0.57 0.45 
2 0.48 0.42 0.84 0.50 0.31 0.49 0.75 0.57 
3 0.46 0.38 0.56 0.32 0.37 0.55 0.56 0.30 
4 0.53 0.42 0.42 0.42 0.37 0.36 0.32 0.29 
5 0.64 0.44 0.42 0.55 0.30 0.62 0.35 0.51 
6 0.52 0.71 0.36 0.71 0.33 0.28 0.33 0.34 
7 0.55 0.61 0.40 0.68 0.35 0.44 0.41 0.38 
8 0.60 0.53 0.39 0.72 0.26 0.62 0.34 0.37 
9 0.48 0.47 0.48 0.57 0.59 0.59 0.34 0.23 
10 0.70 0.72 0.53 0.56 0.85 0.35 0.36 0.53 
Average 0.56 0.52 0.50 0.56 0.41 0.48 0.43 0.40 
Std Dev 0.08 0.12 0.14 0.13 0.18 0.12 0.15 0.11 
P-value 
    
0.029707 0.412986 0.314352 0.006944 
         TE 75 Air- Dried 
  
Hydrated 
   Thread 60 min 30 min 5 min Control 60 min 30 min 5 min Control 
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Slice 
        1 0.68 0.54 0.45 0.42 0.45 0.44 0.57 0.49 
2 0.48 0.45 0.75 0.51 0.26 0.48 0.74 0.45 
3 0.50 0.33 0.59 0.38 0.33 0.51 0.32 0.33 
4 0.53 0.42 0.41 0.48 0.40 0.38 0.31 0.31 
5 0.62 0.44 0.44 0.42 0.28 0.31 0.36 0.27 
6 0.52 0.65 0.39 0.77 0.37 0.33 0.33 0.20 
7 0.51 0.65 0.37 0.66 0.40 0.42 0.39 0.41 
8 0.59 0.53 0.40 0.83 0.38 0.64 0.35 0.36 
9 0.46 0.56 0.61 0.68 0.51 0.52 0.40 0.28 
10 0.87 0.87 0.47 0.79 0.99 0.44 0.40 0.32 
Average 0.57 0.54 0.49 0.59 0.43 0.45 0.42 0.34 
Std Dev 0.12 0.15 0.12 0.17 0.21 0.10 0.14 0.09 
P-value 
    
0.084977 0.112613 0.253743 0.000644 
         TE 100 Air- Dried 
  
Hydrated 
   Thread 60 min 30 min 5 min Control 60 min 30 min 5 min Control 
Slice 
        1 0.72 0.57 0.67 0.45 0.37 0.46 0.54 0.46 
2 0.46 0.48 0.93 0.53 0.34 0.61 0.77 0.39 
3 0.46 0.36 0.56 0.39 0.41 0.58 0.52 0.34 
4 0.54 0.41 0.49 0.56 0.44 0.38 0.33 0.33 
5 0.66 0.38 0.40 0.47 0.42 0.46 0.37 0.25 
6 0.48 0.66 0.36 0.65 0.32 0.33 0.35 0.24 
7 0.47 0.63 0.41 0.54 0.41 0.42 0.40 0.26 
8 0.51 0.48 0.38 0.73 0.42 0.43 0.37 0.43 
9 0.42 0.43 0.49 0.52 0.48 0.58 0.37 0.28 
10 0.80 0.63 0.40 0.61 0.73 0.45 0.39 0.32 
Average 0.55 0.50 0.51 0.55 0.43 0.47 0.44 0.33 
Std Dev 0.13 0.11 0.18 0.10 0.11 0.09 0.13 0.08 
P-value 
    
0.042642 0.494173 0.351082 3.78E-05 
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Optical Images 
Actual Air- Dried 
   
Hydrated 
   Thread 60 min 30 min 5 min Control 
 
60 min 30 min 5 min Control 
Slice 
         1 0.42 0.39 0.40 0.47 
 
0.36 0.71 0.44 0.45 
2 0.43 0.45 0.42 0.46 
 
0.35 0.54 0.43 0.41 
3 0.44 0.46 0.41 0.49 
 
0.44 0.50 0.44 0.47 
4 0.42 0.45 0.46 0.49 
 
0.44 0.48 0.41 0.47 
5 0.42 0.44 0.42 0.46 
 
0.40 0.39 0.40 0.43 
6 0.43 0.44 0.42 0.40 
 
0.42 0.38 0.41 0.43 
7 0.44 0.43 0.41 0.45 
 
0.32 0.43 0.43 0.47 
8 0.46 0.43 0.46 0.49 
 
0.38 0.50 0.44 0.44 
9 0.48 0.45 0.43 0.45 
 
0.75 0.47 0.47 0.44 
10 0.49 0.44 0.42 0.38 
 
0.65 0.46 0.48 0.43 
Average 0.44 0.44 0.42 0.45 
 
0.45 0.49 0.43 0.44 
Std Dev 0.02 0.02 0.02 0.04 
 
0.14 0.09 0.03 0.02 
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Percent Change of Air-Dried and Hydrated 
Percent Change 
        
 
Air- Dried 
   
Hydrated 
   
 
60 min 30 min 5 min Control 
 
60 min 30 min 5 min Control 
TE 25 0.21 0.11 0.14 0.15 
 
0.05 0.00 0.03 0.09 
TE 50 0.21 0.17 0.15 0.19 
 
0.10 0.01 0.00 0.12 
TE 75 0.23 0.19 0.13 0.23 
 
0.04 0.09 0.04 0.30 
TE 100 0.20 0.13 0.16 0.17 
 
0.05 0.03 0.02 0.35 
Average 
Percent 
Change 0.21 0.15 0.15 0.19 
 
0.06 0.03 0.01 0.20 
Hydrated 
    Average 0.43 0.47 0.43 0.37 
Std Dev 0.16 0.11 0.14 0.09 
Air-Dried 
    Average 0.56 0.52 0.50 0.56 
Std Dev 0.11 0.12 0.15 0.14 
P-value 0.006 
   
 
60 min 30 min 5 min Control 
Average 
Percent 
Change 0.21 0.15 0.15 0.19 
 
60 min 30 min 5 min Control 
Average 
Percent 
Change 0.06 0.03 0.01 0.20 
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Appendix 8: Compiled and Revised Gantt Charts 
Revised C-Term Gantt Chart – January 28th 2010 
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Revised D-term Gantt Chart – February 10th, 2010 
 
 
 
 
